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Using the 1999-2004 Medicare Current Beneficiary Survey linked with Medicare 
claims, this dissertation identified the most sensitive and specific alternatives for selecting 
who has Alzheimer’s disease (AD). This dissertation examined expenditure concentration 
and persistence patterns among seniors with AD, and was the first, to our knowledge, to 
compare the performance of different risk adjustment measures to predict overall and drug 
expenditures in the AD population. 
The use of survey-reported AD, diagnosis in medical claims, and Alzheimer-specific 
prescription medicine identified different subsets of seniors with AD. Per capita health 
expenditures ranged from $16,547 to $24,937, and drug expenditures ranged from $2,303 to 
$3,519, depending on how AD was defined. Using at least one of the three disease markers 
as our case definition, overall and drug expenditures were highly concentrated and persistent 
over a two-year period. Prior expenditures and comorbidities, but not functional ability, were 
highly predictive of the level of subsequent-year expenditures. 
In single-measure, diagnosis-based risk adjustment models, the Charlson 
Comorbidity Index outperformed the Diagnostic Cost Group-Hierarchical Condition Category 
used by Medicare and the Chronic Illness and Disability System-Medicare in predicting total 
and drug expenditures. The frailty adjuster based on limitations of activity of daily living 
improved overall prediction and predictive accuracy of diagnosis-based models. Only prior 
drug expenditures predicted drug expenditures well. Future research is needed to evaluate
 iv 
the performance of risk adjustment measures based on ambulatory pharmacy data. 
In conclusion, the development of a comprehensive case definition that is reasonably 
sensitive and specific is crucial in observational studies to identifying individuals at different 
phases of AD and to assessing their health care needs. With proper organization of 
information, risk adjustment appears promising in predicting health expenditures even in a 
population with substantial disabilities. Predictive models identifying seniors with AD who are 
at risk for higher future expenditures can help managed care organizations to mitigate costs 
or change care patterns through disease management, which may delay time to nursing 
home care. Better care coordination, such as medication management by nurses or 
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Predictive modeling increasingly has been used to explain variation in concurrent or 
prospective health care utilization, especially in managed care systems. As health care 
spending for Medicare beneficiaries continues to rise, there is a critical need to identify 
high-risk populations, predict resource use, and control costs using tools such as risk 
adjustment models. However, observers report that Medicare risk-adjusted capitation models 
do not adequately compensate health plans serving primarily disabled or frail populations 
[Riley, 2000; Kautter and Pope, 2004]. Improvements to risk adjustment models are 
necessary for certain Medicare subpopulations, such as individuals with functional 
impairments. 
This study examined the dynamics of overall health care and prescription drug 
expenditures for Medicare beneficiaries with Alzheimer’s disease (AD), a population with 
progressive disabilities and high expenditures. The following sections summarize the burden 
of AD in the United States and describe the policy significance, followed by the purpose and 
structure of this dissertation. 
 
1.1 Burden of Alzheimer’s Disease 
AD is a neurodegenerative disease characterized by a progressive decline in 
cognition, memory and functional ability. Individuals with AD often experience prominent and 
multiple symptoms, including psychological symptoms and behavioral disturbances, that are 
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distressing and place substantial financial burdens both on individuals and the health care 
system [Grossberg, 2002; Fillit and Hill, 2004; Kaufer et al., 2005]. AD is the most common 
form of dementia in the elderly, comprising approximately half of all dementia cases 
[Katzman, 1986]. Although currently there is no cure for AD, drug and non-drug treatments 
may help with both cognitive and behavioral symptoms. As of 2007, there are only four Food 
and Drug Administration (FDA) approved prescription medicines for AD. Mild to moderate AD 
is typically treated with acetycholinesterase inhibitors (AChEIs), including donepezil 
(Aricept®), rivastigmine (Exelon®), and galantamine (Reminyl® or Razadyne®). 
Moderate-to-severe cases often are treated with a N-methyl-D-aspartate receptor antagonist, 
memantine (Namenda®), alone or as a combination therapy with AChEIs. These drugs may 
temporarily delay memory decline but none of them is known to stop the underlying 
degeneration of brain cells [Alzheimer's Association, 2007]. 
In randomized controlled trials, cognitive function commonly is measured by the 
Mini-Mental State Examination (MMSE) scores or the Alzheimer’s Disease Assessment 
Scale-Cognitive Subscale (ADAS-cog). The MMSE evaluates cognitive decline on a scale of 
0–30, with a higher score indicating less impairment [Folstein, 1975]. MMSE scores are 
calculated by summing subscores for seven domains: orientation to time, orientation to place, 
registration, recall, attention/concentration, language, and figure copy representing 
constructional praxis. The ADAS-cog uses 11 cognitive items, including spoken language 
ability, comprehension of spoken language, recall of test instructions, word-finding difficulty in 
spontaneous speech, following commands, naming objects and fingers, constructional praxis, 
ideational praxis, orientation, word-recall task and word-recognition task [Rosen et al., 1984]. 
The ADAS-cog scale ranges from 0 to 70, with higher scores indicating greater impairment. 
Individuals are categorized as having mild, moderate, or severe AD based on their cognitive 
function. From the time of diagnosis, individuals with AD survive about half as long as those 
of similar age without dementia [Larson et al., 2004]. A recent, fifteen-year prospective
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epidemiological study [Ganguli et al., 2005] estimated that the mean duration of survival with 
AD was 5.9 (standard deviation=3.7) years; the average survival time is affected by age at 
diagnosis and severity of other medical conditions. 
Aging is one of the greatest risk factors for AD. Approximately one in ten individuals 
older than 65 and nearly half of those older than 85 are affected [Evans et al., 1989]. AD has 
gained importance as a cause of death among older persons over the past two decades. In 
2002, it was the sixth leading cause of death for persons older than 65; approximately 3.2% 
of all deaths among older persons were attributable to AD [Gorina et al., 2006]. The disease 
affects approximately 4.5 million Americans and this number is projected to increase to 
11.3-16 million by 2050 [Evans, 1990; Hebert et al., 2003]. 
The economic burden of AD is well recognized in the literature. Bloom and colleagues 
reviewed 21 cost-of-illness studies on AD using 1985–2000 data and found that annual 
inflation-adjusted total expenditures for AD varied from $5.6 billion to $88.3 billion [Bloom et 
al., 2003]. Total (direct plus indirect) expenditures per patient varied from $1,500 to $91,000; 
indirect/family expenditures varied from $3,700 to $21,000. Although these estimates are 
widely variable due to differences in study design, data sources and services included, 
Bloom’s study indicated that the cost of AD are likely to increase given the aging population. 
Medicare pays for most of the cost of hospitalization and a large portion of other medical care 
among individuals with AD. In 2000, individuals with AD represented fewer than 5% of 
Medicare beneficiaries [Taylor and Sloan, 2000], whereas they accounted for 14.4% of 
overall Medicare spending [Alzheimer's Association, 2001]. According to a report 
commissioned by the Alzheimer’s Association, total health expenditures of Medicare 
beneficiaries with AD are expected to increase 75%, from $91 billion in 2005 to $160 billion in 
2010; Medicaid expenditures for residential dementia care will increase 14%, from $21 billion 
in 2005 to $24 billion in 2010 [Alzheimer's Association, 2004]. 
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1.2 Policy Significance 
Accurate estimation of population-level prevalence is crucial to forecasting future 
burden of AD and to assessing the health care needs. Although prevalence estimates 
consistently shows an increasing trend over time and by advancing age, the figures vary 
widely due to data source and methodological differences [Johnson et al., 2000; Rice et al., 
2001]. Using a single measure, such as an AD diagnosis in administrative data, to identify 
individuals with AD has been shown to introduce errors of omission and commission 
[Newcomer et al., 1999; Fillit, 2000; Rice et al., 2001; Pressley et al., 2003]. This dissertation 
investigated the utility of two supplements to claims data, Alzheimer’s medication use and 
survey report of AD, to provide greater confidence in case ascertainment. The extent to 
which the costs of AD vary by case definition also was examined to provide insight into 
causes of wide cost variations, and to further discussions about the need for improving cost 
estimates to aid planning AD policy initiatives. 
Additionally, despite numerous cost-of-illness studies on AD, little is known about the 
characteristics of individuals with AD who accrue high expenditures, and who continue to 
spend a disproportionately large share of money. This dissertation examined the 
concentration and persistence of overall and prescription drug expenditures in individuals 
with AD, and evaluated person-level characteristics, such as functional ability and 
comorbidities, to predict the level of future expenditures. Results from this study may further 
our knowledge of how expected high expenditures in individuals with AD may be reduced 
with improved care coordination and effective disease management. 
Building on the foundation of accurate identification of individuals with AD and better 
understanding of high-expenditure concentration and persistence, this dissertation next 
evaluated various risk adjustment measures in predicting overall and drug expenditure. Risk 
adjustment models have been used to set capitation payments with the expectation that they 
will mitigate financial consequences of adverse risk selection into particular health plans. The 
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technique also is used to identify prospectively future high-risk, high-cost cases. However, a 
concern has been raised about whether predictive models using only diagnoses in claims 
data (i.e., diagnosis-based approaches) can make adequate risk-adjusted payments to 
Medicare plans, especially plans mainly serving frail or disabled beneficiaries. To improve 
model performance, researchers have suggested the inclusion of self-reported health from 
survey data as predictors of future expenditures [Lamers, 1999; Pacala et al., 2003]. 
However, more research is needed to refine risk adjustment models for certain Medicare 
subpopulations, such as individuals with functional limitations. Because individuals with AD 
generally have some level of functional impairment, they represent a distinct group for 
examining the performance of various risk adjustment measures (e.g., demographic 
characteristics, diagnoses in medical claims, and functional status from survey data). This 
dissertation provided recommendations for improving the predictive accuracy and usefulness 
of risk adjustment models in the context of predicting future expenditures. Additionally, the 
acquisition, cleaning, and use of medical cost data are often time-consuming and costly for 
health plans and employers [Powers et al., 2005]. This analysis also provides guidance to 
managed care organizations (MCOs) on routinely collecting selective, important risk 
adjustment measures at the individual level. 
 
1.3 Purpose of This Dissertation 
The purpose of this dissertation is to evaluate the following primary policy question: 
How well do current risk adjustment models predict overall and prescription drug 
expenditures for Medicare beneficiaries with AD and how can we improve the existing 
models? In order to answer the primary research question, this dissertation has three specific 
aims, with the first two aims being the foundation for the third. 
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Aim 1.  Improve insight into the identification of community-dwelling individuals with 
AD in observational data 
A concern has been raised about the use of a single measure, such as specific 
diagnosis codes in claims data, to identify community residents with AD. Potential 
underdiagnosis and undercoding in administrative data result in substantial underestimates 
of prevalence, which, in turn, leads to underestimates of the total expenditures for treating AD 
[Rice et al., 2001; Pressley et al., 2003]. This is of particular concern for both payers and 
providers who rely on claims records to determine capitation rates. Aim 1 sought to improve 
existing Alzheimer’s case-finding methodologies by identifying the most sensitive and 
specific alternatives for case ascertainment, and to provide insight on causes of widely-varied 
expenditure estimates in the cost-of-illness literature. 
 
Aim 2.  Investigate the extent of high-expenditure concentration and persistence 
among individuals with AD 
Aim 2 focused on an important risk adjustment measure, prior expenditures, and 
examined whether high-expenditure cases account for a disproportionate share of total 
expenditures among individuals with AD. This dissertation also sought to determine to what 
extent the individuals in high-expenditure percentiles persist from one year to the next and 
what characteristics are associated with persistence. This analysis can help to fill the 
knowledge gap in existing cost-of-illness studies and provide empirical rationale for 
developing AD-specific risk adjustment models.  
 
Aim 3.  Evaluate the performance of commonly-used risk adjustment measures in 
predicting expenditures among individuals with AD 
Aim 3 sought to evaluate the performance of existing risk adjustment models, 
including diagnosis-based and survey-based measures, in predicting overall and drug 
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expenditures. This analysis can provide guidance on refining risk-adjusted capitation 
payment methods for frail Medicare beneficiaries. 
 
1.4 Structure of This Dissertation 
Chapter 2 reviews approaches to identifying individuals with AD from observational 
data and the limitations of existing studies. A literature review of high-expenditure 
concentration and persistence as well as risk adjustment modeling also is presented in 
Chapter 2. These sections are intended to provide background on and justification for this 
dissertation. 
The data source and research design used in this dissertation are presented in 
Chapter 3. This chapter also contains a detailed description of study hypotheses and the 
analysis plans. Chapters 4 through 6 are individual manuscripts, each accomplishing one of 
the three study aims described in Section 1.3. These manuscripts take the place of a single 
results chapter, and each is intended for submission for independent publication. The 
references for the manuscripts are combined with other more general references in a single 
bibliography. Finally, Chapter 7 concludes this dissertation summarizing results and 
providing recommendations for future research and policy implications.
CHAPTER 2 
LITERATURE REVIEW 
This chapter describes the limitations of existing approaches to identifying community 
residents with Alzheimer’s disease (AD) in observational data and highlights the need for 
improving the case-finding methodology. An overview of concentration and persistence in 
health care expenditures then is presented, followed by a review of risk adjustment models, 
applications and the associated limitations. Finally, a conceptual framework adapted from the 
“Algebra of Effectiveness” model [Iezzoni, 2003b] is provided to illustrate variables of interest 
and associations among them. 
 
2.1 Identifying Individuals with AD from Observational Data 
Validly identifying individuals with AD is a foundational step to estimate prevalence 
and costs of the disease. Researchers have employed several different sources of measures, 
such as self or proxy report, diagnosis codes in medical claims, and cognitive screening test, 
to define AD in observational data sets. For instance, self- or proxy-reported AD in survey 
data is easy to use. Individuals are assigned an AD status based on the question “Has a 
doctor ever told you that you had Alzheimer’s disease or dementia?” Kane and Atherly used 
the 1991-1995 Medicare Current Beneficiary Survey (MCBS) to compare the use of Medicare 
covered services for individuals who reported having a diagnosis of AD or dementia with 
those who did not, adjusting for the prevalence of comorbidities and functional limitations 
[Kane and Atherly, 2000]. Based on self report, the estimated prevalence rates of AD or 
dementia were 1.30 for the 65–74 age group, 5.75 for 75–84, and 19.88 for 85 and older per 
100 population; the overall prevalence rate was 6.8 per 100 population for women and 3.93 
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per 100 population for men. 
Hill et al. used the 1995-1998 MCBS to investigate the relationship between the 
degree of functional impairment in individuals with AD or other dementia as well as their 
healthcare expenditures and prevalence of institutionalization in the absence of treatment 
[Hill et al., 2006]. Individuals with AD or dementia were defined as persons who reported 
having an AD or dementia diagnosis, excluding those receiving tacrine or donepezil (i.e., the 
two therapies available for treatment of AD during the study period). This study sample was 
equivalent to between 1.8 and 2 million Medicare members in each of the four calendar years 
in the study period. 
Other researchers have relied on diagnosis codes in medical claims data to identify 
individuals with AD for the purpose of determining the prevalence and cost of the illness. 
Weiner and colleagues used claims files to analyze health care expenditures and utilization 
patterns for Medicare beneficiaries with dementia of the Alzheimer type (DAT), comparing 
with those of all Medicare beneficiaries [Weiner et al., 1998]. International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code of 331.0 in Medicare claims 
was used to define the DAT sample. In fiscal year 1992, 9,323 out of 1,221,615 beneficiaries, 
or 0.76%, in the study had DAT; per capita Medicare expenditures for individuals with DAT 
were $6,208, almost twice as much as the per capita expenditure for all beneficiaries. 
Medicare payments increased with comorbidities, such as heart failure, chronic pulmonary 
diseases, and cerebrovascular disease. This study also suggests that current Medicare 
capitation payments to health plans may not meet the higher expected annual expenditures 
for caring beneficiaries with DAT. 
Hill et al. carried out a retrospective analysis on administrative data for 3,934 
individuals with AD and related dementias (ADRD), compared with 19,300 age/sex-matched 
control subjects enrolled in a large Medicare MCO [Hill et al., 2002]. Individuals with ADRD 
were defined based on diagnoses (ICD-9-CM codes: all 290 codes, 797, 292.82, 291.2, 
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294.1, 294.8, and 331.0-331.2) in medical claims and the National Drug codes (NDC) for 
donepezil during a two-year period. The prevalence of ADRD was 4.4%, substantially higher 
than reported in previous studies of Medicare MCOs. This study also analyzed the 
relationship between comorbidities and costs for individuals with ADRD. Their annual 
expenditures were found 1.6-times higher than individuals without ADRD ($10,723 vs. 
$6,589), after controlling for age, sex and comorbidities. Moreover, health care expenditures 
were even higher for individuals with ADRD who had other comorbid conditions, such as 
diabetes and congestive heart failure. Hill and colleagues’ study suggests that better 
treatment and care management of ADRD may reduce the costs of managing comorbidities 
experienced by the frail elderly. 
On the other hand, Taylor and Sloan argued that using only one or two years of 
claims data to identify individuals with AD may underestimate the prevalence and bias cost 
estimates [Taylor and Sloan, 2000]. They defined Alzheimer’s cases using ICD-9-CM code 
331.0 in the 1994 National Long Term Care Survey merged with a twelve-year (1984-1995) 
period of Medicare claims history. The effect of time since diagnosis on health care 
expenditures was analyzed. Approximately 3.1% of the Medicare population had a 
claims-based diagnosis of AD; their average total annual expenditures were 2.6-times higher 
compared to individuals without an AD diagnosis ($6,021 vs. $2,310 per year, p<0.001). 
In addition, a concern has been raised about the prevalence and cost estimates when 
AD is defined based solely on claims records [Newcomer et al., 1999; Rice et al., 2001; Fillit 
et al., 2002a; Pressley et al., 2003]. Using the Medicare Alzheimer’s Disease Demonstration, 
a longitudinal sample known to have some form of dementia, Newcomer and colleagues 
tested the adequacy of claims data for identifying individuals with DAT (defined by ICD-9-CM 
code: 331.0) and examined biases in expenditure differences between those flagged or not 
flagged by diagnoses using up to 36 months of claims data. Claim-based AD prevalence was 
underestimated substantially because of underreporting chronic conditions in claims files. 
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Specifically, less than 20% of the sample was classified DAT based on a single year of 
claims, whereas 68% actually had an AD diagnosis from a referring physician at the time of 
entering the demonstration program. 
Many mild AD cases are underdiagnosed and, therefore, not coded in claims data 
[Fillit, 2000; Rice et al., 2001]. Rice et al. conducted a literature review on the prevalence, 
costs, and treatment of ADRD, focusing on the economics of the illness from a managed care 
perspective [Rice et al., 2001]. According to the US General Accounting Office (GAO) [1998], 
the prevalence of AD in 1995 was approximately 5.7% among those aged 65 and older. The 
prevalence of dementia in a Medicaid population (i.e., “Medi-Cal”) was estimated at 4%, with 
only 1.1% having an AD diagnosis [Menzin et al., 1999]. Among the studies examined in 
Rice’s review, the prevalence estimates from managed care claims are lower. For instance, 
the prevalence of diagnosed ADRD was only 0.86% among those aged 60 years and older in 
an MCO population [Gutterman et al., 1999]. In addition to data source and methodological 
differences, widely varied prevalence and expenditure estimates, in part, are attributable to 
the choice of diagnosis code. Different coding in medical claims may be influenced by 
reimbursement scheme, which provides few financial incentives for coding AD as the primary 
diagnosis and instead encourages coding comorbidities, such as aspiration pneumonia 
[Newcomer et al., 1999; Fillit, 2000; Rice et al., 2001]. Table 2.1 summarizes the AD 
prevalence estimates in the elderly. 
Poor agreement in AD determination across different sets of measures also was 
observed in an analysis of a nationally representative sample of community-dwelling elderly 
people from the National Long-Term Care Survey data linked with Medicare claims [Pressley 
et al., 2003]. Dementia cases were defined by: 1) survey report; 2) moderate or severe 
impairment as measured on the cognitive screening test (i.e., Short Portable Mental Status 
Questionnaire, SPMSQ); 3) dementia diagnoses in Medicare claims (ICD-9-CM codes: 
290.0-290.4, 291.2, 294.1, 331.0-331.2 and 797); 4) overlapping reports of dementia from at 
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least two measures; or 5) any evidence of dementia based on either survey report, SPMSQ, 
or diagnosis codes. The disease prevalence among individuals 65 years of age or older was 
found to range from 4.5% to 16.8% across the five measures; the kappa coefficient 
measuring agreement in case identification was low, ranging from 0.15 to 0.41. Because the 
non-overlapping cases (i.e., individuals identified in only one data source) also were validly 
determined, the authors argued that these cases should not be excluded or considered 
separately just because they were not explicitly identified in another measure. Considering 
that different measures may define different subsets of individuals with AD, the use of any 
single source of measure is likely to fail to capture the burden of AD at the population level. 
Highly variable prevalence and cost estimates, in part, are attributable to lack of a 
uniformly accepted definition of AD or a gold standard diagnostic test [Bloom et al., 2003]. 
Researchers have suggested using supplements to claims data, such as procedure codes, 
interviews, medical record reviews, and physician reports, in case ascertainment [Newcomer 
et al., 1999]. This dissertation assessed the sensitivity and specificity of three measures, 
including self report, Medicare claims, and Alzheimer’s medications use, to provide greater 
confidence in case determination (Chapter 4). 
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Table 2.1: Summary of AD prevalence rates in elderly population 
 
Author (Year) Population Sample Case definition Prevalence estimate 
Newcomer et al. (1999) Medicare DAT  ICD-9-CM: 331.0 < 20% of the sample 
was classified DAT, 
whereas 68% had an 
AD diagnosis 
Kane and Atherly (2000) Medicare AD or 
dementia 
Survey report 1.3% in age 65-74, 
5.75% in 75-84, and 
19.88% in age 85+  
Taylor and Sloan (2000) Medicare AD ICD-9-CM: 331.0 3.1% 
Hill et al. (2002) Medicare 
MCO 
ADRD ICD-9-CM: all 290 
codes, 797, 292.82, 
291.2, 294.1, 294.8, 
and 331.0-331.2; 
NDC for donepezil 
4.4% 




receiving tacrine or 
donepezil 
Equivalent to 1.8-2 
million Medicare 
members each year 
Additional studies reviewed by 
Rice et al. (2000) 
    
US General Accounting Office 
(1998) 
General AD Literature review and 
population estimates 
5.7% 
Weiner et al. (1998) Medicare DAT ICD-9-CM: 331.0 0.76% 










290.9, 294.9, 331.2, 
331.89, 331.9, and 
797 
4% 
Gutterman et al. (1999) Medicare 
MCO 
ADRD ICD-9-CM: all 290 
codes, 797, 292.82, 
291.2, 294.1, 294.8, 
331.0, 331.1, 331.2 
0.83% 
AD: Alzheimer’s disease; ADRD: Alzheimer’s disease and related dementias; DAT: dementia of the Alzheimer type; ICD-9-CM: 
International Classification of Diseases, 9th Revision, Clinical Modification; MCO: managed care organization; NDC: National 
Drug Codes.  
 
2.2 Concentration and Persistence in Health Care Expenditures 
The use of health care services in the U.S. is highly concentrated (i.e., the majority of 
expenditures are incurred by a relatively small group of individuals). Using the 1996 Medical 
Expenditure Panel Survey (MEPS), Berk and Monheit examined the distribution of health 
care expenditures, in terms of the share of aggregate expenditures accounted for by the top 
spenders, in a nationally representative sample [Berk and Monheit, 2001]. The top 1% of 
individuals used 27% of overall health expenditures and the top 5% accounted for more than 
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half of health expenditures. Such a right-skewed distribution remained stable since the 1970s. 
Among Medicare beneficiaries, Garber and colleagues demonstrated that the top 1% of 
individuals accounted for nearly 20% of overall Medicare expenditures, and that the portion 
of expenditures attributable to this group appeared to increase over time [Garber et al., 1997]. 
Moreover, individuals with high expenditures in one year were likely to have 
higher-than-average expenditures in other years. 
In line with previous studies, managed care expenditures also were found to be highly 
concentrated in a small group of people. An analysis examined the model sensitivity and 
specificity of forecasting high-expenditure users in a random sample of enrollees from three 
staff/group health plans [Meenan et al., 1999]. The most expensive 1% of users represented 
25% of total expenditures in this sample. Using similar approaches, another study by 
Meenan et al. identified high-expenditure members using data from six health maintenance 
organizations (HMOs) [Meenan et al., 2003]. In this sample, the most expensive 0.5% and 
1% of cases represented 20% and 29%, respectively, of total expenditures. 
This consistent trend of expenditure concentration has motivated researchers to 
investigate to what extent individuals in high expenditure percentiles persist from one year to 
the next. Russell and Chaudhuri evaluated the inequality of medical expenditures for several 
years using data collected from the Rand Health Insurance Experiment [Russell and 
Chaudhuri, 1992]. The experiment studied a nonelderly population covered by employer 
health plans for periods up to five years. In any given year, individuals in the top 5% of 
expenditure distribution accounted for approximately 50% of total spending. However, the 
expenditure persistence decreased when longer periods were examined. The proportion of 
total expenditures accounted for by the top 5% only represented 40% of total expenditures in 
the subsequent year. 
In an analysis of risk adjustment models for individuals with high utilization of public 
mental health care, the correlation coefficients for mental health and substance abuse 
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expenditure were examined by type of expenditure and by year [Kapur et al., 2000]. 
Administrative data of severely mentally ill persons were drawn from the Los Angeles County 
Department of Mental Health for the fiscal years 1991 to 1994. All expenditures exhibited a 
relatively stable correlation over time, although the correlation was somewhat smaller for 
outpatient expenditures than for inpatient and total expenditures. 
Persistence in the top percentiles of health care expenditures may be distributed 
randomly or may be correlated with personal characteristics or previous expenditures and, 
therefore, can be predicted. In an analysis of a longitudinal panel of the MEPS data, Monheit 
investigated the extent of high-expenditure persistence over a two-year period [Monheit, 
2003]. Of the individuals in the top 5% of the expenditure distribution in 1996, 30% remained 
in this group and 45% were in the top 10% in 1997. Cancer, mental disorders, diabetes, 
infectious diseases, and being in the top decile (i.e., 10%-tile) of the expenditure distribution 
in the prior year increased the probability of expenditure persistence. However, when 
considering all individuals in the high-expenditure group in a given year, expenditures 
appeared to regress to the mean, meaning that the lower-expenditure cohorts increase and 
the higher-expenditure cohorts decrease their expenditures (towards the group mean) over 
time [Beebe, 1988; Barnett et al., 2005]. For instance, individuals who were in the top 5% of 
the expenditure distribution in 1996 accounted for 55.9% of aggregate expenditures but only 
25% in the next year. 
The high-expenditure concentration and persistence phenomenon also is observed in 
children. Liptak et al. analyzed data from two consecutive years of the MEPS and investigated 
whether high-expenditure children continue to accrue high expenditures over time [Liptak et 
al., 2006]. Of the total of 2,938 children, the top 10% accounted for 54% of all expenditures in 
2000. Almost half of the children in the top 10% in 2000 persisted in that position in 2001, 
whereas 12% moved into the bottom half. Children in the top 10% in 2000 were ten times 
more likely their peers to be in the top 10% in the next year. 
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Not only overall health care expenditures, but also drug spending exhibits persistence 
over time, especially in the elderly population. Two studies in the early 1990s examined the 
persistence in drug expenditures using claims data from the Pennsylvania Pharmaceutical 
Assistance Contract for the Elderly program [Stuart et al., 1991; Coulson and Stuart, 1992]. 
Evidence suggests a strong degree of persistence in prescription drug expense by the elderly, 
particularly among the heaviest users. In the regression models predicting future drug 
expenditures, past use was found to have substantial predictive power for present use, much 
stronger than the effect of sociodemographic characteristics. Coulson and Stuart also 
demonstrated that regression to the mean may take more than four years to complete when 
assessing the persistence in pharmaceutical use by the elderly. In the short run, the two 
highest-expenditure cohorts were found to be well above the overall mean, and the three 
lowest cohorts were still well below the group mean. 
Persistence in drug expenditures also is observed in a nationally representative 
sample of Medicare beneficiaries. Wrobel et al. evaluated the predictability of drug 
expenditures using the 1999-2000 Medicare Current Beneficiary Survey (MCBS) [Wrobel et 
al., 2003]. Predictors included demographic characteristics, health status, and prior drug 
expenditures. Demographic variables in 1999 explained only 5% of the variation in drug 
expenditures in 2000; adding health status measures increased the adjusted R2 to 10%-24%. 
Furthermore, incorporating lagged drug expenditures (i.e. drug expenditures in 1999) raised 
the explanatory power to 55%. 
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Table 2.2: Summary of concentration and persistence in overall health care 
expenditures and pharmacy expenditures 
 
Author (Year) 









The top 1% of spenders used 27% of health care 
resources; the top 5% accounted for more than half of 
health expenditures. 
Garber et al. 
(1997) 
Medicare enrollees  The top 1% of users accounted for nearly 20% of 
Medicare expenditures; that the portion of expenditures 
attributable to this group appeared to increase over 
time. 
 High-expenditure individuals in one year were likely to 
have higher-than-average expenditures in other years. 
Meenan et al. 
(1999) 
Managed care The top 1% of users represented 25% of total expenditures. 




The top 0.5% and 1% of users represented 20% and 29%, 











The top 5% of users accounted for 50% of total 
expenditures. 
Kapur (2000) Severely mentally ill 
persons with high 
utilization of public 
mental health care 
Total, inpatient and outpatients expenditures all exhibited 
stable correlation over time. 





 Of the top 5% of users in 1996, 30% remained in this 
group and 45% were in the top 10% of users in 1997. 
 Those who were in the top 5% of users in 1996 
accounted for 55.9% of aggregate expenditures but 
only 25% in the next year. 








 The top 10% of the children in 2000 accounted for 54% 
of all expenditures. 
 Almost half of the children in the top 10% in 2000 
persisted in that position in 2001, whereas 12% moved 
into the bottom half. 
 Children in the top 10% in 2000 were ten times more 
likely their peers to be in the top 10% in the next year. 
High-expenditure persistence in pharmacy spending 







for the Elderly 
 A strong degree of persistence in prescription drug 
expenditures by the elderly, particularly among the 
heaviest users. 
 Past drug spending had substantial predictive power for 
present expenditures. 
Wrobel (2003) Medicare Current 
Beneficiary Survey 
Incorporating prior drug expenditures substantially raised 
explanatory power of the model predicting drug 
expenditures in the subsequent year. 
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As summarized in Table 2.2, results from these studies generally demonstrate that a 
small proportion of individuals account for a disproportionately large share of health care 
expenditures, and that a small group exhibits persistently high expenditures. However, it is 
unclear whether the same pattern of expenditure concentration and persistence holds in 
individuals with AD given that this population has substantially more functional disabilities 
and greater burden of comorbidities. The uneven distribution may suggest that some groups 
obtain excessive care with benefits not commensurate with expenditures, whereas other 
groups underuse medical care. Understanding the dynamics of expenditure distribution can 
help decision makers plan equitable health insurance strategies, such as catastrophic care, 
carve-outs, reinsurance, and risk adjustment [Liptak et al., 2006]. Moreover, understanding 
the characteristics that predict persistence can be used as a management tool to help health 
plans identify individuals at risk of accruing high expenditures earlier in the process, and 
target members for intensive disease management and better care coordination [Russell and 
Chaudhuri, 1992; Ash et al., 2001]. 
 
2.3 Predictive Modeling and Risk Adjustment Measures 
Predictive modeling increasingly has been used to forecast health care services use 
and expenditures in managed care [Pope et al., 2000; Powers et al., 2005; Zhao et al., 2005]. 
One of the most important applications of predictive models is for risk-adjusted payment 
systems. The Balanced Budget Act of 1997 required the Centers for Medicaid and Medicare 
Services (CMS, formerly Health Care Financing Administration [HCFA]) to implement 
risk-adjusted Medicare capitation payments for managed care plans by January 1, 2000, in 
order to fairly compensate health plans for the expected costs associated with the disease 
burden of their enrollees. CMS first adopted a form of risk adjustment based on inpatient 
hospital diagnoses (i.e., principal inpatient diagnostic cost groups system, PIPDCG) [Pope et 
al., 2000]. Beginning 2004, the CMS applied Medicare-specific modifications to the 
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Diagnostic Cost Group-Hierarchical Condition Category (DCG-HCC) model, which 
incorporates both inpatient and outpatient claims, as the new risk adjustment capitation 
payment system (hereafter known as CMS-HCC). Some states, such as Maryland, Colorado, 
Oregon, Delaware, Utah, Minnesota and Michigan, also use diagnosis-based classification 
systems to make risk-adjusted capitation payments for beneficiaries with disabilities or who 
receive Temporary Assistance to Needy Families (TANF) [Kronick et al., 2000]. 
Without risk adjustment, payers using the capitation payment methods are likely to 
overpay (or underpay) providers for healthier beneficiaries (or sicker groups). If payers do not 
reimburse more money to providers who serve enrollees with above-average levels of health 
care needs, plans will be penalized for attracting sicker individuals and quality of care may be 
jeopardized [Kronick et al., 2000]. On the other hand, without adequate payment adjustment, 
potential adverse selection problems may lead health plans to “enroll the healthy and spurn 
the sick” [Newhouse et al., 1997]. 
The following sections review commonly used risk adjustment models and how they 
are used in health care settings, with a special emphasis on elucidating the limitations of 
these models and the need for further refinement. 
 
2.3.1 Risk Adjustment Models 
Risk adjustment models generally use regression modeling techniques to predict 
outcomes (e.g., health care expenditures). The models differ from each other in the 
characteristics used to explain expenditures and how this information is organized in the 
classification system [Greenwald, 2000]. This dissertation evaluated the performance of 
various risk adjustment measures, including diagnoses in medical claims, functional status 
from survey data, and prior expenditures, in predicting future expenditures. Operational 
details of these risk adjustment measures are described in Section 3.7. 
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Studies have examined various risk adjusters, such as diagnoses [Ellis et al., 1996; 
Meenan et al., 1999; Ash et al., 2000; Pope et al., 2000; Riley, 2000; Meenan et al., 2003; 
Hughes et al., 2004; Pope et al., 2004; Noyes et al., 2006], pharmacy claims data [Von Korff 
et al., 1992; Fishman et al., 2003; Powers et al., 2005], prior utilization [Ash et al., 2001; 
Monheit, 2003], health status from survey data [Epstein and Cumella, 1988; Fowles et al., 
1996; Pope et al., 1998; Lamers, 1999; Temkin-Greener et al., 2001; Pacala et al., 2003; 
Kautter and Pope, 2004; Fleishman et al., 2006]], or some combination thereof [Zhao et al., 
2001; Maciejewski et al., 2005; Zhao et al., 2005; Farley et al., 2006]. Table 2.3 summarizes 
the main findings of these risk adjustment studies. 
Studies focusing on diagnosis-based measures 
Using 1991-1992 data for a 5% Medicare sample, Ellis and colleagues evaluated risk 
adjustment models that used diagnoses from both inpatient and ambulatory claims to adjust 
payments for aged and disabled Medicare enrollees [Ellis et al., 1996]. Hierarchical 
coexisting conditions (HCC) models achieved greater explanatory power than DCG models 
by taking account of multiple coexisting medical conditions (adjusted R2 = 8.08 and 6.34, 
respectively). Although more than 90% of the variation in Medicare payments was left 
unexplained, the authors argued that their best-performing models may account for nearly 
half of the explainable variation, given that a maximum explainable portion of medical 
expenditure variation is estimated to be 20-25% [Newhouse, 1996]. 
Pope et al. described the model HCFA used in 2000, known as the PIPDCG, and 
assessed its performance [Pope et al., 2000]. The PIPDCG model calculates each 
beneficiary's relative risk factor by taking into account his/her demographic characteristics 
and the principal medical condition that led to an inpatient admission. Relying on the single 
most predictive inpatient diagnosis only, this model had an R2 of 6.2%, approximately 
two-thirds of the performance of Ellis and colleagues’ model [1996]. PIPDCG predicted 
expenditures more accurately than the model with demographic information and prior-year 
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expense, especially for high-cost cases. For instance, among the beneficiaries with the top 
1% of prior expenditures, the PIPDCG model predicted expenditures that were 47% of actual 
expenditures, as opposed to only 19% by the demographic model. They concluded that the 
PIPDCG is a conservative model focusing on the most severely ill and expensive hospital 
events. The authors concluded that more refined and comprehensive models can be 
implemented as more experience is gained with risk adjustment. 
Ash and colleagues described the structure and examined the performance of a 
diagnosis-based model, DCG-HCC, as developed and validated on three databases (i.e., 
privately insured, Medicaid, and Medicare) [Ash et al., 2000]. DCG-HCC is different from the 
single-condition PIPDCG model in that the hierarchies are formed to reflect chronic and 
serious acute manifestations of particular diseases, as well as their impact on expected 
expenditures. The model’s explanatory power measured by R2 ranged from 8% to 20% 
across the three populations. This study demonstrated that the DCG-HCC characterized the 
disease burden of populations and predicted future resources use, and that the model 
predictions can help payers to establish fair risk-adjusted payments. 
Using the 1991-1994 MCBS data, Riley examined the adequacy of two 
diagnosis-based risk adjusters, PIPDCG and DCG-HCC, for paying health plans that 
disproportionately enroll frail Medicare beneficiaries, defined by institutional status and by 
difficulty with activities of daily living (ADLs) [Riley, 2000]. Both models were found to 
over-predict average expenditures for unimpaired beneficiaries and to under-predict average 
expenses for community-dwelling beneficiaries with functional impairments. The degree of 
under-prediction increased with number of ADL limitations, which were associated with 
Medicare expenditures, but not fully captured in demographic characteristics or diagnosis 
profiles. The authors concluded that functional status may be an appropriate proxy for 
disease severity; further refinements are needed if diagnosis-based models are used to 
make capitation payments to plans that disproportionately enroll frail beneficiaries. 
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The developers of the CMS-HCC described the model's principles, elements, 
organization, calibration, and performance in detail [Pope et al., 2004]. CMS-HCC was 
implemented in 2004 to adjust Medicare capitation payments to private health care plans for 
the health expenditure risk of their enrollees. The R2 was 9.8% for the CMS-HCC model that 
used demographic variables plus hospital and physician claims. The authors concluded that 
the model improved the predictive accuracy of health care expenditures compared with 
previous models both in the general Medicare population and in subpopulations, such as 
beneficiaries entitled by disability, community vs. institutional residents, and new enrollees. 
Accurate prediction for the frail elderly is a particularly important issue for MCOs 
whose models of care focus on the elderly in greatest need. Beginning in 2004, 
frailty-adjusted Medicare payments were applied to MCOs, such as Program of All Inclusive 
Care for the Elderly, Wisconsin Partnership Program, and Minnesota Senior Health Options, 
that specialize in providing care to the community-residing frail elderly. Kautter and Pope 
documented the development of the CMS frailty adjustment model, a Medicare payment 
approach that adjusts payments to MCOs according to the functional impairment of its 
community-residing enrollees [Kautter and Pope, 2004]. In the absence of frailty adjustment, 
the CMS-HCC model would under-predict Medicare expenditures by an average of $4,923, 
$1,531, and $809, respectively, for beneficiaries with 5-6, 3-4, and 1-2 impairments of ADLs, 
and over-predict by $697 for those with no ADL difficulties. The CMS frailty adjuster improved 
the explanatory power of the CMS-HCC model by 11%. They suggested that frailty 
adjustment could be applied to more Medicare MCOs in the future. 
Kronick and colleagues developed the Chronic Illness and Disability Payment System 
(CDPS), a diagnostic classification system that used by many Medicaid programs to make 
health-based capitation payments for beneficiaries with disabilities or persons receiving 
Temporary Assistance to Needy Families (TANF) [Kronick et al., 2000].The developers of the 
CDPS analyzed claims data of seven state Medicaid programs and found that, for 
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beneficiaries with disabilities, the CDPS had a higher explanatory power than the DCG-HCC 
model (R2 = 18.3% vs. 14.3%, respectively), and almost twice that of the Adjusted Clinical 
Group (ACG) model (R2 = 18.3% vs. 9.8%, respectively). Overall the predicted expenditures 
in the subsequent year were very close to the actual expenditures (with slightly 
under-prediction for the plans with sick enrollees and over-prediction for the plan with healthy 
enrollees). The CDPS has a modified version which is more appropriate to predict 
expenditures for Medicare beneficiaries (hereafter known as CDPSM) [Kronick et al., 2002]. 
However, the CDPS does not show consistently superior performance across 
populations. Cumming et al. compared several currently available risk adjusters using claims 
data for a nationwide mix of preferred provider organizations (PPO) and HMO commercial 
employer group business [Cumming et al., 2002]. The CDPS model had a R2 of 10.3% with a 
mean absolute prediction error of $2,299 (equal to 1.03 times the actual mean of $2,232), 
compared to DCGs with R2 of 14.3% and a mean absolute prediction error of $2,187 (0.98 
times actual mean). 
Unlike previous studies evaluating various diagnosis-based risk adjustment models 
for the overall Medicare population, Noyes et al. examined the accuracy of CMS-HCC in a 
disease-specific context for beneficiaries with Parkinson’s disease, a high-expenditure group 
with substantial disabilities [Noyes et al., 2006]. Using the 1992-2000 MCBS, this study 
demonstrated that, for the general Medicare population, the CMS-HCC model over-predicted 
medical expenditures for individuals without functional limitations by 15.58%. Expenditures 
were under-predicted as the level of disability increased, from 14.5% for individuals with 1-2 
ADL limitations to 33.1% with 5-6 ADL limitations. However, such relationship was not 
observed for individuals with Parkinson’s disease. The CMS-HCC predictions were no more 
than 10% off from the actual Medicare expenditures. At all ADL impairment levels, no 
statistically significant difference was detected between the actual cost ratios and ratios 
predicted by the CMS-HCC. In contrast with Kautter and Pope’s conclusions, Noyes et al. 
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concluded that health plans covering mainly individuals with Parkinson’s disease would be 
compensated fairly if the CMS-HCC payment model were applied. 
In addition to making capitation payments, risk adjustment models can be used to 
identify proactively high-risk, high-expenditure plan enrollees for disease management 
programs. Meenan et al. compared the ability of three risk adjustment models to predict 
enrollees’ high- and low-expenditure status in the subsequent year within a managed care 
population [Meenan et al., 1999]. Models examined included the Global Risk Assessment 
Model (GRAM) developed at the Kaiser Permanente Center for Health Research, a logistic 
version of GRAM, and a model based on prior expenditures. GRAM is a diagnosis-based 
model that incorporates demographic characteristics as well as classification of ICD-9-CM 
diagnoses from inpatient and outpatient encounter records. Judging by the receiver operating 
characteristic (ROC) curves, which illustrate the tradeoff between true positives (sensitivity) 
and false positives (1-specificity) across different high-expenditure thresholds, GRAM had 
better predictive accuracy in discriminating high- and low-expenditure individuals than did its 
comparators. 
Another study by Meenan and colleagues evaluated the performance of five risk 
adjustment models, including GRAM, DCGs, ACGs, RxRisk (a model based on outpatient 
prescription drug fills), and prior expenditures, to identify high-expenditures individuals in an 
overall managed care population and within certain demographic subgroups, such as 
enrollees over 64, children under 13, and Medicaid recipients [Meenan et al., 2003]. They 
also applied the risk adjustment models to three disease groups amenable to case 
management: asthma, diabetes and depression. All models except RxRisk had comparably 
good discrimination ability (i.e., the area under the ROC: 0.83-0.86). GRAM and DCGs 
captured the largest proportion of total expenditures. Identifying high-risk, high-expenditure 
individuals is an important application of risk adjustment models. This is more useful for 
targeting individuals with particular chronic disease in which case management has been 
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shown effective, as opposed to identifying “generic” high-expenditures members. For 
individuals with AD who have multiple comorbidities, MCOs have many opportunities to 
implement interventions for improving health outcomes and lowering expenditures, including 
the use of appropriate medications (e.g., cholinesterase inhibitors), care coordination by 
nurse case managers and/or primary care physicians (e.g., discharge planning specific to 
AD), and education, counseling and support for caregivers [Fillit et al., 2002b; Kaufer et al., 
2005]. 
Studies focusing on pharmacy-based measures 
In addition to diagnoses, pharmacy data have been used in risk adjustment. Von Kroff 
and colleagues utilized patterns of use of selected prescription medications during a one year 
time period to construct the Chronic Disease Score (CDS) [Von Korff et al., 1992]. They 
concluded that scoring automated pharmacy data can provide a stable measure of chronic 
disease status that is associated with physician-rated disease severity and patient-rated 
health status, and is predictive of subsequent mortality and hospitalization rates, after 
controlling for age, gender and health care visits. 
Fishman et al. developed and estimated the RxRisk model, a risk adjustment 
technique that uses automated ambulatory pharmacy data to identify chronic conditions and 
predict future health care costs [Fishman et al., 2003]. The RxRisk model's performance in 
predicting subsequent-year expenditures was compared with a demographic model and two 
diagnosis-based models (i.e., ACG and DCG-HCC). The DCG-HCC produced more accurate 
forecasts of total expenditures than its comparators, explaining 15.4% of the expenditure 
variation, whereas only 8.7% and 10.2% were accounted for by RxRisk and ACGs, 
respectively. However, all three models had similar predictions for the middle 60% of the 
expenditure distribution. The authors concluded that the pharmacy-based RxRisk is an 
alternative risk adjustment instrument to diagnostic-based models; depending on the nature 
of the application, pharmacy-based models may be an appropriate option for risk adjustment. 
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Powers and colleagues evaluated the performance of the Pharmacy Health 
Dimensions (PHD) model, which incorporates 51 drug categories classified based on 
pharmacy claims, age, gender, and drug expenditures in the baseline year to predict annual 
total health expenditures in follow-up year [Powers et al., 2005]. Several model specifications, 
including ordinary least squares (OLS) regression, log-transformed OLS regression with 
smearing estimator, and three two-part models using OLS regression, log-OLS regression 
with smearing estimator, and generalized linear modeling (GLM), respectively, were 
examined. They concluded that the PHD model derived solely from pharmacy claims data 
can be used to predict future total health expenditures. Using PHD with a simple OLS model 
may provide similar predictive accuracy in comparison to more advanced econometric 
models. 
Studies focusing on prior expenditures 
As with diagnosis and pharmacy data, prior expenditures are highly correlated with 
expenditures accrued in the next year [Garber et al., 1997; Pope et al., 1998]. Ash et al. 
[2001] compared prior expenditures with diagnosis-based methods for identifying a very 
small subgroup of a general population with high future expenditures (e.g. top 0.5%) that may 
be mitigated with medical management. Diagnosis-based risk models were found at least as 
powerful as prior expenditures for identifying future high-expenditure cases. The author 
concluded that combining expenditure and diagnosis data may be more powerful and more 
operationally useful for targeting the medical problems that may be managed to achieve 
better outcomes and lower costs. However, inclusion of prior expenditures in a prospective 
risk adjustment model to set payment might not be practical because of the perverse 
incentives created [Ash et al., 2000; Greenwald, 2000; Ash et al., 2001]. For instance, 
models that identify illness only through hospitalizations favor admissions, and models that 
pay more for high spenders encourage both appropriate and inappropriate, unnecessary 
services. 
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Studies focusing on survey-based health status 
In addition to diagnosis information, pharmacy data, and prior expenditures, 
researchers have used health status from survey data as a predictor of future expenditures. 
Fowles et al. [1996] compared the performance of different health status measures, such as 
functional ability and chronic conditions, for risk-adjusted capitation methods in a sample of 
the group-network HMO in Minnesota. Capitation adjustment based solely on demographic 
characteristics was found to perform poorly, whereas both survey-reported health status and 
diagnoses predicted future expenditures twice as better as the demographic model. When 
predicting expenditures for groups rather than individuals, the demographic model worked 
well for overall average but tended to over-predict expenditures for healthier groups and 
under-predict sicker groups. In this HMO sample, the diagnosis-based ACG model performed 
better than survey-reported health status and across healthier and sicker groups. 
Lamers evaluated the performance of the DCG capitation model using data from a 
health survey of Dutch sickness fund members [Lamers, 1999]. Using stepwise regression 
procedures, relevant survey variables that could improve the predictive accuracy of the DCG 
model were identified. Results from this study showed that predictive accuracy of the model 
was improved further by incorporating a subset of survey variables, including perceived 
health, having functional limitations, consultation with general practitioners, used of home 
nursing, number of prescription medications used, cancer, diabetes, and use of rheumatoid 
arthritis medicine. 
Pacala et al. conducted a mailed survey to collect data, such as demographic 
characteristics, general health, life style, and use of health care, to predict future 
expenditures for community-dwelling Medicare beneficiaries [Pacala et al., 2003]. The 
predictive ratios (i.e., predicted-to-actual expenditures) for the low-expenditure individuals 
were 0.97 for the health status model method and 1.37 for the PIPDCG method; for the 
high-expenditure group, the ratios were 1.01 for the health status model and 1.06 for the 
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PIPDCG, suggesting that PIPDCG was more likely to over-predict future expenditures. The 
authors concluded that survey-based health status was at least as accurate as the 
diagnosis-based PIPDCG model to adjust capitation payments to Medicare+Choice plans. 
The difference in accuracy between the two methods was greatest in relatively healthy and 
low-expenditure beneficiaries. 
Studies comparing a comprehensive array of risk adjustment measures 
Many advances in risk adjustment methodology have been made over the past 
decade. Researchers sought to evaluate a comprehensive array of adjustment models, 
including diagnoses, health status, and prior expense, either alone or in combination for 
predicting health care expenditures. Zhao et al. used inpatient encounter data (i.e., inpatient 
only DCG-HCC) and outpatient pharmacy claims (i.e., RxGroups) to forecast 
subsequent-year health care expenditures in a privately insured, non-elderly population [Zhao 
et al., 2001]. Both models performed comparably overall; RxGroups performed better in terms 
of identifying a group of truly low-expenditure individuals, whereas the inpatient DCG-HCC 
model was superior in finding a small group with extremely high future expenditure. The 
best-performing model comprised both inpatient diagnoses and pharmacy data and explained 
11.2% of variation in future expenditure, higher than either model alone, suggesting that 
properly combining pharmacy and inpatient diagnoses data is promising for predicting future 
expenditure. 
An updated analysis by Zhao et al. found that models using both pharmacy and 
diagnosis data best predicted subsequent-year total health care expenditures (adjusted R2 = 
16.8% vs. 11.6% for RxGroup and 0.146 for DCG-HCC), and had higher predictive accuracy 
measured by predictive ratios (0.95-1.05) for subgroups with major medical conditions [Zhao 
et al., 2005]. Pharmacy-based models predicted future drug spending better than 
diagnosis-based models (adjusted R2 = 48.2% vs. 24.3%), whereas diagnosis-based models 
predicted total expenditures (adjusted R2 = 14.6% vs. 11.6%) and other medical expenditure 
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(adjusted R2 = 11.6% vs. 7.1%) better than pharmacy-based models. This study suggested 
that combined drug and diagnostic data predicted total health care expenditure better than 
either type of data alone. Diagnosis-based models are more useful than pharmacy data for 
predicting overall and medical expenditures. 
Using Veterans Affairs (VA) data, Maciejewski and colleagues [2005] examined the 
performance of various risk adjustment models, including five diagnosis-based techniques 
(i.e. Charlson Comorbidity Index, ACG, DCG-HCC, Chronic Illness and Disability Payment 
System, and RxRisk-V), two survey-reported health status measures (i.e., SF-36 and Seattle 
Index of Comorbidity [SIC]), and prior expenditures, for predicting outpatient, inpatient, and 
total expenditures. In this VA sample, diagnosis-based measures had better predictive ability 
than survey-reported measures. Specifically, the best-performing model, DCG-HCC, 
accounted for 7.2% of total expenditure variation, higher than its comparators. Prior 
outpatient expenditures predicted a substantial part of subsequent-year outpatient 
expenditures (adjusted R2 = 42%). In line with previous findings, models with combined 
measures were found to have the best overall predictions, smaller over-prediction for 
low-expenditure groups, and smaller under-prediction for individuals with extremely high 
expenditures. 
In a managed care population, Farley et al. [2006] compared various comorbidity 
measures to predict healthcare expenditures: two diagnosis-based models (i.e., Elixhauser 
and Charlson Comorbidity Index), one pharmacy-based measure (i.e., RxRisk-V), and 
several simple count measurements, including counts of prescriptions, physician visits, 
hospital claims, unique prescription classes, and diagnosis clusters. The Charlson 
comorbidity index and the Elixhauser index performed similarly (adjusted R2 = 11.7% and 
11.5%, respectively), whereas the pharmacy-based RxRisk-V (adjusted R2 = 15.7%) 
outperformed both indices. An age- and gender-adjusted regression model that included a 
count of diagnosis groups was the best individual predictor of expenditures (adjusted R2 = 
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18.1%). They concluded that simple count measures appear to predict future expenditures 
better than the comorbidity indices. 
As summarized in Table 2.3, these studies generally support the claim that combined 
models (i.e., diagnoses plus other measures) explain more variation in expenditures and 
improve predictive power, relative to single-measure models (i.e., diagnoses alone). 
Combining diagnosis and expenditure data are more powerful and operationally useful in that 
the diagnostic information identifies the medical problems that may be amenable to disease 
management; thus, better outcomes and lower expenditures can be expected [Ash et al., 
2001; Maciejewski et al., 2005]. However, further refinements are necessary to improve 
predictions for particular subgroups, such as individuals with functional impairments. 
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Table 2.3: Summary of risk adjustment studies 
 
Author (Year) Setting 
Risk Adjustment 
Models Conclusions 
Studies focusing on diagnosis-based measures 
Ellis et al. 
(1996) 
Medicare DCG; DCG-HCC DCG-HCC models achieved greater explanatory 
power than DCG models by taking account of 
multiple coexisting medical conditions. 
Pope et al. 
(2000) 
Medicare Age and gender; 
PIPDCG; prior 
expense 
PIPDCG is a conservative model focusing on the 
most severely ill and expensive hospital events. 
Further refinements are needed for improving 
risk adjustment. 




DCG-HCC DCG-HCC characterized the disease burden of 
populations and predicted future resources use; 
the model predictions can help payers to 
establish fair risk-adjusted payments. 




Both PIPDCG and DCG-HCC over-predicted 
average expenditures for unimpaired 
beneficiaries and under-predicted average 
expenses for those with functional impairments. 
Further refinements, such as taking into account 
functional limitations, are needed if 
diagnosis-based models are used to make 
capitation payments to plans that 
disproportionately enroll frail beneficiaries. 
Kronick et al. 
(2000) 
Medicaid CDPS, DCG-HCC CDPS had a higher explanatory power than the 
DCG-HCC or the ACG model. Overall the 
CDPS-predicted expenditures in the subsequent 
year were very close to the actual expenditures 
Cumming et 
al. (2002) 
PPO and HMO ACG, CDPS, DCG CDPS had higher explanatory power and 
smaller mean absolute prediction error 
compared with DCGs. 




CMS-HCC improved the predictive accuracy of 
health care expenditures compared with 
previous models both in the general Medicare 
population and in subpopulations. 
Kautter and 
Pope (2004) 
Medicare CMS-HCC and 
frailty adjustment 
In the absence of frailty adjustment, the 
CMS-HCC model would under-predict Medicare 
expenditures for beneficiaries with ADL 
impairments, and over-predict expenditures for 
those with no ADL difficulties. The CMS frailty 
adjuster improved the explanatory power of the 
CMS-HCC model by 11%. 






CMS-HCC For the general Medicare population, CMS-HCC 
over-predicted medical expenditures for 
individuals without functional limitations and 
under-predicted the expenditures as the level of 
disability increased. However, for patients with 
Parkinson’s disease, the CMS-HCC predictions 
were no more than 10% off from the actual 
Medicare expenditures. 
Meenan et al. 
(1999) 
Managed care GRAM; logistic 
GRAM; prior 
expenditures 
GRAM had better predictive accuracy in 
discriminating high- and low-expenditure 
individuals than did its comparators. 
Meenan et al. 
(2003) 
Managed care GRAM; DCG; 
ACG; RxRisk; prior 
expense 
All models except RxRisk had comparably good 
discrimination ability. The high-expenditure 
cases correctly predicted by GRAM and DCGs 
 32 
Author (Year) Setting 
Risk Adjustment 
Models Conclusions 
captured the largest proportion of total 
expenditures. 
Studies focusing on pharmacy-based measures 
Von Kroff et 
al. (1992) 
HMO CDS Automated pharmacy data can provide a stable 
measure of chronic disease status that is 
associated with physician-rated disease severity 
and patient-rated health status, and is predictive 
of subsequent mortality and hospitalization 
rates. 
Fishman et al. 
(2003) 
HMO Age and gender; 
ACG; DCG-HCC; 
RxRisk 
The pharmacy-based RxRisk is an alternative 
risk adjustment instrument to diagnostic-based 
models; depending on the nature of the 
application, pharmacy-based models may be an 
appropriate option for risk adjustment. 
Powers et al. 
(2005) 
HMO Age and gender; 
PHD; prior drug 
expenditures 
The PHD model derived solely from pharmacy 
claims data can be used to predict future total 
health costs. Using PHD with a simple OLS 
model may provide similar predictive accuracy in 
comparison to more advanced econometric 
models. 
Study focusing on prior expenditures 
Ash et al. 
(2001) 
HMO Prior expenditures; 
DCG 
Diagnosis-based risk models are at least as 
powerful as prior expenditures for identifying 
future high-cost cases. Combining expenditure 
and diagnosis data may be more powerful and 
more operationally useful for targeting the 
medical problems that may be managed to 
achieve better outcomes and lower 
expenditures. 
Studies focusing on survey-based health status 
Fowles et al. 
(1996) 
HMO Age and gender; 
ACG; SF-36 
Risk adjustment using the diagnosis-based 
ACGs model performed better than 
survey-reported health status and across 
healthier and sicker groups. 









Predictive accuracy of the DCG model was 
improved further by incorporating a subset of 
survey variables, including perceived health, 
having functional limitations, consultation with 
general practitioners, used of home nursing, 
number of prescription medications used, 
cancer, diabetes, and use of rheumatoid arthritis 
medicine. 
Pacala et al. 
(2003) 
Medicare Age and gender; 
PIPDCG; general 
health; life style; 
use of health care 
Survey-based health status was at least as 
accurate as the diagnosis-based PIPDCG model 
to adjust capitation payments to 
Medicare+Choice plans. The difference in 
accuracy between the two methods was 







Age and gender; 
SF-12 
Survey-reported health status is useful in 
predicting medical expenditures. More research 
is needed to evaluate the extent to which the 
SF-12 adds predictive power over a 
comprehensive array of claim-based diagnosis 
data. 
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Author (Year) Setting 
Risk Adjustment 
Models Conclusions 
Studies comparing a comprehensive array of risk adjustment measures 








Properly combining pharmacy and inpatient 
diagnoses data is promising for predicting future 
expenditures. 







Combined drug and diagnostic data predicted 
total health care expenditures better than either 
type of data alone. Diagnosis-based models are 
more useful than pharmacy data for predicting 








SF-36; SIC; prior 
expense 
Models with combined measures had the best 
overall predictions, reduced over-prediction of 
low-expenditure groups, and reduced 
under-prediction for individuals with extremely 
high expenditures. 
Farley et al. 
(2006) 










Simple count measures appear to predict future 
expenditures better than the comorbidity indices. 
ACG: Adjusted Clinical Group; CDPS: Chronic Illness and Disability System; CMS-HCC: Centers for Medicare and Medicaid 
Services modified version of Diagnostic Cost Group-Hierarchical Condition Category; DCG: Diagnostic Cost Group; DCG-HCC: 
Diagnostic Cost Group-Hierarchical Condition Category; GRAM: Global Risk Assessment Model; PHD: Pharmacy Health 
Dimensions; PIPDCG: Principal Inpatient Diagnostic Cost Groups; SIC: Seattle Index of Comorbidity. 
 
2.3.2 Estimation Methods 
The objective of this dissertation was to apply the globally estimated measures and to 
evaluate the performance of different measures among individuals with AD, rather than to 
recreate or to modify each risk adjustment classification system. In estimating prospective 
models, regression modeling techniques were applied to incorporate age and gender 
categories plus risk adjustment measures in year t to forecast expenditures in prediction year 
t+1. Although there are several methods for modeling skewed health care expenditures, 
many risk adjustment models have employed (weighted) ordinary least squares (OLS) 
estimation (Equation 2.1 [Wooldridge, 2003]) [Pope et al., 1998; Ash et al., 2000; Kronick et 
al., 2000; Riley, 2000; Ash et al., 2001; Fishman et al., 2003; Pope et al., 2004; Maciejewski 
et al., 2005; Zhao et al., 2005; Noyes et al., 2006], whereas other researchers have utilized 
two-part models (Equation 2.2) [Duan et al., 1983] to estimate mixed distributions that consist 
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of a mass of observations at zero (i.e., nonusers) and a right-skewed distribution for users 
[Pacala et al., 2003; Powers et al., 2005]. 
OLS regression: E[Y] = Хβ                    (Equation 2.1) 
 
Two-part model: Pr[Y>0|X] = ( )υγ ,ΧΦ   (Equation 2.2) 
       E[Y|Y>0,X] = Хβ + E[ε|y>0,X] = Хβ 
 
Alternatively, a class of predictive models, generalized linear models (GLMs), has 
been introduced into the analysis of expenditure data [Blough et al., 1999; Manning and 
Mullahy, 2001]. As shown in Equation 2.3, GLM assumes a distribution for the underlying 
data with a scale for the linear procedure. The function g(.) is known as the link function. The 
GLM approach does not require any retransformation (as needed in log-transformed OLS 
regressions) in that the dependent variable is an expected value and is modeled on its 
original scale. Usually a gamma distribution and a log link are utilized for modeling 
expenditure data. Therefore, the expected expenditures are derived by exponentiation of the 
linear predictor. 
    GLM: g[E(Y)] = Хβ (Equation 2.3) 
 
OLS estimation is used commonly probably because it allows easy calculation of a 
risk profile expressed in dollar terms for each patient by summing across coefficients for each 
risk adjuster [Fishman et al., 2003]. Also, empirically, the predictive power of the OLS and 
two-part models is very close, whereas two-part models tend to be computationally 
burdensome and more difficult to interpret [Pope et al., 1998]. Buntin and Zaslavsky modeled 
health care expenditures incurred by Medicare beneficiaries and compared eight alternative 
methods, including OLS and GLM estimators and one- and two-part models [Buntin and 
Zaslavsky, 2004]. Buntin and Zaslavsky showed that the untransformed OLS regression 
perfectly predicted the overall mean and the means of the subgroups, such as beneficiaries 
with chronic conditions, with ADL limitations, and in poor health. Compared with the GLMs, 
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the standard OLS models performed fairly well in terms of mean squared error although less 
well in terms of mean absolute prediction error. 
Powers and colleagues [2005] also suggested that a standard OLS model may 
provide similar predictive accuracy compared with more advanced econometric models. 
Powers’ study evaluated several estimation methods in predicting prospective health care 
costs using a pharmacy claims-based risk index. Of the modeling approaches assessed, 
OLS had the lowest mean absolute prediction error and highest adjusted R2; the 
log-transformed OLS and two-part log-OLS models did not predict expenditures accurately 
due to log-scale heteroskedasticity. The two-part GLM had lower adjusted R2 but similar 
performance in other assessment measures compared with the OLS or two-part OLS 
estimators. This dissertation used OLS and other model specifications to estimate 
prospective risk adjustment models (details described in Chapters 3 and 6). 
 
2.3.3 Limitations of Risk Adjustment Models 
The generalizability of a risk adjustment model can vary across populations. 
Observers report that current diagnosis-based risk adjustment measures do not adequately 
predict the expenditures of the frail elderly, with frailty defined as functional impairment [Riley, 
2000; Robinson and Karon, 2000; Temkin-Greener et al., 2001; Kautter and Pope, 2004]. 
There is insufficient evidence to draw conclusions about the predictive accuracy of different 
risk adjustment models in a disease-specific context. As risk adjustment models continue to 
be developed, further refinement is necessary for particular Medicare subpopulations, such 
as persons with functional limitations. 
Cucciare and O’Donohue reviewed recent studies on risk adjustment models and 
found that, in general, diagnosis-based models are more accurate than demographic models, 
and can more accurately reflect expenditures of patients within disease categories [Cucciare 
and O'Donohue, 2006]. Also, diagnosis-based models are useful for identifying high-risk, 
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high-cost individuals. However, with regard to predictive power, risk adjustment models 
generally account for relatively little variation in future health expenditures. The majority of 
prospective risk adjustment models reviewed in this study have adjusted R2 of 2%-16%. 
Moreover, some risk adjustment measures tend to under- or over-predict health care 
expenditures, which may lead to inappropriate risk-adjusted capitation payment to health 
plans. For example, Ash et al. [2000] found that the DCG-HCC model under-predicted health 
care expenditures for individuals with arthritis by as much as 36%. Kautter and Pope [2004] 
showed that, without frailty adjustment, the CMS-HCC model may underpay MCOs which 
specialize in providing care to the community-residing frail elderly.  
CHAPTER 3 
RESEARCH DESIGN AND METHODS 
 
3.1 Overview 
This dissertation examined multiple-source case ascertainment approaches, 
including survey report, diagnosis, and use of Alzheimer’s prescription medicine, for 
identifying individuals with AD. Using an inclusive case definition to define AD, this 
dissertation then described patterns of expenditure distribution in terms of concentration and 
persistence. Student’s t-tests and chi-square tests were performed to assess the statistical 
significance of differences in characteristics between the highest-spending 10%, 25%, and 
50% versus the lowest-spending 50% of individuals with AD. A transition probability matrix 
illustrated the change in expenditure percentiles from a given year to the next year. Ordered 
logit regression techniques were used to model individual-level characteristics associated 
with future expenditures. The risk adjustment measures assessed in this study included three 
diagnosis-based measures from Medicare claims files, one functional status measure from 
survey data, and prior expenditures aggregated from both claims and survey data. Adjusted 
R2, log likelihood values, predictive ratios, and the area under the receiver operating 
characteristic (ROC) curves were used to compare performance across models. 
 
3.2 Research Hypotheses 
This dissertation has five testable hypotheses. Hypothesis 1 corresponds to Aim 1 
and explores the sensitivity and specificity of alternative definitions for case ascertainment. 
Hypotheses 2, 3 and 4 relate to Aim 2 and examine high-expenditure concentration and 
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persistence over-time in individuals with AD. Finally, Hypothesis 5 corresponds to Aim3, 
assessing the performance of various risk adjustment models in AD. 
H1: Different disease definitions, including survey report of AD, AD diagnosis in medical 
claims records, and use of Alzheimer’s medications, have poor agreement in case 
determination. 
H2: A relatively small proportion of individuals with AD account for a disproportionately 
large share of overall health care and prescription drug expenditures. 
H3: A large percentage of individuals with AD who are in the top percentiles for overall 
and drug expenditures in year t remain in the top percentiles in year t+1, whereas 
most individuals in the bottom half of the expenditure distribution in year t remain in 
the low-expenditure groups in year t+1. 
H4: Greater burden of comorbidities and functional impairments, and higher prior 
expenditures in year t are associated with increased likelihood of being in the top 
percentiles for overall and prescription drug expenditures in year t+1. 
H5: Risk adjustment models with combined measures (i.e., diagnoses plus other risk 
adjusters) have higher explanatory ability and better predictive accuracy compared 
with single-measure models (i.e., diagnoses alone) in predicting subsequent-year 
overall and drug expenditures. 
 
3.3 Conceptual Framework 
A broad range of risk adjustment factors can affect an individual’s health expenditures. 
However, no risk adjustment methods can account for all relevant factors. From a practical 
standpoint, Iezzoni argued that one of the most important features of any risk adjustment 
approaches involves which measures to include and how they are represented and handled 
analytically [Iezzoni, 2003a]. The current research builds upon the concept of “algebra of 
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effectiveness,” which recognizes outcomes as complex functions of individual-level attributes 
and other factors [Iezzoni, 2003b]. 
Figure 3.1 illustrates the “algebra of effectiveness,” for which risk adjustment 
measures are integral. As shown in the diagram, outcomes are a function of intrinsic 
individual-level factors, treatment effectiveness, random events, and quality of care. Many 
diverse attributes contribute to individual-level factors, including both clinical (e.g., principal 
diagnosis) and nonclinical (e.g., patient attitudes and preferences) factors. This dissertation 
examined the relationship between a subset of individual factors (shown in shaded boxes) 














Figure 3.1: The algebra of effectiveness model 
Source: Iezzoni, L. I. 2003a. "Ch.1: Reasons for risk adjustment." Risk adjustment for measuring 
health care outcomes, 3rd ed., Chicago, Illinois, Health Administration Press. Copyright 2003. 
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Figure 3.2 shows the individual-level risk adjustment factors of interest, including age, 
sex, diagnoses (i.e., principal diagnosis and comorbid illness in Iezzoni’s model) and 
survey-based functional status (i.e., physical functional status in Iezonni’s model). 
Additionally, prior expenditures also were examined. Outcomes were measured by total and 
prescription drug expenditures. 
 
Figure 3.2: Conceptual framework 
 
3.4 Data Source 
This dissertation used data from the 1999-2004 waves of the Medicare Current 
Beneficiary Survey (MCBS) Cost and Use files, linked with Medicare claims data. The sample 
for MCBS is drawn from the Medicare enrollment file covering the entire Medicare population, 
whether aged or disabled, living in the community or in institutions. The data set features a 
nationally representative and comprehensive survey of health care use, expenditures, 
sources of payment, supplementary health insurance, living arrangements, income, health 
status, and physical functioning for the Medicare population [CMS, 2006b]. Prescription use 







- Charlson index 
Survey-based measure 
- Functional status 







Year (t) Year (t+1) 
CMS-HCC: CMS version of the diagnostic Cost Group-Hierarchical Condition Category; 
CDPSM: Chronic Illness and Disability System-Medicare version 
Outcomes 
- Total expenditures 
- Prescription drug 
expenditures 
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by visual verification (i.e., of prescription containers, pharmacy bags) by interviewers for the 
corresponding medication. Follow-ups of prescribed medicine are conducted by phone 
interview. Available Medicare Part A (i.e., hospitalization, skilled nursing facility, hospice, and 
home health care) and Part B (i.e., physician visits, specified outpatient care and some 
outpatient medications) claims records include diagnosis codes, utilization, charges, and 
reimbursement for all medical services [CMS, 2003]. 
Survey interviews are completed by either sample members or proxy respondents 
(usually a family member or close acquaintance) if the sample member is unable to respond 
due to physical or mental problems. Each individual is interviewed three times per year to 
form a continuous profile of the individual’s health care experience [CMS, 2006b]. The survey 
features a longitudinal rotating panel design, in which sampled individuals remain in the 
panel for no more than four years by the time they are retired, resulting in a cumulative 
sample size of three 4,000-beneficiary cohorts or approximately 12,000 beneficiaries in any 
given year. Therefore, the MCBS Cost and Use data set can support both cross-sectional 
(e.g., concentration of health expenditures) and longitudinal analyses (e.g., persistence of 
health expenditures). Moreover, it allows us to construct risk adjustment measures using 
base-year information to predict subsequent-year expenditures. 
 
3.5 Sample 
The sample extraction flowchart is shown in Figure 3. Our study sample consisted of 
elderly, community-dwelling Medicare beneficiaries, defined as adults aged 65 and older who 
were not institutionalized for more than 90 days at a time during a year [CMS, 2006c] 
(n=69,092). Eligible beneficiaries were categorized as having AD based on the following 
three definitions: 
1) affirmative answer to the question “Has a doctor ever told you that you had 
Alzheimer’s disease or dementia?”; or 
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2) at least one AD diagnosis, defined by International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM) codes: all 290 codes (senile and  
presenile organic psychotic conditions) and 331.0 (AD) in Medicare Part A or Part 
B claims files; or 
 
3) use of any Alzheimer’s medications, including donepezil (Aricept®), rivastigmine 
(Exelon®), galantamine (Reminyl® or Razadyne®), and memantine (Namenda®). 
These medications were identified by the drug names in survey-reported data, i.e., 
pharmacy administration data were not used 
 
For the case-finding analysis presented in Chapter 4, individuals with AD were 
classified into six categories: three single-definition groups (AD by survey report, AD by 
ICD-9-CM diagnosis codes in Medicare claims, and AD by any prescription mention of 
Alzheimer’s medications), one group of AD cases indicated by at least two definitions, one 
group with all three definitions, and one composite group representing individuals identified 
by any of the three definitions. In Chapters 5 and 6, individuals who met any of the three 
definitions were defined as having AD. Individuals with AD who had any managed care 
participation during that year were excluded because these Medicare MCOs do not submit 
claims with diagnoses to the CMS, which were required to construct diagnosis-based 
comorbidity profiles. Thus, a total of 2,779 observations from 1,861 unique individuals with 
AD from the 1999-2004 waves of the MCBS were pooled for the expenditure concentration 
analysis (Chapter 5). For the expenditure persistence analysis (Chapter 5) and the risk 
adjustment analysis (Chapter 6), we excluded persons with only one year of claims. We then 
retained individuals who had medical claims data for both year t and year t+1, and excluded 
data for year t+2 among those who were observed more than twice in the data set. Therefore, 
two-year panels of 671 unique individuals with AD were analyzed. 
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Figure 3.3: Sample extraction flow diagram 
 
3.6 Expenditure Measures 
Expenditure data in the MCBS were developed through a reconciliation process 
combining Medicare administrative files and survey information [CMS, 2003]. Expenditure 
data from claims include complete billing records of services used and payments made under 
Medicare fee-for-service transactions, and therefore allow for matching MCBS reports to 
billing records [CMS, 2006b]. The MCBS Cost and Use files link Medicare claims to 
survey-reported events, and thus provide a comprehensive picture of expenditures and 
sources of payment for all health care services, including those not covered by Medicare 
such as outpatient prescription drugs. Personal total health care expenditures in our study 






At least one AD diagnosis 
(ICD-9-CM codes: all 290 
codes or 331.0) in Part A 
or Part B claims  
(1,589 obs) 
Survey report of AD 
 
Have been told s/he has 
AD or dementia  
(1,994 obs) 
Age ≥ 65 years 
(57,669 obs) 
Excluded: Age < 65 
years (11,423 obs) 
Use of AD medications 
 
Any prescription mentions 
of donepezil, rivastigmine, 
galantamine or memantine 
(1,160 obs) 
Individuals with AD (3,198 obs) 
1,861 unique individuals with AD who had 
complete medical claims data (2,779 obs) 
Excluded individuals with only one year 
of claims (1,190 obs) and individuals 
with year t+2 claims (247 obs) 
Excluded individuals with managed care 
participation (419 obs) 
AD: Alzheimer’s disease; obs: observations; ICD-9-CM: International Classification of Disease, 9th Revision, Clinical Modification 
671 unique individuals with AD who had 
medical claims data for both year t and year 
t+1 (1,342 obs) 
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hospitalizations, outpatient hospital care, physician services, home health services, durable 
medical equipment, skilled nursing home services, hospice services, and other medical 
services. The payments do not include rebates that may be paid by the manufacturer to the 
insurer. Prescription drug expenditures are imputed total payments in the MCBS for 
prescription medicines received from all sources, including Medicare, Medicaid, Medicare 
MCOs, private MCOs, the Veterans Administration, employer-sponsored private insurance, 
individually-purchased private insurance, private insurance from an unknown source, 
out-of-pocket payments and public health plans other than Medicare or Medicaid [CMS, 
2003]. Detailed procedures and criteria used in the MCBS to impute missing payments for 
medical services and prescription drugs are discussed elsewhere [England et al., 1994]. 
Briefly, a full set of internally consistent expenditure and payment records were created from 
these sources with very little partial data discarded. All expenditures were converted into 
constant 2007 dollars using the Consumer Price Index for medical care [Bureau of Labor 
Statistics, 2007], which reflects the average price paid for a typical market basket of health 
care services. 
 
3.7 Comorbidity and Functional Status Measures 
This dissertation evaluated the performance of six risk adjustment techniques in 
predicting future overall and drug expenditures. The simplest technique considers only age 
categories (e.g., 65-69, 70-74, 75-79, 80-84, and 85+) and gender; three techniques are 
based on diagnoses in Medicare claims data, and one is based on survey-reported functional 
status. The final one is prior-year expenditures. These latter five risk adjustment measures 
are discussed individually in Sections 3.7.1-3.7.5. 
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3.7.1 CMS Diagnostic Cost Group-Hierarchical Condition Category (DCG-HCC) 
The DCG-HCC model uses age, sex and ICD-9-CM diagnosis codes from inpatient 
admissions and outpatient services to predict health care expenditures associated with 
various comorbidities [Pope et al., 2000]. Beginning 2000, the CMS has adopted the 
DCG-HCC model for Medicare risk adjustment largely because of its transparency, ease of 
modification, and good clinical coherence [Pope et al., 2004]. In 2004, the CMS implemented 
Medicare-specific modifications to the DCG-HCC model to adjust Medicare capitation 
payments to private health care plans (hereafter known as CMS-HCC). Under this model, 
individuals are assigned to multiple Hierarchical Condition Categories (HCCs) based on 
demographic characteristics and diagnoses in both inpatient and outpatient claims in the 
prior year. The model also incorporates the original reason for Medicare entitlement 
(disability or age), location of residence (community or facility), recent enrollment (covered by 
Medicare for fewer than 12 months in the prior year), and Medicaid eligibility. The model 
aggregates clinically and economically meaningful disease categories into 70 HCCs (i.e., 
metastatic cancer and acute leukemia). We employed the count of HCCs per beneficiary as a 
risk adjustment measure. The CMS-HCC algorithm was obtained from the CMS website 
[CMS, 2006a]. 
 
3.7.2 Chronic Illness and Disability Payment System-Medicare version (CDPSM) 
The Chronic Illness and Disability Payment System (CDPS) is an expansion of a prior 
model, the Disability Payment System, developed by Kronick and colleagues [Kronick et al., 
1996]. At least eight state Medicaid programs use this diagnostic classification system to 
make risk-adjusted capitation payments for beneficiaries with disabilities or who receive 
Temporary Assistance to Needy Families [Kronick et al., 2000]. We used the CDPS Medicare 
version (CDPSM), a modified model more appropriate to predict expenditures for Medicare 
beneficiaries [Kronick et al., 2002] (Table 3.1). Compared with the CMS-HCC, the CDPSM is 
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more conservative in counting diagnoses and, therefore, has fewer categories. The CDPSM 
uses ICD-9-CM codes in both inpatient and outpatient claims to create 16 major disease 
categories, which correspond to body systems or type of diagnosis. The major categories are 
divided further into 66 subcategories to reflect the level of increased expenditures associated 
with the diagnoses. The CDPSM software was acquired under license agreement at no 
charge (http://cdps.ucsd.edu, last accessed on 25 January, 2008).
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Table 3.1: Chronic Illness and Disability Payment System, Medicare version 
 
Cardiovascular Skin 
Very high High 
Ischemic heart disease, high Low 
Ischemic heart disease, low  
Valvular, conductive and other heart disease, medium Renal 
Valvular, conductive and other heart disease, low Extra high 
Valvular, conductive and other heart disease, very low Very high 
Peripheral vascular, medium Medium 
 Low 
Psychiatric Very low 
High  
Medium Substance abuse 
Low Low 
 Very low 
Skeletal and connective  
Medium Cancer 
Very Low Very high 
Extra Low High 
 Medium 
Nervous system Low 
High Very low 
Peripheral, high  
Peripheral, low Metabolic 
Multiple sclerosis, muscular dystrophy and others High 
Parkinson's disease Low 
Convulsions and epilepsy  
Super low Cerebrovascular 
 High 
Delirum and dementia Medium 
Deliruim Low 
Dementia Very low 
 Extra low 
Pulmonary  
High Infectious disease 
Medium Acquired immunodeficiency syndrome (AIDS) 
Pneumonia, high High 
Pneumonia, low Human immunodeficiency virus (HIV) 
Chronic obstructive pulmonary disease, high Medium 
  
Gastrointestinal Hematological 






Type 1 or 2 with rare complications  
Type 1 with common complications  
Type 1  
Type 2 with common complications  
Type 2  
 
3.7.3 Charlson Comorbidity Index (CCI) 
The original CCI is a general comorbidity index consisting of 19 disease categories 
developed to predict one-year mortality using hospital chart review data [Charlson et al., 
1987]. Other researchers have adapted the CCI for use with comorbidity data from 
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administrative databases that include ICD-9-CM diagnosis codes [Deyo et al., 1992; D'Hoore 
et al., 1993; Romano et al., 1993; Ghali et al., 1996; Quan et al., 2002]. We used the CCI with 
the Deyo modification containing 17 comorbidity categories [Charlson et al., 1987; Deyo et al., 
1992]. Each condition is assigned a weight as 1, 2, 3, or 6, reflecting the magnitude of the 
adjusted relative risks associated with each comorbidity. The CCI score then sums the 
weights for all conditions, with higher numbers representing a greater burden of comorbidity. 
The CCI for this study was derived using the presence of various ICD-9-CM codes in 
Medicare claims (Table 3.2). 
Table 3.2: Charlson comorbidity categories and corresponding ICD-9-CM codes 
 
Comorbidity categories ICD-9-CM codes Comorbidity categories ICD-9-CM codes 
Myocardial infarction 410-410.9, 412 Diabetes 250-250.3, 250.7 





443.9, 441-441.9, 785.4, 
V43.4, 38.48(P) 
Hemiplegia or paraplegia 344.1, 342-342.9 
Cerebrovascular disease 430-438 Renal disease 582-582.9, 583-583.7, 
585, 586, 588-588.9 










Rheumatologic disease 710.0, 710.1, 710.4, 
714.0-714.2, 714.81, 725 
Metastatic solid tumor 196-199.1 




Mild liver disease 571.2, 571.4-571.49, 
571.5, 571.6 
  
ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification 
 
3.7.4 Survey-reported Functional Status 
Kautter and Pope [2004] developed a CMS frailty adjustment model that incorporates 
functional status in addition to the CMS-HCC to adjust for capitation payments to certain 
health plans specializing in providing care to the community-dwelling, frail elderly. The use of 
functional ability frailty adjuster, in particular measured by ADLs, is preferred to other health 
status measures because it has good face validity and has been shown to explain Medicare 
expenditures not accounted for by diagnosis-based measures [Pope et al., 1998; Riley, 2000; 
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Kautter and Pope, 2004]. The frailty adjuster uses a scale based on the count of ADL 
impairments, including bathing, dressing, eating, transferring in and out of chairs, walking, 
and toileting, and categorized as none, 1-2, 3-4, and 5-6. For each activity, individuals were 
asked whether they had any difficulty performing the activity, received help with the activity, 
needed supervision with the activity, or were unable to perform the activity because of health 
problems. An individual was coded as impaired for an ADL if he or she needed any 
assistance doing (i.e., received help or needed supervision) or could not perform the activity. 
 
3.7.5 Prior Expenditures 
Expenditures incurred in the prior year are highly correlated with subsequent-year 
expenditures [Garber et al., 1997; Pope et al., 1998]. We modeled baseline expenditures as 
continuous variables on their original scale, and used the generalized linear model (GLM, 
described in the next section) as an alternative to transforming the non-normally distributed 
data. 
 
3.8 Analysis Plans 
Analytical strategies used in this dissertation varied by research hypotheses. For 
Hypothesis 1 (Chapter 4), we quantified the agreement between case definitions using raw 
agreement (%) illustrated by a Venn diagram and chance-corrected agreement measured by 
the kappa coefficient [Cohen, 1960]. McNemar’s test was used to test the significance of 
discordance between two case definitions [McNemar, 1947]. The sensitivity (i.e., the rate of 
true positives) is the ability of the case definition to correctly identify AD cases, whereas the 
specificity (i.e., the rate of true negatives) is the ability to correctly identify those who do not 
have AD. Positive predictive value (PPV) represents the proportion of individuals with AD 
among the identified cases, whereas negative predictive value (NPV) represents the 
proportion of individuals without AD among those identified as not having AD [Szklo and 
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Nieto, 2004]. These statistics provide a measure of the validity of the three case definitions, 
using one of them at a time as the “gold standard” definition for AD. Student’s t-tests and 
chi-square tests were performed to assess the statistical significance of differences in 
characteristics among individuals in each of the six AD groups versus non-AD individuals. 
For Hypotheses 2 and 3 (Chapter 5), the study sample was rank-ordered by overall 
expenditures and by drug expenditures, and then categorized into four groups based on their 
percentile position in the expenditure distribution of a given year: 1) top 10%, 2) next 
11%-25%, 3) next 26%-50%, and 4) bottom 50%. We first used cross-sectional data to 
examine expenditure concentration by calculating the proportion of all expenditures incurred 
by the top 10%, top 25% and top 50% of individuals in each year. Characteristics of 
individuals with AD in various high-expenditure groups (i.e., top 10%, top 25%, top 50% and 
bottom 50%) were examined. Student’s t-tests and chi-square tests were performed to 
assess the statistical significance of differences in characteristics between the top 10%, top 
25% and top 50% versus the lower 50% of individuals. A transition probability matrix was 
presented to illustrate the change in expenditure percentiles from one year to a subsequent 
year [Monheit, 2003; Liptak et al., 2006]. Ordered logit models [Maddala, 1983] were 
performed to predict the probability of being in a certain expenditure group in the next year, 
accounting for the ordinal nature of the outcome variable (i.e., top 10%, next 11%-25%, next 
26%-50% and bottom 50%). 
A comparative evaluation of various risk adjustment measures to predict overall 
health care and prescription drug expenditures is presented in Chapter 6. A Pearson 
correlation coefficient matrix was used to evaluate the correlation among various risk 
adjustment measures. Ordinary least squares (OLS) regressions were employed to predict 
expenditures in year t+1 using each risk adjustment measure plus age-gender categories in 
year t. Because the expenditure data were non-normally distributed, we also performed GLM 
with a gamma variance and a log link function, which models expenditures in their natural 
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scale rather than in a transformed scale (e.g., log transformation) [Shwartz and Ash, 2003]. 
The full models are described in Equations 3.1 and 3.2. 
OLS: E[Expendituret+1] = β1 Ageit + β2 Sexit + β3 Diagnosisit + β4 ADLit + β5 Expenditureit 
(Equation 3.1) 
GLM: g[E(Expendituret+1)] = β1 Ageit + β2 Sexit + β3 Diagnosisit + β4 ADLit + β5 Expenditureit 
(Equation 6.2) 
Risk adjustment models in the all-disease context conventionally have used a 
split-sample design to evaluate predictive accuracy, in which a small randomly selected 
sample of the total study population is withheld for model validation [Ellis et al., 1996; 
Fishman et al., 2003; Meenan et al., 2003; Pacala et al., 2003; Powers et al., 2005]. This 
technique helps to avoid over-fitting to a specific sample, but requires a large sample size to 
make statistically meaningful comparisons between a “training sample” and a model 
“validation sample.” Since this study focuses on an AD-specific population with a sample size 
of 671 unique individuals, which is not sufficiently large, alternative statistical evaluation 
criteria were adopted. We used adjusted R2 from OLS models to demonstrate the proportion 
of total variance in the dependent variable (e.g., expenditures) accounted for by the risk 
adjustment model [Ellis et al., 1996]. For GLMs, we compared the log likelihood values 
across models, with higher numbers indicating better model fit. 
Although adjusted R2 and log likelihood values provide a summary measure of overall 
prediction, these statistics give little information about how well a model discriminates 
between high- and low-expenditure cases [Shwartz and Ash, 2003]. Therefore, an 
individual’s actual expenditures in the prediction year (i.e., year t+1) were categorized into 
quartiles; then, predictive ratios (i.e., predicted expenditures divided by actual expenditures) 
were calculated within each quartile [Ash et al., 2000; Cucciare and O'Donohue, 2006]. If the 
model performs well for a population, its predictive ratio is close to one. In a prospective 
payment system, a predictive ratio close to one indicates that aggregate payments under the 
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risk adjustment model are equivalent to payments under the fee-for-service [Ellis et al., 
1996]. 
Predictive model performance was examined further using receiver operating 
characteristic (ROC) curves, representing how well the model classifies individuals by 
illustrating the tradeoff between true positive (sensitivity) and false positive (1-specificity) 
across different cutpoints for various high-expenditure threshold [Meenan et al., 1999]. This 
is done by rank-ordering actual and predicted expenditures from high to low, and setting 
pre-determined percentage thresholds within each expenditure distribution to define “true” 
high-expenditure cases (i.e., top 10% and top 20%) [Meenan et al., 1999; Meenan et al., 
2003; Weiner, 2003]. A c-statistic representing discrimination power then can be calculated 
using a nonparametric trapezoidal method to approximate the area under the ROC curve 
[Shwartz and Ash, 2003]. It takes values from 0 to 1 with higher numbers indicating a better 
model fit, except for a value of 0.5 indicating no ability to discriminate.
CHAPTER 4 
IDENTIFYING COMMUNITY-DWELLING INDIVIDUALS WITH ALZHEIMER’S DISEASE 
FROM OBSERVATIONAL DATA 
 
4.1 Abstract 
Introduction: Using diagnosis codes in administrative data to estimate the prevalence of 
Alzheimer’s disease (AD) has been shown to introduce errors of omission and commission. 
The objectives of this study were to identify the most sensitive and specific alternatives for 
case ascertainment and to provide insight on causes of widely-varied cost estimates in the 
cost-of-illness literature. 
Methods: Retrospective cross-sectional analyses were performed on a nationally 
representative sample of elderly, community-dwelling Medicare beneficiaries using the 
1999-2004 waves of the Medicare Current Beneficiary Survey (MCBS) (n=57,669). 
Individuals with AD were identified based on six definitions according to (1) survey report only, 
(2) diagnosis only, or (3) use of Alzheimer’s prescription medicine only, or some combination 
of the three. Agreement between different case definitions was assessed using a Venn 
diagram, kappa coefficient, sensitivity and specificity. We also explored the extent to which 
estimates in overall health expenditures and drug expenses vary by how AD is defined. 
Results: Using any of the three case definitions, 3,198 individuals (5.55%) were identified as 
having AD. Using survey report alone yielded more cases (n=1,994 or 3.46%) than diagnosis 
codes alone (n=1,589 or 2.76%) or Alzheimer’s medication use alone (n=1,160 or 2.01%). 
Kappa coefficients were low, ranging from 0.37 to 0.40. Using diagnosis in medical claims as 
a definitive measure for AD (i.e., “gold standard”), survey report was specific (97.7%) but had 
low sensitivity (44.2%) and Alzheimer’s medication use was slightly more specific (98.9%) 
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but less sensitive (34.8%). Per capita health expenditures ranged from $16,547 to $24,937, 
and drug expenditures ranged from $2,303 to $3,519, depending on how AD was defined. 
Conclusion: Different case definitions identify different subsets of individuals with AD. 
Survey-report appears to be a highly specific approach to identifying AD without the loss of 
sensitivity found with Alzheimer’s medication use. As a consequence of different case 
definitions employed, health expenditures among individuals with AD varied widely. One 
should exercise caution in interpreting current cost-of-illness studies and in applying these 
estimates to policy initiatives. A crucial first step to assessing the health care needs for 
individuals with AD is to develop a comprehensive definition for case ascertainment. 
 
Keywords: Alzheimer’s disease, case identification/ascertainment, Medicare, prevalence, 
cost, functional status 
 
4.2 Introduction 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly, 
comprising approximately half of all dementia cases [Katzman, 1986]. Albeit numerous 
cost-of-illness studies exist for AD, great variation exists in current and projected prevalence 
estimates. A meta-analysis conducted by the US General Accounting Office (GAO) 
estimated that 2.17 million individuals had AD in 2000 [US GAO, 1998]. This number is 
projected to increase to 7.98 million in 2050. Much higher estimates were reported by Evans 
et al. [1990] and Hebert et al. [2003]. Using data from a cohort of 32,000 individuals in East 
Boston, an estimated 2.88 million persons aged 65 or older had AD in 1980 [Evans, 1990]. 
Applying U.S. Census Bureau projections of the population growth yielded 10.3 million 
individuals with AD in 2050. Using a similar approach, Hebert and colleagues calculated the 
national prevalence of AD based on data from 3,838 residents age 65 and over in a biracial 
Chicago community [Hebert et al., 2003]. Their results suggest that 4.5 million persons had 
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AD in 2000 and that 13.2 million individuals will be affected by this disease by 2050, 
projections even higher than those of Evans et al. Other estimates are mid-range between 
the GAO’s and Hebert’s estimates [Brookmeyer et al., 1998; Sloane et al., 2002]. Depending 
upon the populations of interest, the proportion of persons age 65 years and older with AD 
and related dementia range from 0.76% [Weiner et al., 1998] to 3.1% [Taylor and Sloan, 
2000] among Medicare beneficiaries, from 0.83% [Gutterman et al., 1999] to 4.4% [Hill et al., 
2002] in managed care organization (MCO) populations, compared with 5.7% [US GAO, 
1998] to 10.3% [Evans et al., 1989] in the general population. 
Similar to widely-varied prevalence figures, the estimated costs of AD also vary 
considerably. Bloom and colleagues reviewed 21 cost-of-illness studies using 1985-2000 
data and found that inflation-adjusted total (direct plus indirect) costs per patient varied from 
$1,500 to $91,000 per year, equivalent to $5.6 to $88.3 billion nationally [Bloom et al., 2003]. 
This review calls into question the usefulness of extant estimates of health care expenditures 
for AD. Particularly, it may be difficult to assess health care needs and to conduct public 
health planning for persons with AD based on these widely-varied estimates. 
These widely divergent prevalence and cost estimates primarily arise from the data 
sources employed and methodological differences in defining Alzheimer’s cases [Johnson et 
al., 2000; Rice et al., 2001]. Although administrative data commonly are used to conduct 
burden-of-illness research, some researchers question the accuracy and adequacy of AD 
diagnosis codes in medical claims for identifying individuals with AD [Newcomer et al., 1999; 
Rice et al., 2001; Fillit et al., 2002a]. Pressley and colleagues [2003] analyzed a sample of 
community-dwelling elderly persons from the 1991-1994 National Long-Term Care Survey 
data linked with Medicare claims. Dementia cases were selected using survey report (i.e., 
“Has a doctor ever told you that you had Alzheimer’s disease or dementia?”), the Short 
Portable Mental Status Questionnaire, dementia diagnoses in Medicare claims (defined by 
the International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] 
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codes: 290.0-290.4, 291.2, 294.1, 331.0-331.2 and 797) or some combination thereof. They 
found that relying on a single case definition to forecast national dementia-related resource 
use could produce serious underestimates of future need. Because the non-overlapping 
individuals also were validly determined, the authors argued that these cases should not be 
excluded or be considered separately just because they were not explicitly identified in 
another sample. 
During the time frame of Pressley’s study, there were few pharmacologic treatment 
options available for dementia. However, the availability of new pharmacologic agents, such 
as acetylcholinesterase inhibitors and memantine, may affect current and projected 
estimates of the burden of AD [Brookmeyer et al., 1998; Fillit and Hill, 2004]. Using more 
recent data on a nationally-representative sample of Medicare enrollees enables us to 
investigate the utility of two supplements to claims data, Alzheimer’s medication use and 
survey report of AD, to provide greater confidence in case ascertainment. We also explore 
the extent to which overall and drug expenditures vary by case definition to provide insight 
into causes of wide expenditure variations, and to further discussions about the need for 




This study used the 1999-2004 Cost and Use files from the Medicare Current 
Beneficiary Survey (MCBS), which is sponsored by the Centers for Medicare and Medicaid 
Services (CMS). The MCBS is a comprehensive survey of health care use, expenditures, 
sources of payment and health status [CMS, 2006b].The survey data are linked to 
corresponding Medicare claims records to form the Cost and Use files. The survey features a 
longitudinal, rotating panel design. Each individual, or an appropriate proxy respondent 
(usually a family member or close acquaintance), is interviewed three times a year during a 
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4-year period to form a continuous profile of the subject’s health care experience. Each year, 
one round is retired and another round is initiated, giving the survey a cumulative sample size 
of three 4,000-beneficiary cohorts. In any given year, the MCBS is composed of 
approximately 12,000 individuals selected to be representative of the entire Medicare 
population. 
The survey-reported data include information on the cost and use of all types of 
medical services rendered. Prescription use also is obtained from survey report and 
ascertained during face-to-face interviews as well as by visual verification (i.e., of prescription 
containers, pharmacy bags) by interviewers for the corresponding medication. Available 
Medicare Part A (i.e., hospitalization, skilled nursing facility, hospice, and home health care) 
and Part B (i.e., physician visits, specified outpatient care and some outpatient medications) 
claims records include diagnosis codes, utilizations and charges and reimbursement for all 
medical services. The richness of the MCBS Cost and Use data provides a unique 
opportunity to examine various definitions for selecting individuals with AD because it 
integrates survey information, which can be obtained only directly from a beneficiary, with 
reliable information on services used and Medicare payments made from administrative 
billing files [CMS, 2003]. 
 
Sample 
The study sample consisted of elderly, community-dwelling beneficiaries, defined as 
adults aged 65 and older who were not institutionalized for more than 90 days at a time 
during a year [CMS, 2006c], in the 1999-2004 MCBS Cost and Use files (n=69,092) (Figure 
4.1). For community residents, survey interviews were completed by either sample members 
or proxy respondents if the sample member was unable to respond due to physical or mental 
problems. Eligible beneficiaries were categorized as having AD based on the following three 
definitions: 
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1) affirmative answer to the question “Has a doctor ever told you that you had 
Alzheimer’s disease or dementia?”; or 
 
2) at least one AD diagnosis, defined by International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM) codes: all 290 codes (senile and 
presenile organic psychotic conditions) and 331.0 (AD) in Medicare Part A or Part 
B claims files; or 
 
3) use of any Alzheimer’s medications, including donepezil (Aricept®), rivastigmine 
(Exelon®), galantamine (Reminyl® or Razadyne®) and memantine (Namenda®). 
These medications were identified by the drug names in survey-reported data, i.e., 
pharmacy administration data were not used. 
 
Then, individuals with AD were classified into six categories: three single-definition 
groups (AD by survey report, AD by ICD-9-CM diagnosis codes in Medicare claims, and AD 
by any prescription mention of Alzheimer’s medications), one group of AD cases indicated by 
at least two definitions, one group meeting all three definitions, and one composite group 
representing individuals identified by any of the three definitions. Proportions of individuals 
with AD were estimated for each of these six groups. Individuals with negative answers to all 
three case definitions were categorized as “non-AD” (i.e., not having AD).  
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Figure 4.1: Sample extraction flowchart 
 
Measures 
Memory and cognitive problems, a core feature of AD, were assessed using two 
available variables in the MCBS: memory loss interfering with daily activities (yes/no) and 
decision-making problems interfering with daily activities (yes/no). Functional limitations as a 
critical part of the progression of AD are studied in most longitudinal and treatment studies 
[Mohs et al., 2000]. They are measured in the MCBS using six basic activities of daily living 
(ADLs) (i.e., bathing, dressing, eating, transferring in and out of chairs, walking and toileting), 
and six instrumental ADLs (IADLs) (i.e., using the phone, doing light housework, doing heavy 
housework, making meals, shopping and managing money). For each activity, survey 
respondents were asked whether they had any difficulty performing the activity, received help 






At least one AD 
diagnosis (ICD-9-CM: 
all 290 codes or 331.0) 




Have been told 
s/he has AD or 
dementia  
Age ≥ 65 years  
(n=57,669) 
+ 
Excluded: Age < 65 
years (n=11,423) 
Never been told to 
have AD or 
dementia 









No AD diagnosis 




cases indicated by at 
least two measures 
Any evidence of AD 
indicated by at least 
one measure  
Non-AD 
All three measures 
indicative of AD 
     Six groups of individuals with AD identified by different case definitions 
     Individuals without AD 
AD: Alzheimer’s disease; ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification 
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ADL, they also were asked whether they needed supervision with the activity. A survey 
subject was coded as impaired for an ADL or IADL if she or he needed any assistance 
performing or could not perform the activity. Three approaches were used to characterize the 
degree of functional limitations: 1) the number of ADL impairments and the number of IADL 
impairments (two separate, continuous variables); 2) dummy variables indicating 
impairments of specific ADLs and IADLs; and 3) Katz Index of ADLs, a hierarchical 
classification of individuals into eight mutually exclusive groups by type and number of ADL 
impairments [Katz et al., 1963]. The Katz Index incorporates continence but excludes walking 
as an ADL. The Katz index ranges from no impairments (level A) to total dependency on all 
six ADLs (level G), plus a category of “all other“ to capture individuals not classified in levels 
A through G. This hierarchical classification allows a comparison between individuals with 
several specific impairments on ADLs and those without any impairments [Hill et al., 2006]. 
Additionally, general health status (coded as excellent, very good, good, fair and poor) also 
was studied. 
Expenditure data in the MCBS were developed through a reconciliation process 
combining survey information and Medicare administrative files [CMS, 2003]. Personal total 
health care expenditures are defined as the MCBS aggregated payments across all types of 
services, not including rebates that may be paid by the manufacturer to the insurer. 
Prescription drug expenditures are imputed total payments in the MCBS for prescription 
medicines received from all sources, including Medicare, Medicaid, Medicare MCOs, private 
MCOs, the Veterans Administration, employer-sponsored private insurance, 
individually-purchased private insurance, private insurance from an unknown source, 
out-of-pocket payments and public health plans other than Medicare or Medicaid [CMS, 
2003]. Detailed procedures and criteria used in the MCBS to impute missing payments for 
medical services and prescription drugs are discussed elsewhere [England et al., 1994]. 
Briefly, a full set of internally consistent expenditure and payment records were created from 
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these sources with minimal partial data discarded. The Consumer Price Index (CPI) for 
medical care [Bureau of Labor Statistics, 2007], which reflects the average price paid for a 
typical market basket of health care services, was used to adjust for inflation and to 
standardize all expenditures to 2007 dollars. 
 
Analysis 
We quantified the agreement between case definitions using raw agreement (%) 
illustrated by a Venn diagram and chance-corrected agreement measured by the kappa 
coefficient [Cohen, 1960]. Kappa coefficients were interpreted as follows: values of less than 
0: poor agreement; 0-0.20: slight; 0.21-0.40:fair; 0.41-0.60: moderate; 0.61-0.80 substantial; 
and 0.80-1.00: almost perfect agreement [Landis and Koch, 1977]. McNemar’s test was used 
to test the significance of discordance between two case definitions [McNemar, 1947].  
The sensitivity (i.e., the rate of true positives) is the ability of the case definition to 
correctly identify AD cases, whereas the specificity (i.e., the rate of true negatives) is the 
ability to correctly identify those who do not have AD. Positive predictive value (PPV) 
represents the proportion of individuals with AD among the identified cases, whereas 
negative predictive value (NPV) represents the proportion of individuals without AD among 
those identified as not having AD [Szklo and Nieto, 2004]. These statistics provide a measure 
of the validity of the three case definitions, using one of them at a time as the “gold standard” 
definition for AD. Student’s t-tests and chi-square tests were performed to assess the 
statistical significance of differences in characteristics among individuals in each of the six 
AD groups versus non-AD individuals. All analyses were conducted using SAS version 8.2 






Agreement between case definitions 
A total of 3,198 individuals (5.55%) were classified as having AD using any of the 
three case definitions (Figure 4.2). Using survey report alone yielded more cases (n=1,994 or 
3.46%) than did either diagnosis codes in medical claims (n=1,589 or 2.76%) or AD 
prescription drugs alone (n=1,160 or 2.01%). Of those with survey-reported AD, only 35.3% 
had an AD diagnosis in the medical claims in a given year and 32.8% took 
acetylcholinesterase inhibitors or memantine. Eleven hundred seventy-nine (2.04%) of the 
57,669 elderly study sample were categorized as having AD according to at least two 
measures: 703 (1.22%) by survey report and diagnosis codes, 655 (1.14%) by survey report 
and pharmacologic treatments for AD, and 553 (0.96%) by diagnosis and pharmacologic 
treatments. Only 366 (0.63%) cases were indicated by all three definitions.  
Chance-corrected agreement measured by kappa coefficients was low: 
survey-reported AD vs. AD diagnosis in claims records (kappa=0.37, 95% confidence interval 
[CI]: 0.35-0.39); survey report vs. use of Alzheimer’s prescription medicine (kappa=0.40, 95% 
CI: 0.38-0.42); and AD diagnosis vs. use of Alzheimer’s medications (kappa=0.38, 95% CI: 
0.36-0.41). According to McNemar’s tests, proportions of individuals with AD were 
significantly different between case definitions: survey report vs. diagnosis (χ2=75.34, 
p<0.001); survey report vs. medication use (χ2=377.20, p<0.001); and diagnosis vs. 




Figure 4.2: Venn diagram of raw agreement between classifications according to 
different definitions for identifying individuals with Alzheimer’s disease (AD) 
 
Sensitivity, specificity, positive and negative predictive values of case definitions 
Using diagnosis in medical claims as a definitive measure for AD (i.e., “gold 
standard”), survey report correctly identified only 44.2% (i.e., the sensitivity) of individuals 
with AD, indicating that more than 55% of individuals with a diagnosis AD did not report this 
illness. The percentage of false negatives was even higher: 65%, among users of AD 
medications (sensitivity=34.8%). The PPVs were poor—only 35.3% truly had AD among the 
survey-reported cases and 47.7% among AD medications users. However, survey report and 
medication use did not falsely classify non-AD individuals as having AD (specificity=97.7% 
and 98.9%, NPV= 98.4% and 98.2%, respectively). If survey report had been used as the 
“gold standard”, AD diagnosis and use of AD medicine were specific (98.4% and 99.1%) but 
had low sensitivity (32.3% and 32.8%). When changing the “gold standard” to medication use, 
survey report and diagnosis were more sensitive (56.5% and 47.7%) but slightly less specific 






Survey report AND 
Use of AD medications 
n=655 (1.14%) 
AD diagnosis AND 
Use of AD medications 
n=553 (0.96%) 











Use of Alzheimer’s 
medications 
n=1,160 (2.01%) 
All 3 definitions 
n=366 (0.63%) 
Any evidence of AD indicated 
by survey report, diagnosis 
codes, or use of AD 
medications 
n=3,198 (5.55%) 
Overlapping AD cases 




Table 4.1: Sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of different case definitions for identifying individuals with 
Alzheimer’s disease (AD) 
 
Case definition 












Gold standard: AD diagnosis in 
medical claims 1589     
Survey report 703 44.2 97.7 35.3 98.4 
Use of AD medications 553 34.8 98.9 47.7 98.2 
      
Gold standard: survey report  1994     
AD diagnosis in medical claims 703 32.3 98.4 44.2 97.7 
Use of AD medications 655 32.8 99.1 56.5 97.6 
      
Gold standard: Use of AD 
medications 1160     
Survey report 655 56.5 97.6 32.8 99.1 
AD diagnosis in medical claims 553 47.7 98.2 34.8 98.9 
 
Prevalence of AD by patient characteristics 
The prevalence of AD increases with age for each definition (Table 4.2). In the 
youngest age group (65 to 69 years), the proportions of AD ranged from 0.11% to 1.38%, 
compared with 1.21%-10.59% in the oldest age group (80+ years). As expected, using at 
least one case definition to identify individuals with AD produced estimates on the high end of 
the range; classification based on all three case definitions yielded estimates on the low end 
of the range. Using only a single definition, survey report produced slightly higher prevalence 
rates than did AD diagnosis, which in turn produced higher prevalence rates than did use of 
AD medications. 
Table 4.2: Percentage with Alzheimer’s disease (AD) by age group and by case 
definition 
 

















65-69 (n=12,637) 0.91 0.56 0.33 1.38 0.32 0.11 
70-74 (n=13,606) 1.71 1.17 1.06 2.67 0.92 0.35 
75-79 (n=11,697) 2.88 2.35 2.00 4.89 1.78 0.56 
80+ (n=19,729) 6.64 5.49 3.75 10.59 4.09 1.21 
Total (n=57, 669) 3.46 2.76 2.01 5.55 2.04 0.63 
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Individuals with AD were on average 82 years old, and were significantly older than 
their peers without AD (p<0.001) (Table 4.3). Individuals with AD were predominately female 
(>60%) and white (>80%). Individuals meeting all three case definitions and those with 
survey-reported AD had the highest rates of proxy use—64.5% and 63.5%, respectively. 
Individuals identified by use of Alzheimer’s medications had the lowest rate of proxy use 
(43.0%) among the six case definition groups. Proxy use was even lower, only 11.2%, in the 
non-AD population. The impact of AD also is reflected by poorer general health, memory and 
decision-making skills relative to individuals without such illness. Among individuals with AD, 
37.9%-47.5% rated themselves in fair or poor health, compared with 22.0% in the non-AD 
population (p<0.001). On average, 57.4%-84.9% and 50.1%-75.7% of individuals with AD 
had memory loss and decision-making problems, respectively, to the point that they 
interfered with daily activities, whereas only 8.1% and 4.5%, respectively, of the non-AD 
beneficiaries reported these symptoms (p<0.001).
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Table 4.3: Patient characteristics by case definition identifying individuals with 





















Mean age (s.d.), 
year 82.1 (7.5) 82.3 (6.9) 81.3 (6.3) 81.9 (7.2) 82.2 (6.7) 81.6 (6.6) 76.0 (7.3) 
Male, % 38.3 36.5 38.8 37.7 37.2 40.2 43.2 
Race/ethnicity, %        
  White, not 
Hispanic 81.1 82.4 86.3 82.7 83.0 83.9 86.4 
  Black, not 
Hispanic 13.0 12.6 9.1 11.8 12.4 11.5 8.8 
  Hispanic 2.2 2.5 2.8 2.2 2.5 3.8 2.4 
  Other 3.7 2.5 1.8 3.3 2.1 0.8 2.4 
Proxy 
respondent, % 63.5 53.2 43.0 51.6 61.3 64.5 11.2 
General health 
status, %        
  Excellent 8.0 8.3 8.9 8.7 7.8 6.6 15.9 
  Very good 16.6 17.4 18.5 17.6 16.7 16.5 28.8 
  Good 27.9 29.0 34.7 29.7 30.8 29.4 33.3 
  Fair 28.3 26.9 26.7 27.0 27.0 32.7 16.6 
  Poor 19.2 18.4 11.2 17.0 17.7 14.8 5.4 
Memory loss 
interferingwith 
daily activities, % 




daily activities, % 
67.8 50.1 52.6 52.0 69.4 75.7 4.5 
  s.d.: standard deviation 
 
Functional status 
Functional limitations were much more common among individuals with AD, 
regardless of the case definition employed, than in individuals identified as not having this 
condition (Table 4.4). Individuals meeting any of the three case definitions had an average of 
1.4 ADL impairments, compared with 0.2 ADL limitations in those without AD. Across all AD 
groups, bathing and dressing were the two most prevalent ADL impairments, and eating was 
the least prevalent. In general, ADL impairments were more pronounced in individuals 
identified by survey report and less prevalent in users of AD medications. The same trend 
was reflected by the Katz hierarchical index: 35.7% of individuals with survey-reported AD 
were fully independent in all ADLs (level A), compared with 51.1% of individuals identified by 
 67 
use of AD medications. More than 15% of individuals with survey-reported AD were impaired 
in five or all six ADLs (levels F or G), compared with 8.4% of AD medicine users. 
Performing IADLs is more cognitively demanding than is ADLs. Hence, IADL 
limitations were even more pronounced in individuals with AD. On average, individuals 
meeting all three case definitions had 2.6 IADL impairments, compared with 0.6 IADL 
impairments reported by individuals without AD (p<0.001). Of the six IADL items assessed, 
individuals with AD were more likely to receive help with or fail to perform heavy housework 
due to health problems, but were less likely to have difficulty using the telephone. Nearly half 
of the individuals with any of the three case definitions reported difficulty or inability to make 
meals (42.8%), shop (49.9%) and manage money (49.8%), each of which requires higher 
levels of cognitive functioning than doing housework. Similar to the trend observed for ADLs, 
individuals with survey-reported AD were more likely to have IADL impairments relative to 
other AD groups, whereas those identified by medications were less likely to report IADL 
limitations. 
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Number of ADL 
impairments, mean 
(s.d.) 
1.7 (2.1) 1.4 (2.0) 1.0 (1.7) 1.4 (2.0) 1.6 (2.1) 1.6 (2.0) 0.2 (0.7) 
ADL limitation, %        
   Bathing 44.5 37.1 27.9 35.3 56.8 44.3 5.3 
   Dressing 36.0 30.1 22.0 28.3 37.8 37.2 3.7 
   Eating 13.6 12.4 6.5 10.7 13.4 11.8 0.7 
Transferring in 
and out of chairs 27.9 23.4 16.2 22.4 25.7 26.0 2.9 
Walking 27.5 21.7 15.6 21.9 24.3 24.0 3.5 
Toileting 21.6 18.7 12.2 17.0 21.3 20.2 1.4 
Katz index of 
ADLs, %        
A: independent in 
all activities 35.7 42.3 51.1 43.5 38.3 36.9 73.1 
B: independent in 
all but one 
activity 
21.0 21.3 22.3 21.8 20.3 21.0 22.0 
C: dependent in 
bathing and one 
other activity 
7.3 6.6 5.6 6.4 7.2 7.1 1.5 
D: dependent in 
bathing, dressing 
and one other 
activity 
6.6 5.0 4.5 5.0 6.5 6.8 0.8 
E: dependent in 
bathing, 
dressing, going 
to toilet and one 
other activity 
2.6 2.6 1.7 2.3 2.6 2.7 0.3 
F: dependent in 
bathing, 
dressing, going 
to the toilet, 
transferring and 
one other activity 
8.0 6.0 4.9 6.2 7.1 8.8 0.6 
G: dependent in 
all activities 7.7 7.1 3.5 6.0 7.8 6.0 0.3 
Other: dependent 
in at least two 
activities and not 
classified in A-G 
11.1 9.1 6.4 8.8 10.2 10.7 1.4 
Number of IADL 
impairments, mean 
(s.d.) 
3.2 (2.3) 2.7 (2.4) 2.4 (2.3) 2.6 (2.4) 3.2 (2.3) 3.4 (2.3) 0.6 (1.3) 
IADL limitation, %        
  Using the phone 33.0 26.0 21.4 25.1 32.8 36.3 3.1 
  Doing light 
housework 48.6 40.8 33.1 40.2 45.5 48.9 9.5 
  Doing heavy 
housework 63.5 58.5 52.6 56.8 63.2 66.4 24.4 
  Making meals 53.2 43.4 37.3 42.8 51.3 57.1 7.2 
  Shopping 60.5 50.4 44.6 49.9 59.2 63.9 12.2 
  Managing money 63.2 49.9 47.0 49.8 63.7 69.1 5.6 
   ADL: activity of daily living; IADL: instrumental activity of daily living; s.d.: standard deviation 
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Expenditure variations by case definition 
We plotted average total health care expenditures (Figure 4.3) and prescription drug 
expenditures (Figure 4.4) against the various case definitions. Regardless of the definition 
employed, individuals with Alzheimer’s disease, on average, had significantly higher total and 
prescription drug expenditures compared with Medicare beneficiaries without AD. The mean 
total expenditures were 1.6- to 2.4-times higher in those with AD than in the non-AD 
population ($16,547-$24,937 vs. $10,371, respectively, p<0.001). Individuals with AD 
diagnoses in their medical claims were very costly and produced mean total expenditure 
estimates on the high end of the range, whereas those with survey-reported AD were on the 
low end. Drug expenditures for individuals with AD were on average 1.4- to 2.1-times higher 
than beneficiaries without AD ($2,303-$3,502 vs. $1,681, respectively, p<0.001). Drug 
expenditures were approximately 40% higher in users of Alzheimer’s medications ($3,298) 



































Figure 4.3: Total health care expenditures by Alzheimer’s disease (AD) case definition 



































Figure 4.4: Prescription drug expenditures by case definition of Alzheimer's disease 
(mean and 95% confidence interval, 2007$) 
 
4.5 Discussion 
Our investigation into identifying individuals with AD in the MCBS showed that 
prevalence of and expenditure estimates associated with AD varied widely by the definition 
used for case determination. Use of any single case definition in observational studies may 
fail to capture the actual burden of AD at the population level. Therefore, one should exercise 
caution in interpreting current cost-of-illness studies and in applying these estimates to policy 
initiatives. Because different case definitions may select different subsets of individuals with 
AD, incorporating all sources of cases definitions available to researchers for case 
ascertainment is a crucial first step to assessing health care needs for individuals with AD.  
Using a single case definition, such as an AD-associated diagnosis code in 
administrative data alone, to define individuals with AD has been shown to introduce errors of 
omission and commission [Newcomer et al., 1999; Fillit, 2000; Rice et al., 2001]. In our 
sample, survey report appeared to be the best single-definition approach, given the smallest 
number of missed cases: 505 cases with an AD diagnosis in medical claims or 886 users of 
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Alzheimer’s medications. Relying on a diagnosis in claims data alone would have missed 
1,291 survey-reported cases or 607 medication-identified cases who had no AD diagnosis in 
their medical claims. Using pharmacy data alone would even more seriously under-estimate 
the burden of AD—1,339 survey-reported cases or 1,036 diagnosed cases would have been 
missed. If an AD diagnosis in medical claims were used as a “gold standard,” survey report 
and use of Alzheimer’s medications were highly specific (i.e., low false-positive rates) but not 
sensitive (i.e., high false-negative rates). When we changed the “gold standard” to either 
survey report or medication use, our case definitions all yielded high specificities, which is not 
surprising in that the prevalence of AD is relatively low in the population. However, low 
sensitivities suggest that use of a single case definition may fail to capture all individuals with 
AD. 
An analysis of the Medicare Alzheimer’s Disease Demonstration, a longitudinal 
sample of individuals known to have some form of dementia, showed that claim-based AD 
prevalence rates were substantially underestimated because of underreporting of chronic 
conditions [Newcomer et al., 1999]. Fewer than 20% of the sample were classified as having 
dementia of the Alzheimer type (ICD-9-CM code: 331.0) based on a single year of claims, 
whereas 68% actually had an AD diagnosis from a referring physician at the time of entering 
the demonstration. Moreover, observers complain that many mild AD cases are 
underdiagnosed or uncoded in claims data because of social resistance to ageism and 
disabling stigma [Fillit, 2000; Rice et al., 2001]. The choice of diagnosis code also may be 
influenced by reimbursement scheme, which provides little financial incentive for coding AD 
as the primary diagnosis and instead encourages coding comorbidities, such as aspiration 
pneumonia as the primary diagnosis, to enhance reimbursement [Newcomer et al., 1999; 
Fillit, 2000; Brummel-Smith, 2001; Rice et al., 2001]. In our data, only 35% of individuals with 
survey-reported AD and 48% among users of AD medications had an Alzheimer’s diagnosis 
listed as any diagnosis in their Medicare claims. Our findings support the evidence that 
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claims data only identify a subset of individuals with AD and that different case definitions 
produce widely divergent prevalence estimate [Fillit, 2000; Rice et al., 2001; Bloom et al., 
2003; Pressley et al., 2003]. The disparity is, in part, attributable to the lack of a uniformly 
accepted definition or a gold-standard diagnostic test to identify Individuals with AD, which, in 
turn, poses a challenge to assess accurately the actual burden of AD. In order to enhance 
case ascertainment, researchers have suggested supplementing diagnoses in claims data 
with procedure codes, survey report, medical record reviews and direct physician reports of 
AD [Newcomer et al., 1999]. Our findings reinforce the use of survey report and suggest that 
pharmacy data also may be a valid supplement to claims records for case determination.  
Using survey report, Kane and Atherly estimated that the prevalence per 100 
population for Alzheimer’s or other dementia was 1.30 for individuals 65-74, 5.75 for those 
75-84, and 19.88 for individuals 85 and older; the overall prevalence rate was 6.8 for women 
and 3.93 for men in the 1991-1995 MCBS [Kane and Atherly, 2000]. Hill et al. [2006] 
estimated that, in the 1995-1998 MCBS, individuals with survey-reported AD (n=3,138, 
including community and facility residents) were equivalent to between 1.8 and 2 million 
Medicare beneficiaries in each of the four calendar years in the study period, which is 
consistent with estimates in epidemiological studies [Brookmeyer et al., 1998; US GAO, 
1998]. Our analysis showed that, using only survey report, 1,994 (3.46 cases per 100 
population) were classified as having AD: 1.32 for the 65-74 age group, 3.88 for the 75-84 
age group and 8.69 for those age 85 and older, equivalent to between 0.77 to 1.18 million 
Individuals with AD annually during 1999-2004. Our estimates compare closely to those 
reported in the literature. 
Using Medicare claims records, Weiner and colleagues estimated that per capita 
Medicare expenditures for individuals with dementia of the Alzheimer type (ICD-9-CM code 
331.0) in 1992 fiscal year were $9,300 (2007$), almost twice as much as the expenditures for 
all beneficiaries [Weiner et al., 1998]. Hill et al. used Medicare MCO claims data for a 
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two-year period and reported 1.6-times higher annual costs for individuals with AD and 
related dementias (ICD-9-CM codes: all 290 codes, 797, 292.82, 291.2, 294.1, 294.8, and 
331.0-331.2 or/and donepezil users) than those without such illness ($15,015 vs. $9,226, 
2007$), after controlling for age, sex and comorbidities [Hill et al., 2002]. Taylor and Sloan 
[2000] argued that using only one or two years of claims data to identify AD cases may 
underestimate prevalence and bias cost estimates. Using the 1994 National Long Term Care 
Survey merged with 12 years (1984-1995) of claims, 3.1% of the Medicare population 
(including both community and institutional population) were classified as having AD 
(ICD-9-CM code: 331.0). On average, individuals with AD had 2.6-times higher annual health 
care costs compared to individuals without AD ($9,588 vs. $3,678, age- and sex-adjusted 
2007$). Our study showed that using AD-associated diagnosis codes in a single year of 
claims data produced the highest mean total health care costs ($24,905), or 2.4-times the 
mean costs of non-AD individuals in the community. However, the total health care 
expenditures varied by as much as 50%, depending on the definition used for case 
identification. Therefore, one should be aware of methodological differences in calculating 
costs in the literature, especially when applying these estimates to AD policies [Bloom et al., 
2003]. 
In interpreting the results presented here, several notes of caution are important. One 
involves the completeness of administrative claims records in the MCBS. Because Medicare 
MCOs do not submit claims with diagnoses to the CMS, Medicare does not have a record of 
covered or noncovered services provided to beneficiaries in these plans [CMS, 2003]. As a 
result, it is possible that conditions occurring during the group health coverage period may 
not be reflected in Medicare claims provided in the Cost and Use files. This may lead to 
underestimating the proportion of individuals with AD covered by Medicare using ICD-9-CM 
diagnosis codes in the claims data. Therefore, we performed subgroup analyses excluding 
managed care enrollees to verify the robustness of our findings (results not shown). In 
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general, excluded individuals with group health participation (n=10,204) were found 
somewhat younger and healthier, and had lower average health care costs. Twenty-seven 
hundred seventy-nine (5.85% vs. 5.55% for all) of those not enrolled in managed care were 
classified as having AD using any of three case definitions. The results throughout the 
subgroup analyses were consistent with our findings for the entire sample composed of a mix 
of fee-for-service and MCO enrollees. Total health care costs and drug expenditures varied 
by as much as 41% and 49%, respectively, depending on the definition used for case 
determination. Therefore, our findings are not sensitive to MCO enrollment status. 
Another issue concerns the quality of self versus proxy report. Our data showed that 
11% of non-AD beneficiaries’ interviews were conducted by proxy, whereas 43%-64% 
(depending on the case definitions) of proxy response occurred on behalf of beneficiaries 
with AD. Among those with survey-reported AD, proxy-reported cases had poorer health and 
more functional impairments than self-reported cases as one would expect in that proxy was 
used if the sample person was unable to respond due to physical or mental problems. 
Although self-report may have greater errors in individuals with cognitive impairment relative 
to the general population, it is not clear whether proxy reports are systematically more or less 
accurate than self reports. Using an AD diagnosis in medical claims as a “gold standard,” we 
recalculated the sensitivity and specificity of survey-reported AD by proxy use. Self report 
appeared more specific (98.8%) then proxy (88.7%), but much less sensitive (24.8% vs. 
61.4%), indicating that individuals with a diagnosis of AD may be more likely to under-report 
this condition than proxy respondents. Some studies have shown that individuals with 
dementia may overestimate their cognitive and functional abilities compared with proxy 
ratings [Koss et al., 1993; Tierney et al., 1996; Farias et al., 2005]. On the other hand, a 
concern has been raised that greater caregiver burden may lead to overstated functional 
impairments of individuals with cognitive impairment [Rothman et al., 1991; Long et al., 1998]. 
A review of the validity of proxy respondents for older persons with cognitive impairment and 
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other chronic debilitating conditions found that proxies tend to describe more functional 
impairment and poorer emotional well-being than do patients themselves [Neumann et al., 
2000]. Additionally, proxy ratings of ADL and IADL disability were found to increase with 
caregiving hours and higher perceived caregiver burden. Our data showed that proxy use 
was higher in individuals with survey-reported AD, who also had higher prevalence of 
memory loss and decision-making problems and poorer functional status. However, we were 
not able to determine whether proxy respondents rated these impairments more negatively 
than they truly were. In the future it will be important to investigate the validity of proxy reports 
in order to accurately assess the cognitive ability and functional status in individuals with 
dementia. 
A third limitation pertains to the accuracy of prescribed medicine events in the MCBS. 
Information on prescription drug use was ascertained from survey data rather than from 
actual pharmacy claims (which were not paid by Medicare). Survey respondents were asked 
to bring to the interview bottles, tubes and prescription bags provided by the pharmacy as a 
way to verify survey-reported medication use. However, the prevalence of AD still may be 
underestimated due to under-reporting of medication use by a demented patient or by a 
proxy respondent. Prescriptions filled several months earlier may not be a salient event in the 
typical respondent’s memory [England et al., 1994]. Individuals may have a difficult time 
saving all prescription containers (especially prescription bags) over the typical four-month 
span between interviews. Furthermore, it is noteworthy that an estimated 50% of individuals 
with AD are diagnosed, and only half of those diagnosed are being treated [Evans, 1990]. 
Therefore, pharmacy data should be used only as a supplement definition for case 
ascertainment rather than a definitive measure for AD. 
Despite these concerns, we believe that our analyses convey important information 
on methodological improvements for estimating the prevalence and costs of AD, and hope 
that they provide greater confidence in case ascertainment using secondary data. Future 
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research should seek to evaluate the performance of other supplements to medical claims 
data, such as cognitive function assessment, apolipoprotein E genotype testing (i.e., a 
genetic test for Alzheimer risk gene) and medical record review and longitudinal data, for 
case ascertainment.  
 
4.6 Conclusions 
Alzheimer’s disease is set to become one of the developed world’s largest health care 
burdens over the coming decades. Current estimates using only a single case definition may 
fail to capture the full burden of AD at the population level. Thus, one should exercise caution 
in interpreting current cost-of-illness studies and in applying these estimates to policy 
initiatives. Future studies using secondary data to assess the health care needs for 
individuals with AD should first develop a comprehensive definition to identify a broad 





THE CONCENTRATION AND PERSISTENCE OF HEALTH CARE EXPENDITURES AND 




Introduction: Health care expenditures in Medicare are highly concentrated in a small 
proportion of beneficiaries. The purpose of this study was to quantify the concentration and 
persistence of overall and prescription drug expenditures in individuals with Alzheimer’s 
disease (AD) and to determine the person-level characteristics associated with future 
expenditure levels. 
Methods: Data were obtained from the 1999-2004 Medicare Current Beneficiary Survey 
linked with Medicare claims. Elderly, community-dwelling individuals with AD were 
rank-ordered by overall and drug expenditures. The proportion of expenditures accounted for 
by the top 10%, top 25% and top 50% of individuals was calculated. A transition probability 
matrix was used to illustrate the change in expenditure percentiles from one year to the next. 
Ordered logit models incorporating prior expenditure, the Charlson Comorbidity Index, 
functional status and other background covariates were estimated to predict the level of 
subsequent-year expenditures. 
Results: Average per capita health care expenditures in our AD sample ranged from 
$19,927 to $22,144, and prescription drug expenditures ranged from $1,797 to $2,943 during 
the study period. Individuals in the top 10% of the expenditure distribution accounted for 
38%-47% of overall health expenditures and incurred 31%-36% of overall drug expenditures. 
A quarter of the highest-spending 10% for total health expenditures remained in the top
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decile in the next year, whereas 21% of them moved to the bottom half of the distribution in 
the subsequent year. Half of the highest 10% with drug expenditures retained this ranking but 
only 9% became the bottom 50% in a second year. Prior expenditures and Charlson 
comorbidity scores, but not functional status, were strong predictors of the level of future 
expenditures. 
Conclusions: Overall health care and drug expenditures were highly concentrated and 
persistent over a two-year period in this AD population. Prescription drug expenditures 
exhibited less concentration but more persistence than did overall health expenditures. 
Results from this study may further our knowledge of how expected high expenditures in 
individuals with AD may be reduced with improved care coordination and effective disease 
management. 
 
Keywords: Alzheimer’s disease, high health expenditures, drug expenditures, Charlson 
Comorbidity Index, Medicare 
 
5.2 Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by a 
progressive deterioration in cognition, memory and functional ability. Individuals with AD 
often experience prominent and multiple symptoms, including psychological symptoms and 
behavioral disturbances, that are distressing and place substantial burdens both on the 
individuals themselves and the health care system [Grossberg, 2002; Fillit and Hill, 2004; 
Kaufer et al., 2005]. According to a recent report by the Alzheimer’s Association [2007], 13% 
of individuals age 65 and older are living with AD; nearly half of persons older than 85 are 
affected by this disease. A review of 21 cost-of-illness studies using 1985-2000 data found 
that inflation-adjusted costs ranged from $5.6 to $88.3 billion nationally [Bloom et al., 2003]. 
In 2000, individuals with AD represented less than 5% of Medicare beneficiaries [Taylor and 
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Sloan, 2000], while they accounted for 14.4% of overall Medicare spending [Alzheimer's 
Association, 2001]. Individuals with both AD and comorbid conditions have been shown to 
accrue substantially higher expenditures compared with the matched control subjects without 
AD [Hill et al., 2002]. However, little is known about the extent to which high and persistent 
health expenditures are systematically associated with individual characteristics and prior 
utilization. Despite numerous cost-of-illness studies on AD, there is insufficient understanding 
about the characteristics of individuals with AD who have high expenditures, and who 
continue to spend a disproportionately large share of money. Identifying these 
high-expenditure and persistent users is crucial for managed care organizations (MCOs) 
seeking to target cases for intensive medical and financial management and to improve care 
coordination [Russell and Chaudhuri, 1992; Ash et al., 2001]. 
Health care expenditures in the U.S. are highly concentrated in a small proportion of 
population [Conwell and Cohen, 2005]. In a nationally representative sample from the 1996 
Medical Expenditure Panel Survey (MEPS), the highest-spending 1% of individuals made up 
27% of overall health expenditures and the top 5% accounted for 55% of overall expenditures, 
whereas the bottom 50% accounted for only 3% of overall expenditures [Berk and Monheit, 
2001]. Based on a longitudinal population of Medicare enrollees during 1987-1995, the top 
1% of individuals in the expenditure distribution accounted for nearly 20% of overall 
expenditures, and the proportion of expenditures attributable to this group increased over 
time [Garber et al., 1997]. In a managed care setting, Meenan et al. [2003] demonstrated that 
the most expensive 0.5% and 1% of cases represented 20% and 29%, respectively, of total 
expenditures. 
This consistent trend has motivated researchers to investigate the extent to which 
individuals in high expenditure percentiles persist from one year to the next. Evidence has 
shown that Medicare beneficiaries who incur high expenditures in one year tend to have 
higher-than-average expenditures in other years [Garber et al., 1997]. Based on the 
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1996-2000 MEPS data, 31% of non-institutionalized Medicare beneficiaries whose total 
expenditures were in the top 10% in year 1 retained this ranking in year 2; 49% of those 
beneficiaries ranked in the top 25% remained in the top 25%, and 72% of those in the top 
50% stayed in the top 50% in the next year [Banthin and Miller, 2006]. Previous studies have 
evaluated the persistence of overall health expenditures using administrative claims or 
survey data for the elderly with public insurance [Garber et al., 1997; Kapur et al., 2000], 
individuals with private insurance [Russell and Chaudhuri, 1992; Meenan et al., 1999; 
Meenan et al., 2003], a nationally representative sample of children [Liptak et al., 2006] and a 
national sample of the civilian, noninstitutionalized population [Monheit, 2003; Cohen et al., 
2006]. Results from these studies generally support the notion that high-expenditure 
individuals account for a disproportionate share of health care expenditures and that a small 
group exhibits persistently high expenditures. 
As with total health expenditures, drug expenditures also exhibit persistence over 
time, especially in the elderly population. Two studies conducted during the early 1990s 
examining the persistence in drug expenditures in the Pennsylvania Pharmaceutical 
Assistance Contract for the Elderly program [Stuart et al., 1991; Coulson and Stuart, 1992] 
suggested a strong degree of persistence in prescription drug expenditures by the elderly, 
particularly among the heaviest users. In Medicare, drug expenditures are highly persistent. 
Wrobel et al. [2003] found that demographic variables in the 1999 Medicare Current 
Beneficiary Survey explained only 5% of the variation in drug expenditures in 2000, whereas 
adding health status measures increased the explanatory power (i.e., adjusted R2) to 
10%-24%. Incorporating the prior year’s drug expenditures raised explanatory power to 55%. 
Banthin and Miller [2006] showed that Medicare prescription drug expenditures were even 
more persistent than were total expenditures. Among Medicare beneficiaries whose drug 
expenditures were in the top 10% in year 1, 55% remained in the top decile in year 2; 67% of 
those ranked in the top 25% retained this ranking, and 81% of those in the top 50% retained 
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this ranking in the next year. The predictive model including information on drug treatment 
categories and prior drug expenditures explained nearly 53% of the variation in 
subsequent-year drug expenditures. 
According to the Department of Health & Human Services Administration on Aging 
[2006], the number of individuals age 65 and older is projected to increase from 40.2 million 
in 2010 to more than 71.5 million by 2030. It is likely that the health care needs for individuals 
with AD will continue to rise, as advancing age is the single most important risk factor for AD. 
Unlike studies of the general Medicare beneficiaries, we sought to quantify the concentration 
and persistence of overall and prescription drug expenditures in individuals with AD, a 
population with progressive disabilities and high expenditures. Specifically, the present study 
was designed to examine whether high-expenditure users account for a disproportionate 
share of expenditures among individuals with AD, to determine the extent to which the 
individuals in high-expenditure percentiles persist from one year to the next, and what 




Data for this study were obtained from the 1999-2004 waves of the Medicare Current 
Beneficiary Survey (MCBS) Cost and Use files, which are nationally representative and 
comprehensive data sets of health status survey, health care use and expenditure data for 
the Medicare population. The MCBS is drawn from Centers for Medicare and Medicaid 
Services’ (CMS) Medicare enrollment file. The survey data include information on the cost 
and use of all types of medical services, and can be linked directly with Medicare claims. 
Available Medicare Part A (i.e., hospitalization, skilled nursing facility, hospice, and home 
health care) and Part B (i.e., physician visits, specified outpatient care and some outpatient 
medications) claims records include diagnosis codes, utilization, charges and reimbursement 
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for all medical services [CMS, 2003]. The survey oversamples significant subpopulations 
(e.g., older beneficiaries) allowing increased statistical power for subgroup analyses, such as 
for elderly persons with AD. Each individual, or an appropriate proxy respondent (usually a 
family member or close acquaintance), is interviewed three times per year during a four-year 
period to form a continuous profile of the individual’s health care experience [CMS, 2006b]. 
The survey features a longitudinal rotating panel design, in which one-fourth of the panel is 
replaced by new subjects each year, resulting in a cumulative sample size of three 
4,000-beneficiary cohorts or approximately 12,000 beneficiaries in any given year. Therefore, 
the data can support both cross-sectional (e.g., concentration of expenditures) and 
longitudinal analyses (e.g., persistence of expenditures). 
 
Sample 
The study sample was drawn from community-dwelling Medicare beneficiaries, 
defined as individuals who were not institutionalized for more than 90 days at a time during a 
year [CMS, 2006c]. Survey interviews were completed by either sample members or proxy 
respondents if the sample member was unable to respond due to physical or mental problems. 
The inclusion criteria restrict the sample to community-dwelling beneficiaries aged 65 years 
or older (Figure 5.1). To identify individuals with AD, we incorporated three case definitions. 
Use of a single case definition, such as AD diagnosis in administrative claims data alone, has 
been shown to introduce errors of omission and commission [Newcomer et al., 1999; Fillit, 
2000; Rice et al., 2001; Pressley et al., 2003; Lin, 2008a]. Therefore, we defined individuals 
who met any of the following case definitions as having AD: 
1) affirmative answer to the question “Has a doctor ever told you that you had 
Alzheimer’s disease or dementia?”; or 
 
2) at least one AD diagnosis, defined by International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM) codes: all 290 codes (senile and 
presenile organic psychotic conditions) and 331.0 (AD) in Medicare Part A or Part 
B claims files; or 
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3) use of any Alzheimer’s medications, including acetylcholinesterase inhibitors (i.e., 
donepezil [Aricept®], rivastigmine [Exelon®], and galantamine [Reminyl® or 
Razadyne®]) and memantine (Namenda®). These medications were identified by 




Individuals with AD who had any managed care participation during that year were 
excluded because these Medicare MCOs do not submit claims to the CMS. As a result, 
Medicare does not have a record of covered or noncovered services provided to 
beneficiaries in these plans [CMS, 2003]. Thus, a total of 2,779 observations from the 
1999-2004 waves of the MCBS were pooled for the expenditure concentration analysis. Of 
these, there were 1,861 eligible, unique individuals. We excluded persons with only one year 
of claims (including deaths of sample respondents and nonresponse in later rounds). We 
then retained individuals who had medical claims data for both year t and year t+1, and 
excluded data for year t+2 among those who were observed more than twice in the data set. 
As a result, two-year panels of 671 unique individuals with AD were analyzed for expenditure 
persistence. Of these, 155 (23%) were in the 1999-2000 cohort, 102 (15%) were in the 
2000-2001 cohort, 136 (20%) were in the 2001-2002 cohort, 147 (22%) were in the 
2002-2003 cohort, and 131 (20%) were in the 2003-2004 cohort; seventy-nine individuals 




Figure 5.1: Sample extraction flowchart 
 
Measures 
Expenditure data in the MCBS were developed through a reconciliation process 
combining survey information and Medicare administrative files [CMS, 2003]. Personal health 
care expenditures are defined as the standardized payments aggregated across all types of 
services, not including rebates that may be paid by the manufacturer to the insurer. Drug 
expenditures are imputed total payments for any prescription drugs from Medicare, Medicaid, 
Medicare MCOs, private MCOs, the Veterans Administration, employer-sponsored private 
insurance, individually-purchased private insurance, private insurance from an unknown 
source, out-of-pocket payments and public health plans other than Medicare or Medicaid 
[CMS, 2003]. Detailed procedures and criteria used in the MCBS to impute missing 
1999-2004 MCBS community 
dwelling sample (n=69,092) 
AD diagnosis 
 
At least one AD diagnosis 
(ICD-9-CM codes: all 290 
codes or 331.0) in Part A 




Have been told s/he 
has AD or dementia  
(n=1,994) 
Total sample: Age ≥ 65 years 
(n=57,669) 
Excluded: Age < 65 
years (n=11,423) 





inhibitors or memantine 
(n=1,160) 
Individuals with AD (n=3,198) 
1,861 unique individuals with AD who had 
complete medical claims data (n=2,779) 
671 unique individuals with AD who had 
medical claims data for both year t and 
year t+1 (n=1,342) 
 
Excluded individuals with only one year 
of claims (1,190 obs) and individuals 
with year t+2 claims (n=247) 
Excluded individuals with managed care 
participation (n=419) 
      Sample for expenditure concentration analysis           Sample for expenditure persistence analysis 
AD: Alzheimer’s disease; ICD-9-CM: International Classification of Disease, 9th Revision, Clinical Modification 
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payments for medical services and prescription drugs are discussed elsewhere [England et 
al., 1994]. Briefly, a full set of internally consistent expenditure and payment records were 
created from these sources with very little partial data discarded. All expenditures were 
converted into constant 2007 dollars using the Consumer Price Index for medical care 
[Bureau of Labor Statistics, 2007], which reflects the average price paid for a typical market 
basket of health care services. 
We examined the top five therapeutic classes for prescription medicines, which are 
designated by First Data Bank [CMS, 2007a], used by the top 10%, top 25%, top 50%, and 
bottom 50% of the individuals with AD; drug expenditures included expenditures for all drugs, 
however. We incorporated background covariates in addition to prior expenditure levels for 
regression analyses. Health status measures include perceived general health (categorized 
as excellent or very good, good and fair or poor), memory loss (yes/no) and decision-making 
problems interfering with daily activities (yes/no). Six basic activities of daily living (ADLs) (i.e., 
bathing, dressing, eating, transferring in and out of chairs, walking and toileting) and six 
instrumental ADLs (IADLs) (i.e., using the phone, doing light housework, doing heavy 
housework, making meals, shopping and managing money) were used to measure functional 
status. An individual was coded as impaired for an ADL or IADL if she or he needed any 
assistance performing or could not perform the activity. We tested three different 
specifications to characterize the degree of functional limitations: Model 1 used the number 
of ADL impairments and the number of IADL impairments (two separate, continuous 
variables); Model 2 used dummy variables indicating impairments of specific ADLs and 
IADLs; and Model 3 used Katz Index of ADLs, a hierarchical classification of individuals into 
eight mutually exclusive groups by type and number of ADL impairments [Katz et al., 1963]. 
The Katz Index incorporates continence but excludes walking as an ADL. The index ranges 
from no impairments (level A) to total dependency on all six ADLs (level G), plus a category 
of “all other“ to capture individuals not classified in levels A through G. This hierarchical 
 86 
classification allows a comparison between individuals with several specific ADL impairments 
and those without any impairments [Hill et al., 2006]. 
We used the Charlson Comorbidity Index (CCI) with the Deyo modification [Charlson 
et al., 1987; Deyo et al., 1992] to control for the effects of comorbid conditions on overall and 
drug expenditures. The CCI for a given year was derived from the presence of various 
diagnoses (defined by the ICD-9-CM codes) in the medical claims, including claims for 
inpatient, outpatient, physician visit, skilled nursing facility, home health and hospice service. 
The CCI comprises 17 comorbidity categories; each condition is assigned a weight as 1, 2, 3, 
or 6, reflecting the magnitude of the adjusted relative risks associated with that comorbidity. 
The weights for all conditions are accumulated to calculate the CCI scores, with higher 
numbers representing a greater burden of comorbidity. 
 
Analysis 
The study sample was rank-ordered by overall expenditures and by drug 
expenditures, and then categorized into four groups based on their percentile position in the 
expenditure distribution of a given year: 1) top 10%, 2) next 11%-25%, 3) next 26%-50%, and 
4) bottom 50%. We first used cross-sectional data to examine expenditure concentration by 
calculating the proportion of all expenditures incurred by the top 10%, top 25% and top 50% 
of individuals in each year. Characteristics of individuals with AD in various high-expenditure 
groups (i.e., top 10%, top 25%, top 50% and bottom 50%) were examined. Student’s t-tests 
and chi-square tests were performed to assess the statistical significance of differences in 
characteristics between the top 10%, top 25% and top 50% versus the lower 50% of 
individuals. A transition probability matrix was presented to illustrate the change in 
expenditure percentiles from one year to a subsequent year [Monheit, 2003; Liptak et al., 
2006]. Ordered logit models [Maddala, 1983] were performed to predict the probability of 
being in a certain expenditure group in the next year, accounting for the ordinal nature of the 
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outcome variable (i.e., top 10%, next 11%-25%, next 26%-50% and bottom 50%). All 




In 2007 constant dollars, average per capita health expenditures of elderly, 
community-dwelling Medicare beneficiaries with AD were $19,927 in 1999 and $22,144 in 
2004, representing an 11% increase. The increase was more dramatic for prescription drug 
expenditures, from $1,797 in 1999 to $2,943 in 2004, a 64% increase, possibly due to 
increased use of prescription drugs, new indications for existing drugs, growth in therapeutic 
classes, and increased use of specialty drugs [CMS, 2007b]. As shown in Figures 5.2 and 
5.3, overall and prescription drug expenditures were highly concentrated, with a relatively 
small proportion of high-cost users accounting for a large share of expenditures. The top 10% 
of individuals accounted for 38%-47% of overall health expenditures; the top 25% individuals 
accounted for nearly 70% and the top 50% accounted for nearly 90% of overall expenditures. 
Prescription drug expenditures appeared less concentrated than did overall health 
expenditures. Nevertheless, the top 10% made up approximately one-third, the top 25% 
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Figure 5.2: Concentration of health care expenditures in individuals with AD by 
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Figure 5.3: Concentration of prescription drug expenditures in individuals with AD by 
top-percentile expenditure group and by year (1999-2004) 
 
 
Table 5.1 describes the demographic characteristics, health status and top five 
therapeutic classes for prescription medicines among persons with AD in various percentiles 
of total health expenditures. Individuals with AD who were ranked in the upper percentiles 
reported poorer health status relative to those in the bottom 50%. For instance, 72% of those 
in the top decile rated themselves to be in fair or poor health, in contrast with only 35% in the 
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bottom half. Comorbidities also were more pronounced in persons with AD in the upper 
percentiles, with an average of 5.4 (standard deviation [s.d.]=3.6) conditions in the top 10%, 
4.8 (s.d.=3.4) in the top 25% and 4.1 (s.d.=3.1) in the top 50%, in contrast with an average of 
1.9 (s.d.=2.0) conditions in the bottom half (all p-values<0.001). 
Among individuals ranked in the top 10%, top 25% and top 50%, cardiac and 
cardiovascular medicines are the two most-frequently used therapeutic classes of 
prescription medications, followed by psychotherapeutic drugs, gastrointestinal preparations 
and autonomic agents (e.g., antihypertensive drugs). Individuals ranked in the bottom 50% 
also had the same drug classes ranked in the top five, whereas cardiovascular and 
autonomic medicines were the most frequently used. 
Table 5.1: Characteristics of individuals with Alzheimer’s disease by percentile of total 













(Top 50% vs. 
Bottom 50%) 
Mean age in years (s.d.)     81.3 (6.8)      82.0 (7.1)     82.2 (7.2)      81.7 (7.2) 0.095 
Male, % 42.4 41.3 39.8 36.7 0.087 
Race/ethnicity, %     0.518 
     White, not Hispanic 77.9 80.6 81.7 82.9  
     Black, not Hispanic 16.4 13.4 12.6 11.6  
     Hispanic 2.5  2.3  2.5  1.9  
     Other 3.2  3.7  3.2  3.6  
Proxy respondent, % 64.4 64.0 58.2 46.5 <0.001 
General health status, %     <0.001 
     Excellent / very good 9.3 15.5 18.2 33.2  
     Good 18.3 21.0 13.0 31.7  
     Fair 34.0 32.7 26.1 23.9  
     Poor 38.4 30.8 31.2 11.2  
Charlson Comorbidity Index, mean 
(s.d.)      5.4 (3.6)      4.8 (3.4)      4.1 (3.1)      1.9 (2.0) <0.001 
Memory loss interfering with daily 
activities, % 55.8 58.5 59.8 58.6 0.536 
Decision-making problems 
interfering with daily activities, % 51.6 53.1 52.4 49.9 0.182 
Top 5 therapeutic classes for 
prescription medications, %     <0.001 
     Cardiac drugs 11.0 10.9 10.9 11.1  
     Cardiovascular drugs 10.4 11.0 11.7 15.2  
     Psychotherapeutic drugs 9.2 9.2 10.1 9.1  
     Gastrointestinal preparations 7.7 7.5 7.1 5.4  
     Autonomic drugs 6.6 6.9 7.5 11.8  
   s.d.: standard deviation 
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Functional limitations were much more pronounced in the upper percentiles than in 
the bottom-half users (Table 5.2): the top 10% had an average of 2.4 (s.d.=2.3) ADL and 3.4 
(s.d.=2.2) IADL impairments, compared with 1.0 (s.d.=1.8) ADL and 2.3 (s.d.=3.3) IADL 
limitations in the lower 50% of individuals (all p-values <0.001). Of the six ADL items 
assessed, bathing and dressing were the two most prevalent ADL impairments, and eating 
was the least prevalent. The Katz hierarchical index also suggested more ADL impairments 
among individuals with high expenditures. More than 23% of the highest-spending 10% of 
users, and more than 19% of the highest-spending 25% of users were impaired on five or all 
six ADLs (levels F and G), compared with 11.4% of the bottom 50% of users. Only 28% of the 
individuals in the top decile were fully independent on all ADLs (level A), compared with 53% 
of the bottom-half users. Performing IADLs is more cognitively demanding than ADLs, 
making them more prevalent in community-dwelling individuals with AD. Of the six IADLs 
assessed, individuals with AD were more likely to received help with or be unable to perform 
heavy housework due to health problems, but were less likely to have difficulty using the 
telephone.
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Table 5.2: Functional status of individuals with Alzheimer’s disease by percentile of 













(Top 50% vs. 
Bottom 50%) 
Number of ADL impairments, 
mean (s.d.)     2.4 (2.3) 2.1 (2.2) 1.8 (2.2) 1.0 (1.8) <0.001 
ADL limitation, %      
   Bathing    55.2 50.4 43.9 27.4 <0.001 
   Dressing    48.8 43.0 36.2 21.3 <0.001 
   Eating    19.4 18.9 15.2 7.4 <0.001 
Transferring in and out of chairs    43.4 35.8 30.0 15.9 <0.001 
Walking    38.0 32.6 28.2 16.6 <0.001 
Toileting    30.8 26.6 22.5 12.2 <0.001 
Katz index of ADLs, %     <0.001 
A: independent in all activities    27.6 28.0 33.9 52.6  
B: independent in all but one 
activity    16.1 21.9 22.3 21.0  
C: dependent in bathing and 
one other activity     7.2 7.1 7.2 5.5  
D: dependent in bathing, 
dressing and one other 
activity 
    6.1 6.8 5.8 4.2  
E: dependent in bathing, 
dressing, going to toilet and 
one other activity 
    4.7 3.9 3.0 1.5  
F: dependent in bathing, 
dressing, going to the toilet, 
transferring and one other 
activity 
   12.5 9.1 8.3 3.8  
G: dependent in all activities    10.7 10.2 8.1 4.4  
Other: dependent in at least 
two activities and not 
classified in A-G 
   15.1 13.0 11.4 7.0  
Number of IADL impairments, 
mean (s.d.)     3.4 (2.2)      3.3 (2.3)      3.0 (2.4)       2.3 (3.3) <0.001 
IADL limitation, %      
   Using the phone     31.9 31.9 29.0 21.9 <0.001 
   Doing light housework     60.6 54.7 49.3 31.3 <0.001 
   Doing heavy housework     73.5 69.7 65.7 48.5 <0.001 
   Making meals     56.3 53.5 48.8 37.0 <0.001 
   Shopping     64.2 60.3 56.1 44.1 <0.001 
   Managing money     57.4 56.6 53.3 46.3 <0.001 
   ADL: activity of daily living; IADL: instrumental activity of daily living; s.d.: standard deviation. 
 
Expenditure persistence 
Table 5.3 shows the change in the position in the total expenditure distribution and 
drug expenditure distribution during a two-year period. This matrix illustrates the likelihood of 
being in the various percentiles for the subsequent year, given the position in prior year’s 
expenditure distribution (i.e., transition probability). For example, an individual in the top 10% 
of the distribution would have a probability of 0.25 for remaining in the top decile and a 
probability of 0.21 for moving to the bottom half in the next year. Individuals in the bottom-half 
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of the expenditure distribution would have a probability of only 0.05 for moving up to the top 
decile but 0.70 for retaining this ranking in the next year. Nearly 70% of those in the bottom 
50% stayed in the bottom half for two consecutive years. 
Prescription drug expenditures exhibited even more persistence than did overall 
health expenditures. The highest-spending 10% of users would have a probability of 0.50 for 
retaining this ranking, 0.30 for being in the next 11%-25%, and only 0.09 for becoming the 
bottom half. Individuals in the bottom 50% of the drug expenditure distribution would have a 
probability of only 0.01 for moving up to the top decile, and a probability of only 0.03 for 
moving to the next highest-spending 11%-25%, whereas 75% of those in the bottom 50% 
retained the this ranking in the next year. This matrix confirmed that a large proportion of 
individuals with AD who were in the top percentiles of overall and prescription drug 
expenditures retained this ranking in a second year, whereas most individuals with AD in the 
bottom half of the expenditure distribution remained in the low-spending group in the 
subsequent year. 
Table 5.3: Transition probability matrix for expenditure percentiles moving from the 
baseline year to the subsequent year (1999-2004 pooled data, n=671) 
 
Position in subsequent-year expenditure distribution Position in base-year 
expenditure distribution 
 
 Top 10% Next 11%-25% Next 26%-50% Bottom 50% 
 Total health care expenditures 
Top 10%  0.25 0.17 0.37 0.21 
Next 11%-25%  0.19 0.26 0.24 0.31 
Next 26%-50%  0.08 0.16 0.35 0.41 
Bottom 50%  0.05 0.09 0.19 0.70 
 Prescription drug expenditures 
Top 10%  0.50 0.30 0.11 0.09 
Next 11%-25%  0.18 0.33 0.28 0.21 
Next 26%-50%  0.06 0.20 0.43 0.31 
Bottom 50%  0.01 0.03 0.21 0.75 
 
Predicting the likelihood of future expenditure level 
Prior expenditures had substantial predictive power, much stronger than 
demographic characteristics and functional health status, in predicting the likelihood of being 
in a certain expenditure group in the next year (Table 5.4). An individual’s position in the 
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base-year total expenditure distribution was a strong predictor of high expenditures in a 
second year. Individuals in the top 10%, next 11%-25% and next 26%-50% all were much 
more likely to retain this ranking compared with those in the bottom 50% (p<0.001). Based on 
the model with simple counts of ADL and IADL impairments, we calculated the marginal 
effects of prior expenditure category (Table 5.5). The highest-spending 10% of users were 
16.3-percentage points more likely to be in the top decile in the next year, compared with the 
bottom-half of users in the expenditure distribution. The top 10% of users were 
12.7-percentage points more likely to become the next 11%-25% in the subsequent-year 
expenditure distribution, and were 32.5-percentage points less likely to become the bottom 
50%. The likelihood of being in the upper percentiles also increased with the number of 
comorbidities measured by the CCI (p<0.001). Increase in one comorbidity category would 
result in 2.0-percentage point increase in the likelihood of being in the top 10% in the 
expenditure distribution and 5.8-percentage point decrease in the likelihood of being the 
bottom 50% in the subsequent year.
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Table 5.4: Ordered logit models for the likelihood of persistently high health care 
expenditures: Predicting the position in subsequent-year expenditure distribution 
(1999-2004 pooled data, n=671) 
 







Position in base-year total expenditure 
distribution    
     Top 10% 1.69 (0.31)*** 1.79 (0.32)*** 1.79 (0.32)*** 
     Next 11%-25% 1.44 (0.24)*** 1.38 (0.24)*** 1.38 (0.24)*** 
     Next 26%-50% 0.83 (0.19)*** 0.79 (0.20)*** 0.78 (0.20)*** 
     Bottom 50% --1 -- -- 
Age 0.01 (0.01) 0.01 (0.01) 0.01 (0.01) 
Male sex      -0.10 (0.17) 0.06 (0.17) 0.11 (0.17) 
Race/ethnicity    
     White, not Hispanic -- -- -- 
     Black, not Hispanic 0.07 (0.25) 0.09 (0.25) 0.08 (0.25) 
     Hispanic or other 0.10 (0.34)     - 0.02 (0.35) 0.16 (0.35) 
Charlson Comorbidity Index 0.29 (0.03)*** 0.29 (0.03)*** 0.29 (0.03)*** 
General Health status    
     Excellent/very good -- -- -- 
     Good 0.04 (0.22)      -0.03 (0.22)     -0.08 (0.22) 
     Fair      -0.10 (0.23)      -0.20 (0.24)     -0.27 (0.24) 
     Poor 0.32 (0.27) 0.18 (0.28) 0.13 (0.28) 
Memory loss interfering with daily activities      -0.08 (0.22)      -0.10 (0.22)     -0.16 (0.22) 
Decision-making problems interfering with 
daily activities      -0.12 (0.24) 0.11 (0.24) 0.09 (0.24) 
Functional status    
     Number of ADL impairments 0.10 (0.06)*   
     Number of IADL impairments      -0.03 (0.05)   
     Dummy variables of ADL impairments    
        Bathing  0.19 (0.28)  
        Dressing       -0.06 (0.31)  
        Eating       -0.24 (0.31)  
        Transferring in and out of chairs  0.51 (0.30)*  
        Walking  0.26 (0.27)  
        Toileting       -0.04 (0.31)  
  Dummy variables of IADL impairments    
        Using the phone       -0.48 (0.23)**     -0.48 (0.22)** 
        Doing light housework       -0.02 (0.28) 0.0004 (0.28) 
        Doing heavy housework  0.70 (0.23)*** 0.70 (0.23)*** 
        Making meals       -0.22 (0.31)     -0.19 (0.31) 
        Shopping  0.26 (0.30) 0.20 (0.30) 
        Managing money       -0.65 (0.26)**     -0.62 (0.27)** 
     Katz index of ADL impairments2    
     Level A   -- 
     Level B   0.40 (0.23)* 
     Level C   0.55 (0.37) 
     Level D   0.54 (0.56) 
     Level E       -0.07 (0.54) 
     Level F   1.20 (0.38)*** 
     Level G   0.50 (0.43) 
     Other   0.82 (0.34)** 
Intercept 4      -5.25 (1.00)***      -5.16 (1.02)***     -5.20 (1.03)*** 
Intercept 3      -3.83 (0.98)***      -3.71 (1.01)***     -3.75 (1.01)*** 
Intercept 2      -2.37 (0.98)***      -2.21 (1.00)***     -2.23 (1.01)*** 
Pseudo R2       0.257 0.285 0.290 
      
1
 Reference group 
      
2
 See Table 5.2 for Katz index classifications 
      ADL: activity of daily living; IADL: instrumental activity of daily living; s.e.: standard error. 
      Differences are statistically significant at *(p<0.10), **(p<0.05) and ***(p<0.01) levels 
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Table 5.5: Marginal effects of base-year total expenditures and comorbidities on 
subsequent-year total expenditures 
 
Position in the subsequent-year total expenditure distribution 
Characteristics in the base year Top 10% Next 11%-25% Next 26%-50% Bottom 50% 
Position in the total expenditure 
distribution 
    
        Top 10% 0.163 0.127 0.035 -0.325 
        Next 11%-25% 0.122 0.113 0.052 -0.288 
        Next 26%-50% 0.057 0.061 0.049 -0.167 
        Bottom 50% -- -- -- -- 
Charlson Comorbidity Index 0.020 0.022 0.016 -0.058 
   Note: Predictions are based on the ordered logit model with simple numbers of functional limitations in Table 5.4 (Model 1) 
 
 
Higher prior drug expenditures and higher CCI also significantly increased the 
likelihood of being in the upper percentiles for drug expenditures in the subsequent year, 
regardless of the form of functional status used in the ordered logit model (Table 5.6). 
Individuals with the highest (i.e., top 10%) drug expenditures were 56.5-percentage points 
more likely to retain this ranking, and were 52.0 percentage points less likely to move to the 
bottom-half in the expenditure distribution in the next year, compared to those with the lowest 
drug expenditures (i.e., bottom 50%) (Table 5.7). An increase in one comorbidity category in 
the CCI would result in a 0.5-percentage point increase in the likelihood of being in the top 
10% in the subsequent year and a 1.1-percentage point decrease in the likelihood of being 
the bottom 50%. 
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Table 5.6: Ordered logit models for the likelihood of persistently high prescription 
drug expenditures: Predicting the position in subsequent-year expenditure 
distribution (n=671) 
 







Position in base-year drug expenditure 
distribution    
     Top 10% 4.28 (0.30)*** 4.32 (0.30)*** 4.33 (0.30)*** 
     Next 11%-25% 2.79 (0.24)*** 2.85 (0.25)*** 2.82 (0.25)*** 
     Next 26%-50% 1.87 (0.20)*** 1.96 (0.21)*** 1.89 (0.20)*** 
     Bottom 50% --1 -- -- 
Age -0.04 (0.01)*** -0.04 (0.01)***     -0.04 (0.01)*** 
Male -0.28 (0.17)* -0.26 (0.17) 0.24 (0.17) 
Race/ethnicity    
     White, not Hispanic -- -- -- 
     Black, not Hispanic -0.89 (0.28)*** -0.84 (0.29)***     -0.91 (0.29)*** 
     Hispanic or other 0.02 (0.35) -0.07 (0.35)     -0.01 (0.35) 
Charlson Comorbidity Index 0.07 (0.03)** 0.07 (0.03)** 0.06 (0.03)** 
General health status    
     Excellent/very good -- -- -- 
     Good 0.21 (0.21) 0.23 (0.22) 0.21 (0.22) 
     Fair -0.01 (0.24) 0.04 (0.24) -0.01 (0.24) 
     Poor 0.07 (0.28) -0.02 (0.29) -0.02 (0.28) 
Memory loss interfering with daily activities -0.27 (0.22) -0.26 (0.22) -0.29 (0.22) 
Decision-making problems interfering with 
daily activities -0.10 (0.24) -0.06 (0.25) -0.09 (0.25) 
Functional status    
     Number of ADL impairments -0.02 (0.06)   
     Number of IADL impairments -0.02 (0.05)   
     Dummy variables of ADL impairments    
          Bathing  -0.67 (0.30)**  
          Dressing  0.44 (0.32)  
          Eating  -0.64 (0.34)  
       Transferring in and out of chairs  -0.07 (0.33)  
       Walking  0.56 (0.28)*  
       Toileting  0.02 (0.33)  
  Dummy variables of IADL impairments    
          Using the phone  -0.38 (0.24) -0.41 (0.24)* 
          Doing light housework  0.24 (0.29) 0.16 (0.29) 
          Doing heavy housework  -0.15 (0.23) -0.11 (0.23) 
          Making meals  -0.12 (0.31) -0.12 (0.32) 
          Shopping  0.41 (0.30) 0.43 (0.30) 
       Managing money  -0.15 (0.26) -0.15 (0.26) 
     Katz index of ADL impairments2    
       Level A   -- 
       Level B   0.0006 (0.22) 
       Level C   -0.50 (0.39) 
       Level D   0.03 (0.60) 
       Level E   -0.55 (0.58) 
       Level F   0.41 (0.39) 
       Level G   -0.25 (0.45) 
       Other   0.01 (0.34) 
Intercept 4 -1.07 (0.98) -1.32 (1.01) -1.11 (1.01) 
Intercept 3 0.52 (0.98) 0.31 (1.01) 0.51 (1.01) 
Intercept 2 2.29 (0.99)** 2.12 (1.01)** 2.30 (1.01)** 
Pseudo R-squared 0.409 0.426 0.418 
      
1
 Reference group 
      
2
 See Table 5.2 for Katz index classifications 
      ADL: activity of daily living; IADL: instrumental activity of daily living; s.e.: standard error. 
      Differences are statistically significant at *(p<0.10), **(p<0.05) and ***(p<0.01) levels 
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Table 5.7: Marginal effects of base-year drug expenditures and comorbidities on 
subsequent-year drug expenditures 
 
Position in the subsequent-year drug expenditure distribution 
Characteristics in the base year Top 10% Next 11%-25% Next 26%-50% Bottom 50% 
Position in the drug expenditure 
distribution 
    
     Top 10% 0.565 0.114 -0.159 -0.520 
     Next 11%-25% 0.263 0.160 0.021 -0.443 
     Next 26%-50% 0.146 0.084 0.095 -0.325 
     Bottom 50% (reference group) -- -- -- -- 
Charlson Comorbidity Index 0.005 0.004 0.002 -0.011 
 Note: Predictions are based on the ordered logit model with simple numbers of functional limitations in Table 5.6 (Model 1) 
 
5.5 Discussion 
This study examined the extent of overall and prescription drug expenditure 
concentration and persistence among Medicare beneficiaries with AD, a disease that places 
substantial burdens on both the individuals themselves and the health care system. Our data 
indicated that the highest-spending 10% of users accounted for as much as 47% of overall 
health expenditures and one-third of prescription drug expenditures among individuals with 
AD. At the other end of the spectrum, the lower half was responsible for only 10% of overall 
health expenditures and approximately 15% of drug expenditures. Compared with individuals 
in the bottom 50%, the upper percentiles for total expenditures had more comorbidities, 
poorer health status and more functional impairments. 
Evidence has shown that expenditures for individuals with AD varied considerably by 
comorbid illness [Hill et al., 2002], and comorbid conditions were highly prevalent in our 
sample, especially among higher-expenditure individuals. The CCI scores significantly 
predicted future levels of expenditures. Given the fact that persons with AD are prone to 
forgetting what they were told to manage their comorbid illnesses or even losing their 
self-care skills, better treatments and disease management of AD are needed to facilitate 
care coordination and to reduce the costs of comorbidities commonly experienced by these 
frail elderly. These intervention programs may include use of appropriate medications (e.g., 
acetylcholinesterase inhibitors), care coordination by nurse case managers and/or primary 
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care physicians (e.g., discharge planning), education, counseling and support of caregivers 
[Fillit et al., 2002b; Kaufer et al., 2005]. 
Prescription drug expenditures appeared less concentrated than total expenditures 
probably because infrequent and expensive events such as extended hospitalizations make 
the distribution of overall expenditures more right-skewed [Banthin and Miller, 2006]. 
Nevertheless, drug expenditures exhibited high persistence in this AD population—half of the 
highest 10% retained this ranking but only 9% dropped to the bottom 50% in the expenditure 
distribution in a second year. Persistence in health expenditures may be distributed randomly 
or may be correlated with personal characteristics or previous expenditures and, therefore, 
can be predicted. Our analysis demonstrated that an individual’s position in the prior-year 
expenditure distribution significantly predicted the expenditure percentiles in the subsequent 
year. The greater the degree of high-expenditure persistence, the more likely it is that 
adverse selection into Medicare prescription drug plans will occur [Banthin and Miller, 2006]. 
Under the new Medicare Part D, beneficiaries may self-select their prescription drug 
coverage. Whether beneficiaries decide to enroll may be based on weighing the cost of 
enrollment against their anticipated need for prescription drugs in the future [Coulson and 
Stuart, 1992]. Our data showed that, among individuals with AD, cardiac, cardiovascular, 
psychotherapeutic, gastrointestinal and autonomic drugs were the five most commonly used 
classes of prescription medicines. These therapeutic classes are different from those used by 
general community-dwelling Medicare beneficiaries who use more diuretics and antiarthritics 
in addition to cardiac, cardiovascular and gastrointestinal medicines [Simoni-Wastila et al., 
2007]. Our findings help policymakers to design formularies that offer better and more 
comprehensive drug coverage for seniors with AD to meet their different needs. Identifying 
the characteristics of individuals with high and persistently-high expenditures may help to 
develop equitable health insurance strategies, such as catastrophic care, carve-outs, 
reinsurance and risk adjustment [Liptak et al., 2006], especially in a situation where medical 
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services for the long-term illnesses are expected to cost more than insurance coverage limits 
or more than the amount most families expect to pay with their own resources.  
An important issue that affects the dynamics of expenditures is regression to the 
mean, a statistical phenomenon in which the lower-spending cohorts increase and the 
highest-spending cohorts decrease their expenditures (towards the group mean) over time 
[Beebe, 1988; Barnett et al., 2005]. Our data revealed that regression to the mean occurred 
around both total expenditures and drug expenditures during a two-year period. For instance, 
of those top decile (bottom half) with the highest (lowest) health expenditures, 37% 
decreased (19% increased) their expenditures and moved to the middle-expenditure group 
(i.e., next 26%-50% column in Table 5.3) in a second year. Of those top 10% (bottom 50%) 
individuals with the highest (lowest) drug expenditures, 11% decreased (21% increased) 
their expenditures and became the middle-expenditure group. However, we were unable to 
determine to what degree the change in expenditure percentiles was due to improvement in 
outcomes of care, change in disease severity or simple regression to the mean. Coulson and 
Stuart [1992] examined the persistence in pharmaceutical use by the elderly and found that 
regression to the mean may take more than four years to complete. In the short run, the two 
highest-spending cohorts were found to be well above the overall mean, and the three lowest 
cohorts were still well below the group mean. We did not have a sufficient number of years of 
data to investigate regression to the mean beyond two years. In the future, longer follow-up 
periods may be necessary to accurately quantify this phenomenon. 
Previous research using cross-sectional data suggests a strong relationship between 
functional impairment and health expenditures [Hill et al., 2006]. However, most of the 
functional limitations we tested did not significantly predict future expenditure percentiles. We 
suspect that the lack of significance was due to multicollinearity based on the findings that 
ADLs and IADLs were strongly correlated (Pearson correlation coefficient r=0.68, p<0.001), 
and that both functional disability measures were weakly correlated with prior expenditure 
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percentiles (r=0.12-0.29, p<0.001). Note that functional limitations were highly prevalent in 
our sample, especially among those in the high-expenditure percentiles, indicating that these 
individuals may have greater non-health care needs, such as requiring assistance with 
housework and managing money, in addition to medical attention. 
Several limitations merit discussion. Our sample excluded individuals with any 
managed care participation (n=419) because their medical claims were not available in the 
MCBS. In general, these individuals were somewhat younger and healthier and had lower 
average overall and drug expenditures than our study sample. To provide a point of 
comparison, we also examined expenditure concentration and persistence including MCO 
enrollees and the results were almost numerically identical with our findings for 
fee-for-service members. We also substituted CCI scores with patient- or proxy-reported 
conditions in the ordered logit models. These conditions included heart disease, cancer, 
diabetes, stroke, high blood pressure, chronic obstruction pulmonary disease, paralysis, 
arthritis and mental illness. Prior expenditures remained a strong predictor of the level of 
future overall and drug expenditures, whereas only high blood pressure, but not other 
comorbid conditions, was statistically significant. Finally, our sample excluded individuals 
residing in skilled nursing facilities who generally have more functional impairments and more 
comorbidities than community-dwelling individuals with AD [Hill et al., 2006]. The scope of 
future studies should be expanded to include data from large Medicare MCOs and 




Our analysis of expenditure data from a nationally representative sample of Medicare 
beneficiaries with AD revealed that both overall and prescription drug expenditures were 
highly concentrated in a small group of high-expenditure individuals and were persistent over 
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a two-year period. Prescription drug expenditures exhibited less concentration but more 
persistence than did overall health expenditures in this elderly AD population. Our results 




RISK ADJUSTMENT FOR MEDICARE BENEFICIARIES WITH ALZHEIMER’S DISEASE 
 
6.1 Abstract 
Introduction: Previous research has raised a concern about the adequacy and accuracy of 
risk adjustment models based solely on diagnosis codes in administrative data to make 
capitation payments for health plans with mostly frail or disabled populations. The objective 
of this research was to compare the performance of various prospective risk adjustment 
measures to predict overall and prescription drug expenditures of Medicare beneficiaries with 
Alzheimer’s disease (AD). We also compared the measures in predicting being in the top 
10% of the expenditure distribution. 
Methods: Elderly, community-dwelling individuals with AD were identified from the 
1999-2004 Medicare Current Beneficiary Survey linked with Medicare claims. Risk 
adjustment measures evaluated for this sample were constructed from diagnoses in medical 
claims, functional status in survey report, and prior expenditures. Model performance in 
expenditure analysis was compared using adjusted R2, log likelihood values, predictive ratios, 
and receiver operating characteristic (ROC) curves in high-expenditure outlier analysis. 
Results: Adding diagnosis-based measures to the demographic model substantially 
increased the adjusted R2 from 1% to 17.0% with the Charlson Comorbidity Index (CCI), 
followed by 15.5% with the Chronic Illness and Disability Payment System-Medicare 
(CDPSM), and 12.1% with the Centers for Medicare and Medicaid Services modified version 
of Hierarchical Condition Category (CMS-HCC) model. Prior expenditures were more 
predictive (adjusted R2=20.4%) than any other single measures. Incorporating the frailty
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adjuster based on limitations of activity of daily living modestly increased the adjusted R2 of 
the diagnosis-based models, with the CCI remaining the most predictive (18.5%), but not the 
prior-expenditure model. All three diagnosis-based measures under-predicted the actual total 
expenditures in the highest quartile by approximately 50%, and over-predicted those in the 
lowest quartile by six fold. For drug expenditures, all three diagnosis-based measures 
performed similarly and produced greater over-prediction in the lowest quartile than for total 
expenditures. Prior drug expenditures were more accurate than any other measures but 
tended to over-predict across quartiles. Given a 10% high-expenditure threshold, the area 
under the ROC curves measured by the c-statistics were highest in the CCI (0.667), followed 
by the CDPSM (0.645) and CMS-HCC (0.628). For drug expenditures, no model except past 
use predicted high-expenditure outliers well. 
Conclusions: In single-measure, diagnosis-based models, the CCI outperformed the 
CMS-HCC and the CDPSM in predicting total and drug expenditures in our sample with AD. 
A frailty adjuster based on ADL limitations improved overall prediction and predictive 
accuracy of the diagnosis-based models, especially the CMS-HCC specification currently 
used by Medicare. Only prior expenditures, but not diagnoses, predicted drug expenditures in 
the next year with any accuracy, and can discriminate between high- and low-expenditure 
individuals. Future research is needed to evaluate the performance of risk adjustment 
measures based on ambulatory pharmacy data. 
 




Predictive modeling techniques increasingly have been used to forecast health care 
services use and expenditures in managed care [Pope et al., 2000; Powers et al., 2005; Zhao 
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et al., 2005]. One of the most important applications of predictive models is for making 
risk-adjusted payments. The Balanced Budget Act of 1997 required the Centers for Medicare 
and Medicaid (CMS, formerly Health Care Financing Administration) to implement 
risk-adjusted Medicare capitation payments for managed care plans by January 1, 2000, in 
order to compensate fairly health plans for the expected expenditures associated with the 
disease burden of their enrollees. CMS first adopted a form of risk adjustment based on 
inpatient hospital diagnoses (i.e., using the principal inpatient diagnostic cost groups system, 
PIPDCG) [Pope et al., 2000]. Beginning 2004, CMS applied Medicare-specific modifications 
to the Diagnostic Cost Group-Hierarchical Condition Category (DCG-HCC) model, which 
incorporates both inpatient and outpatient claims, as the new risk adjustment capitation 
payment system (hereafter known as CMS-HCC). 
Risk adjustment models generally rely on some combination of individual-level 
characteristics to predict outcomes, such as mortality or health expenditures. Studies of 
prospective models of expenditures have examined various risk adjustment measures, such 
as diagnoses [Ellis et al., 1996; Meenan et al., 1999; Ash et al., 2000; Pope et al., 2000; Riley, 
2000; Meenan et al., 2003; Hughes et al., 2004; Pope et al., 2004; Noyes et al., 2006], 
pharmacy claims data [Von Korff et al., 1992; Fishman et al., 2003; Powers et al., 2005], prior 
utilization [Ash et al., 2001; Monheit, 2003], health status from survey data [Epstein and 
Cumella, 1988; Fowles et al., 1996; Pope et al., 1998; Lamers, 1999; Temkin-Greener et al., 
2001; Pacala et al., 2003; Kautter and Pope, 2004; Fleishman et al., 2006], or some 
combination thereof [Zhao et al., 2001; Maciejewski et al., 2005; Zhao et al., 2005; Farley et 
al., 2006]. These studies generally find that combined models, such as diagnoses plus other 
risk adjusters, explain more variation in expenditures and improve predictive power, relative 
to single-measure models (e.g., diagnoses alone), probably because different risk 
adjustment measures explain different segments of the distribution.  
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The performance of a risk adjustment model can vary across different demographic 
groups and disease populations. For instance, compared with other diagnosis- or pharmacy- 
based measures, the DCG-HCC model has been shown to capture the largest proportion of 
total expenditures among MCO beneficiaries with asthma, diabetes, or depression [Meenan 
et al., 2003]. However, observers report that diagnosis-based risk adjustment measures do 
not adequately compensate health plans serving primarily disabled or frail populations, 
defined in terms of functional impairment [Riley, 2000; Robinson and Karon, 2000; 
Temkin-Greener et al., 2001; Kautter and Pope, 2004]. Kautter and Pope [2004] found that, 
without frailty adjustment, the CMS-HCC model would under-predict Medicare expenditures 
by an average of $4,923, $1,531, and $809, respectively, for beneficiaries with 5-6, 3-4, and 
1-2 impairments of activities of daily living (ADLs, i.e., bathing, dressing, eating, transferring 
in and out of chairs, walking, and toileting), and over-predict by $697 for those with no ADL 
difficulties. As risk adjustment models continue to be developed, further refinement is 
necessary for certain Medicare subpopulations, such as individuals with functional 
limitations. 
This study compared the performance of various generic risk adjustment models in 
Medicare beneficiaries with Alzheimer’s disease (AD), a population with progressive decline 
in cognition, memory and functional ability. It is estimated that more than 60% of individuals 
with AD have three or more comorbid conditions [Doraiswamy et al., 2002], and that 
comorbidities are an important driver of increased costs for AD [Gutterman et al., 1999]. 
Particularly, ADL limitations are a critical part of the disease progression [Mohs et al., 2000] 
which are correlated strongly with health care expenditures [Taylor et al., 2001; Leung et al., 
2003; Fillit and Hill, 2004; Hill et al., 2006]. Medicare pays for most of the cost of 
hospitalization and a large portion of other medical care among elderly individuals with AD. In 
2000, individuals with AD represented fewer than 5% of Medicare beneficiaries [Taylor and 
Sloan, 2000], whereas they accounted for 14.4% of overall Medicare spending [Alzheimer's 
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Association, 2001]. Despite its progressive disabilities and high cost, AD is not accounted for 
in the current CMS-HCC diagnostic classification system. As health care spending for 
Medicare beneficiaries continues to rise, there is a critical need to identify prospectively 
high-expenditure groups, predict resource use, and control expenditures using tools such as 
risk adjustment models.  
The objective of this study was to evaluate the predictive accuracy of five risk 
adjustment measures, including three diagnosis-based risk adjustment measures derived 
from medical claims records, one frailty adjuster based on functional status (i.e., ADL 
limitations) collected from survey data, and prior expenditures, in prospective models of 
overall and prescription drug expenditures. This study also examined the performance of 
models combining the frailty adjuster and other measures of risk. This comparison sheds 
light on refining current risk-adjusted payment methods, and helps plan managers who seek 
productive areas for disease management investment by identifying future high-expenditure 




Data were obtained from the 1999-2004 waves of the Medicare Current Beneficiary 
Survey (MCBS) Cost and Use files, linked with Medicare claims data. The MCBS is a 
nationally representative and comprehensive survey of health care use, expenditures, 
sources of payment and health status for the Medicare population [CMS, 2006b]. It provides 
a unique opportunity to study risk adjustment models because the data integrate information 
directly from a beneficiary with his/her Medicare claims for provider services and covered 
charges [CMS, 2006b]. Available Medicare Part A (i.e., hospitalization, skilled nursing facility, 
hospice, and home health care) and Part B (i.e., physician visits, specified outpatient care 
and some outpatient medications) claims records include diagnosis codes, utilization, 
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charges and reimbursement for all medical services [CMS, 2003]. The survey oversamples 
significant subpopulations (e.g., older beneficiaries) allowing increased statistical power for 
subgroup analyses, such as for elderly persons with AD. Survey interviews are completed by 
either sample members or proxy respondents (usually a family member or close 
acquaintance) if the sample member is unable to respond due to physical or mental problems. 
Each individual is interviewed three times a year to form a continuous profile of the 
individual’s health care experience [CMS, 2006b]. The survey features a longitudinal rotating 
panel design, in which sampled individuals remain in the panel for no more than four years by 
the time they are retired, resulting in a cumulative sample size of three 4,000-beneficiary 
cohorts or approximately 12,000 beneficiaries in any given year. Therefore, the data set 




The study sample consisted of elderly, community-dwelling beneficiaries, defined as 
adults aged 65 and older who were not institutionalized for more than 90 days at a time 
during a year [CMS, 2006c] (Figure 6.1). To identify individuals with AD, we incorporated 
three case definitions because use of a single definition, such as an AD diagnosis in medical 
claims data, to define Alzheimer’s cases has been shown to introduce errors of omission and 
commission [Newcomer et al., 1999; Fillit, 2000; Rice et al., 2001; Pressley et al., 2003; Lin, 
2008a]. Therefore, we defined individuals who met any of the following case definitions as 
having AD: 
1) affirmative answer to the question “Has a doctor ever told you that you had 
Alzheimer’s disease or dementia?”; or 
 
2) at least one AD diagnosis, defined by International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM) codes: all 290 codes (senile and 
presenile organic psychotic conditions) and 331.0 (AD) in Medicare Part A or Part 
B claims files; or 
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3) use of any Alzheimer’s medications, including donepezil [Aricept®], rivastigmine 
[Exelon®], galantamine [Reminyl® or Razadyne®]) and memantine (Namenda®). 
These medications were identified by the drug names in survey-reported data, i.e., 
pharmacy administration data were not used. 
 
 
Individuals who had any managed care participation during that year were excluded 
because these managed care organizations (MCOs) do not submit claims with diagnoses to 
the CMS, which we require to construct diagnosis-based risk adjustment measures. Of the 
1,861 eligible, unique individuals, we excluded persons with only one year of claims 
(including deaths of sample respondents and nonresponse in later rounds). We then retained 
individuals who had medical claims data for both year t and year t+1, and excluded data for 
year t+2 among those who were observed more than twice in the data set. As a result, the 
study sample consists of two-year panels of 671 unique individuals with AD. Of these, 155 
(23%) were in the 1999-2000 cohort, 102 (15%) were in the 2000-2001 cohort, 136 (20%) 
were in the 2001-2002 cohort, 147 (22%) were in the 2002-2003 cohort, and 131 (20%) were 
in the 2003-2004 cohort; 79 (11.8%) died during the second year. 
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Figure 6.1: Sample extraction flowchart 
 
Measures 
Overall and prescription drug expenditures 
Expenditure data in the MCBS were consolidated from both survey information and 
Medicare administrative files [CMS, 2003]. Personal total health care expenditures are 
defined as the MCBS aggregated payments across all types of services, not including 
rebates that may be paid by the manufacturer to the insurer. Prescription drug expenditures, 
a component of total expenditures, are imputed payments in the MCBS for prescription 
medicines received from all sources, including Medicare, Medicaid, Medicare MCOs, private 
MCOs, the Veterans Administration, employer-sponsored private insurance, 
individually-purchased private insurance, private insurance from an unknown source, 
out-of-pocket payments and public health plans other than Medicare or Medicaid [CMS, 
1999-2004 MCBS community 
dwelling sample (69,092 obs) 
AD diagnosis 
 
At least one AD diagnosis 
(ICD-9-CM codes: all 290 
codes or 331.0) in Part A 
or Part B claims  
(1,589 obs) 
Survey report of AD 
 
Have been told s/he has 
AD or dementia  
(1,994 obs) 
Total sample: Age ≥ 65 years 
(57,669 obs) 
Excluded: Age < 65 
years (11,423 obs) 
Use of AD medications 
 
Any prescription mentions 
of donepezil, rivastigmine, 
galantamine or memantine 
(1,160 obs) 
Individuals with AD (3,198 obs) 
1,861 unique individuals with AD who had 
Medicare claims data (2,779 obs) 
Excluded persons with Medicare claims 
for only year t (1,190 obs); excluded 
year t+2 claims (247 obs) 
Excluded persons with managed care 
participation (419 obs) 
AD: Alzheimer’s disease; obs: number of observations; ICD-9-CM: International Classification of Disease, 9th Revision, Clinical Modification 
671 unique individuals with AD who had 
Medicare claims data for both year t and 
year t+1 (1,342 obs) 
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2003]. Detailed procedures and criteria used in the MCBS to impute missing payments for 
medical services and prescription drugs are discussed elsewhere [England et al., 1994]. 
Briefly, a full set of internally consistent expenditure and payment records were created from 
these sources with minimal partial data discarded. We converted all expenditures into 
constant 2007 dollars using the Consumer Price Index for medical care [Bureau of Labor 
Statistics, 2007], which reflects the average price paid for a typical market basket of health 
care services. 
 
Risk adjustment measures 
The simplest risk adjustment measure includes only age categories (e.g., 65-69, 
70-74, 75-79, 80-84, and 85) and gender. Other risk adjusters are discussed individually 
below. 
CMS Diagnostic Cost Group-Hierarchical Condition Category (CMS-HCC) 
Individuals are assigned to multiple Hierarchical Condition Categories (HCCs) based 
on demographic characteristics and diagnoses in both inpatient and outpatient claims in the 
prior year. The model also incorporates original reason for Medicare entitlement (disability or 
age), location of residence (community or facility), recent enrollment (covered by Medicare 
for fewer than 12 months in the prior year), and Medicaid eligibility. The model aggregates 
clinically and economically meaningful disease categories into 70 HCCs (e.g., metastatic 
cancer and acute leukemia) to which payment weights are assigned to reflect the level of 
increased expenditures associated with the HCC. We employed the HCC scores, which is 
the sum of the weights for all HCCs, of each individual as a risk adjustment measure. The 
CMS-HCC algorithm was obtained from the CMS website [CMS, 2006a]. 
Chronic Illness and Disability Payment System-Medicare (CDPSM) 
The Chronic Illness and Disability Payment System (CDPS) is an expansion of a prior 
model, the Disability Payment System, developed by Kronick and colleagues [Kronick et al., 
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1996]. At least eight state Medicaid programs use this diagnostic classification system to 
make risk-adjusted capitation payments for beneficiaries with disabilities or who receive 
Temporary Assistance to Needy Families [Kronick et al., 2000]. We used the CDPS Medicare 
version (CDPSM), a modified model more appropriate to predict expenditures for Medicare 
beneficiaries [Kronick et al., 2002]. Compared with the CMS-HCC, the CDPSM is more 
conservative in counting diagnoses and, therefore, has fewer categories. The CDPSM uses 
ICD-9-CM codes in both inpatient and outpatient claims to create 16 major disease 
categories, which correspond to body systems or type of diagnosis. The major categories are 
divided further into 66 subcategories. Similarly to the CMS-HCC, payment weights are 
assigned to those subcategories to reflect the level of increased expenditures associated 
with the condition. The CDPSM score then sums the weights for all indicated subcategories. 
The CDPSM software was acquired under license agreement at no charge 
(http://cdps.ucsd.edu, last accessed on 25 January, 2008). 
Charlson Comorbidity Index (CCI) 
The original CCI is a general comorbidity index consisting of 19 disease categories 
developed to predict one-year mortality using hospital chart review data [Charlson et al., 
1987]. Other researchers have adapted the CCI for use with comorbidity data from 
administrative databases that include ICD-9-CM diagnosis codes [Deyo et al., 1992; D'Hoore 
et al., 1993; Romano et al., 1993; Ghali et al., 1996; Quan et al., 2002]. We used the CCI with 
the Deyo modification containing 17 comorbidity categories [Charlson et al., 1987; Deyo et al., 
1992]. Each condition is assigned a weight as 1, 2, 3, or 6, reflecting the magnitude of the 
adjusted relative risks associated with each comorbidity. The CCI score then sums the 
weights for all conditions, with higher numbers representing a greater burden of comorbidity. 
The CCI for this study was derived using the presence of various ICD-9-CM codes in 




Kautter and Pope [2004] developed a CMS frailty adjustment model that incorporates 
functional status in addition to the CMS-HCC to adjust for capitation payments to certain 
health plans specializing in providing care to the community-dwelling, frail elderly. The use of 
functional ability frailty adjuster, in particular measured by ADLs, is preferred to other health 
status measures (such as general perceived health status “Is your health excellent, very 
good, good, fair, or poor?”) because it has good face validity and has been shown to explain 
Medicare expenditures not accounted for by diagnosis-based measures [Pope et al., 1998; 
Riley, 2000; Kautter and Pope, 2004]. In addition, performing instrumental activities of daily 
living (IADLs, i.e., using the phone, doing light housework, doing heavy housework, making 
meals, shopping and managing money) is more cognitively demanding than performing 
ADLs, and is directly impacted by the progression of AD, making IADLs less suitable for 
assessing comorbidities. Therefore, the frailty adjuster in our study uses a scale based on the 
count of ADL impairments, and was categorized as none, 1-2 (low), 3-4 (moderate), and 5-6 
(high). For each activity, individuals were asked whether they had any difficulty performing 
the activity, received help with the activity, needed supervision with the activity, or were 
unable to perform the activity because of health problems. An individual was coded as 
impaired for an ADL if he or she needed any assistance doing (i.e., received help or needed 
supervision) or could not perform the activity. 
Prior expenditures 
Expenditures incurred in year t are highly correlated with expenditures in year t+1 
[Garber et al., 1997; Pope et al., 1998]. The distributions of overall and drug expenditures 
were right-skewed in our sample: less than 1% of the sample had no overall expenditures 
and less than 4% had no drug expenditures. We modeled expenditures in year t as 
continuous variables on their original scale, and used the generalized linear model (GLM, 
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described in the next section) as an alternative to transforming the non-normally distributed 
data.  
Combined models 
We also compared the performance of combined models, which incorporate the frailty 
adjuster or/and prior expenditures in the diagnosis-based measures (i.e., CMS-HCC, 
CDPSM and CCI), against the performance of single-measure models. 
 
Analysis 
A Pearson correlation coefficient matrix was used to evaluate the correlation among 
various risk adjustment measures. Ordinary least squares (OLS) regressions were employed 
to predict expenditures in year t+1 using each risk adjustment measure plus age-gender 
categories in year t. Because the expenditure data were non-normally distributed, we also 
performed the generalized linear model (GLM) with a gamma variance and a log link function, 
which models expenditures in their natural scale rather than in a transformed scale (e.g., log 
transformation) [Shwartz and Ash, 2003]. The full models are described in Equations 6.1 and 
6.2. 
OLS: E[Expendituret+1] = β1 Ageit + β2 Sexit + β3 Diagnosisit + β4 ADLit + β5 Expenditureit  
                                                                     (Equation 6.1) 
 
GLM: g[E(Expendituret+1)] = β1 Ageit + β2 Sexit + β3 Diagnosisit + β4 ADLit + β5 Expenditureit 
                                                                     (Equation 6.2) 
 
Since this study focuses on an AD-specific population with a sample size of 671 
unique individuals, we were unable to use a split-sample design to evaluate predictive 
accuracy, in which a small randomly selected sample of the total study population is withheld 
for model validation [Ellis et al., 1996; Fishman et al., 2003; Meenan et al., 2003; Pacala et al., 
2003; Powers et al., 2005]. Therefore, alternative statistical evaluation criteria were adopted. 
We used adjusted R2 from OLS models to demonstrate the proportion of total variance in the 
dependent variable (e.g., expenditures) accounted for by the risk adjustment model [Ellis et 
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al., 1996]. For GLMs, we compared the log likelihood values across models, with higher 
numbers indicating better model fit. 
Although adjusted R2 and log likelihood values provide a summary measure of overall 
prediction, these statistics give little information about how well a model discriminates 
between high- and low-expenditure cases [Shwartz and Ash, 2003]. Therefore, an 
individual’s actual expenditures in the prediction year (i.e., year t+1) were categorized into 
quartiles; then, predictive ratios (i.e., predicted expenditures divided by actual expenditures) 
were calculated within each quartile [Ash et al., 2000; Cucciare and O'Donohue, 2006]. If the 
model performs well for a population, its predictive ratio is close to one. In a prospective 
payment system, a predictive ratio close to one indicates that aggregate payments under the 
risk adjustment model are equivalent to payments under the fee-for-service [Ellis et al., 1996]. 
A ratio greater than one indicates that payments are set higher than the actual expenditures 
incurred, whereas a ratio less than one represents under-payment for the actual 
expenditures. 
Predictive model performance was examined further using receiver operating 
characteristic (ROC) curves, representing how well the model classifies individuals by 
illustrating the tradeoff between true positive (sensitivity) and false positive (1-specificity) for 
a certain high-expenditure threshold [Meenan et al., 1999]. This is done by rank-ordering 
actual and predicted expenditures from high to low, and setting a pre-determined percentage 
threshold (e.g., top 10%) within each expenditure distribution to define “true” 
high-expenditure cases [Meenan et al., 1999; Meenan et al., 2003; Weiner, 2003]. A 
c-statistic representing discrimination power then can be calculated using a nonparametric 
trapezoidal method to approximate the area under the ROC curve [Shwartz and Ash, 2003]. 





The average age of the sample was 81.2 years, and 60% were female (Table 6.1). All 
three diagnosis-based risk adjustment measures indicated a substantial burden of 
comorbidities: the average CMS-HCC, CDPSM, and CCI scores were 1.6, 1.6, and 2.8, 
respectively. The burden of comorbidities among our AD sample was higher compared with a 
sample of Veterans regularly using primary care [Maciejewski et al., 2005]: the average DCG, 
CDPS, and CCI scores were 1.3, 1.9, and 0.2, respectively. On average, individuals with AD 
had 1.4 ADL limitations: approximately 60% reported no ADL impairment, whereas 14% 
reported impairment for at least five of six ADLs. Average total expenditures in prediction 
year t+1 were $18,736 (standard deviation [s.d.]= $31,163); 11 of the 671 individuals (1.6%) 
had total expenditures exceeding $100,000. Average prescription drug expenditures were 
$2,562 (s.d.= $2,511) in the prediction year; 15 (2.2%) spent more than $10,000 on 
prescription medicine. The average per capita overall and drug expenditures among seniors 
with AD were substantially higher their counterparts without AD ($10,371 for total and $1,681 
for drug expenditures, results not shown). 
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Table 6.1: Descriptive statistics of sample of individuals with Alzheimer’s disease 
 
Characteristics Mean (s.d.) Minimum Maximum 
Age, years 81.2 (7.1) 65 101 
     65-69 6.7% -- -- 
     70-74 13.1% -- -- 
     75-79 18.0% -- -- 
     80-84 29.4% -- -- 
     85+ 32.8% -- -- 
Male 40.1% -- -- 
CCI 2.8 (2.6) 0 15.0 
CMS-HCC 1.6 (1.2) 0.3 8.3 
CDPSM 1.6 (1.2) 0.2 7.5 
Count of ADL limitations 
     0 
     1-2 
     3-4 
















Total expenditures, 2007$ 
    Year 1 
    Year 2 
 
      $16,899 ($21,282) 





     $219,992 
     $364,116 
Drug expenditures, 2007$ 
    Year 1 
    Year 2 
 
      $2,401 ($2,263) 





     $24,832 
     $27,553 
ADL: activity of daily living; CCI: Charlson Comorbidity Index; CDPSM: Chronic Illness and Disability Payment 
System-Medicare; CMS-HCC: Centers for Medicare and Medicaid version of the Diagnostic Cost Group-Hierarchical 
Condition Category; IADL: independent activity of daily living; s.d.: standard deviation 
 
The correlation matrix (Table 6.2) revealed that the three diagnosis-based risk 
adjustment measures had moderate-to-high correlations, especially the CMS-HCC and the 
CDPSM (r=0.93). This high correlation is likely due to similar approaches used in both 
measures to define diagnoses, to assign disease diagnoses, and to aggregate disease 
categories into larger areas according to body system or type of disease [Kronick et al., 2002]. 
The CMS-HCC and the CDPSM also were strongly correlated with total expenditures in year 
t (r=0.67 and 0.68, respectively). The frailty adjuster measured by ADL limitations was only 
moderately correlated with the CMS-HCC and total expenditures in the base year, but not 










Table 6.2: Correlation matrix of risk adjustment measures 
 





CMS-HCC 0.29**     
CDPSM 0.31** 0.93**    
ADL limitations 0.03 0.29** 0.26**   
Prior total expenditures 0.21** 0.67** 0.68** 0.29**  
Prior prescription drug 
expenditures 0.12** 0.16** 0.17** 0.09* 0.23** 
        p<0.05, ** p< 0.01 
ADL: activity of daily living; CCI: Charlson Comorbidity Index; CDPSM: Chronic Illness and Disability Payment 
System-Medicare; CMS-HCC: Centers for Medicare and Medicaid version of the Diagnostic Cost Group-Hierarchical 
Condition Category 
 
Adjusted R2 values for prospective OLS models and log likelihood values of the GLMs 
are reported in Table 6.3. Diagnosis-based risk adjustment models explained more variance 
in total expenditures than in drug expenditures. Age and gender alone explained less than 
1% of the total expenditure variation. Adding diagnosis-based measures to the demographic 
model substantially increased the explanatory power. In predicting total expenditures, the 
CCI had a higher adjusted R2 (17.0%) compared to the CDPSM (15.5%) and the CMS-HCC 
(12.1%). Prior expenditures were more predictive (adjusted R2=20.4%) than any other single 
measures. Incorporating the frailty adjuster modestly increased the adjusted R2 of the 
diagnosis-based models, with the CCI remaining the most predictive (18.5%), followed by the 
CDPSM (15.6%) and CMS-HCC (14.2%), but not the prior-expenditure model. Adding prior 
expenditures to diagnosis-based measures with frailty adjustment increased the adjusted R2 
to 21.1%-31.1%. The log likelihood values in GLMs revealed similar results as with adjusted 
R2 statistics, although the CCI had slightly higher log likelihood values than prior 
expenditures, regardless of whether frailty adjustment was used. 
Diagnoses were not predictive of future prescription drug expenditures (adjusted 
R2=1.4%-2.3%). Incorporating the frailty adjuster even decreased the explanatory power. 
Adding prior drug expenditures increased the adjusted R2 to approximately 37%. The log 
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likelihood values in GLMs also indicated that models incorporating prior drug expenditures 
had a better fit. 
Table 6.3: Adjusted R2 and log likelihood values of risk adjustment measures in 
prospective expenditure models 
 
Adjusted R-squared1 x 100% Log likelihood value2 











Age and gender 0.02 0.9 -7203.3 -5724.7 
Diagnosis-based measures     
     CMS-HCC 12.1 1.4 -7130.8 -5722.6 
     CDPSM 15.5 1.7 -7127.2 -5721.3 
     CCI 17.0 2.3 -7110.3 -5718.3 
Frailty adjuster     
     Counts of ADL limitations3 2.0 0.5 -7185.1 -5724.5 
Prior expenditures4 20.4 37.1 -7119.4 -5599.2 
Combined models     
CMS-HCC + count of ADL 
limitations 14.2 1.0 -7124.6 -5722.6 
CDPSM + count of ADL limitations 15.6 1.3 -7119.5 -5721.3 
CCI + count of ADL limitations 18.5 1.9 -7093.7 -5718.2 
Prior expenditures + count of ADL 
limitations 
20.3 37.3 -7116.5 -5597.0 
CMS-HCC + count of ADL 
limitations + prior expenditures 
21.1 37.2 -7108.9 -5597.0 
CDPSM + count of ADL limitations 
+ prior expenditures 
21.6 37.2 -7105.3 -5596.8 
CCI + count of ADL limitations 
+ prior expenditures 
31.1 37.5 -7054.5 -5596.1 
1
 Adjusted R-squared is obtained from ordinary least square regression. 
2
 Log likelihood is obtained from generalized linear model with a gamma variance and a log link function. 
3
 Counts of ADL limitations were categorized as none, 1-2, 3-4, and 5-6. 
4
 Prior total expenditures were used to predict subsequent-year total expenditures; prior drug expenditures were used to 
predict subsequent-year drug expenditures. 
ADL: activity of daily living; CCI: Charlson Comorbidity Index; CDPSM: Chronic Illness and Disability Payment 
System-Medicare; CMS-HCC: Centers for Medicare and Medicaid version of the Diagnostic Cost Group-Hierarchical 
Condition Category. 
 
Figures 6.2 and 6.3 illustrate predictive ratios (i.e., predicted-to-actual expenditures) 
by expenditure quartile of overall and drug expenditures. For total expenditures, all 
single-measure and combined models substantially under-predicted expenditures in the 
highest quartile, and over-predicted those in the lowest quartile. Compared to the CMS-HCC 
and the CDPSM, the CCI exhibited less deviation from the reference line indicating 
risk-adjusted capitation payments equivalent to payments under the fee-for-service (i.e., 
predictive ratio=1) in the lowest, second lowest and highest quartiles. All three 
diagnosis-based measures under-predicted actual total expenditures in the highest quartile 
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by approximately 50%, and over-predicted those in the lowest quartile by six fold. Inclusion of 
frailty adjustment improved overall explanatory power but only modestly improved the 
predictive accuracy in each expenditure quartile. With frailty adjustment, the CCI also 
exhibited less deviation from the reference line compared with the CMS-HCC and the 
CDPSM. Prior expenditures were more accurate in predicting individuals in the lowest and in 
the highest quartiles compared with diagnosis-based measures, regardless of whether frailty 
adjustment was applied. 
For prescription drug expenditures, all three diagnosis-based measures performed 
similarly: they under-predicted actual drug expenditures among individuals in the highest 
quartile by approximately 50%, and over-predicted those in the lowest quartile by eight fold, a 
greater over-prediction than for total expenditures. Prior drug expenditures were more 
accurate than any other measures but tended to over-predict across quartiles. Inclusion of 













































CMS-HCC and ADL limitations
CDPSM and ADL limitations
CCI and ADL limitations
Prior total expenditures and ADL limitations
Predictive ration = 1
Combined models with frailty adjustment
 
ADL: activity of daily living; CCI: Charlson Comorbidity Index; CDPSM: Chronic Illness and Disability Payment 
System-Medicare; CMS-HCC: Centers for Medicare and Medicaid version of the Diagnostic Cost Group-Hierarchical 
Condition Category. 
 

















































CMS-HCC and ADL limitations
CDPSM and ADL limitations
CCI and ADL limitations
Prior drug expenditures and ADL limitations
Predictive ratio = 1
Combined models with frailty adjustment
 
ADL: activity of daily living; CCI: Charlson Comorbidity Index; CDPSM: Chronic Illness and Disability Payment 
System-Medicare; CMS-HCC: Centers for Medicare and Medicaid version of the Diagnostic Cost Group-Hierarchical 
Condition Category. 
 
Figure 6.3: Predictive ratios of risk adjustment measures in predicting prescription 
drug expenditures 
 
A model’s ability to predict being in the top 10% of the expenditure distribution (i.e., 
“high-expenditure outliers”) was assessed by the area under the ROC curves (Table 6.4). In 
predicting total expenditures, demographic characteristic had no ability to discriminate 
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(c=0.509). Adding diagnoses raised the c-statistics to 0.667 (CCI), 0.645 (CDPSM), and 
0.628 (CMS-HCC). Inclusion of the frailty adjuster slightly improved the discrimination power 
of the CDPSM (c=0.650) and the CMS-HCC (c=0.635), but not the CCI (c=0.664). Prior 
expenditures were more predictive (c=0.703) than any other single-measure models or 
combined models with frailty adjustment. 
For prescription drug expenditures, diagnoses had only modest discrimination power 
of classifying individuals into high-expenditure category. Adding frailty adjustment slightly 
increased the c-statistics of the CCI (0.618) and the CDPSM (0.564), but not the CMS-HCC 
(0.561). Prior drug expenditures had good discrimination power (c=0.848) and outperformed 
any other single-measure models or combined models with frailty adjustment. 
Table 6.4: Area under the receiver operating characteristic curves in prospective 
expenditure models 
 
10% high-expenditure threshold 
Risk adjustment measures Total expenditures Drug expenditures 
Age and gender 0.509 0.587 
Diagnosis-based measures 
  
     CMS-HCC 0.628 0.600 
     CDPSM 0.645 0.561 
     CCI 0.667 0.614 
Frailty adjuster 
  
     Counts of ADL limitations1 0.521 0.585 
Prior expenditures 0.703 0.848 
Combined models 
  
     CMS-HCC + count of ADL limitations 0.635 0.561 
     CDPSM + count of ADL limitations 0.650 0.564 
     CCI + count of ADL limitations 0.664 0.618 
     Prior expenditures + count of ADL 
limitations 
0.685 0.847 
     CMS-HCC + count of ADL limitations + 
       prior expenditures 
0.686 0.846 
     CDPSM + count of ADL limitations + 
       prior expenditures 
0.693 0.845 
     CCI + count of ADL limitations + 
       prior expenditures 
0.713 0.848 
1
 Counts of ADL limitations were categorized as none, 1-2, 3-4, and 5-6. 
ADL: activity of daily living; CCI: Charlson Comorbidity Index; CDPSM: Chronic Illness and Disability Payment 







This study compared the performance of five different risk adjustment measures in 
predicting overall and prescription drug expenditures for Medicare beneficiaries with 
Alzheimer’s disease. Our analysis showed that, in single-measure, diagnosis-based models, 
the CCI outperformed the CMS-HCC and the CDPSM in predicting both total and drug 
expenditures. CCI remained the best-performing measure when adding frailty adjustment 
based on counts of ADL limitations. The frailty adjuster increased overall explanatory power 
and modestly improved the predictive accuracy in each expenditure quartile for predicting 
total expenditures but not for drug expenditures. In high-expenditure outlier analysis, the CCI 
exhibited greater discrimination power than the CMS-HCC and the CDPSM, regardless of 
whether frailty adjustment was applied. 
Our data indicated that, models incorporating prior expenditures generally had 
greater prediction power and predictive accuracy, especially in predicting drug expenditures. 
Past use explained more than 37% of the total variations in drug expenditures. Only prior 
expenditures, but not diagnoses, predicted drug expenditures with any accuracy, and can 
discriminate between high- and low-expenditure individuals. The difference in accuracy 
between prior expenditures and diagnoses was greatest in individuals with the highest drug 
expenditures (i.e., the top 25%). This phenomenon is likely due to a strong degree of 
persistence in prescription drug expenditures among the elderly, in which high-expenditure 
users remain in the upper percentiles and low-expenditure individuals remain in the bottom of 
the expenditure distribution in the next year [Stuart et al., 1991; Coulson and Stuart, 1992; 
Wrobel et al., 2003; Lin, 2008b]. However, inclusion of prior expenditures in a prospective 
risk adjustment model to set payment might not be practical because of the perverse 
incentives created [Ash et al., 2000; Greenwald, 2000; Ash et al., 2001]. For instance, 
models that pay more for heavy users may encourage both appropriate and inappropriate or 
unnecessary services [Ash et al., 2001]. 
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On the other hand, combining expenditure and diagnosis data may be more powerful 
and more operationally useful for identifying beneficiaries who may be at risk for higher future 
expenditures. Particularly for AD, MCOs have many opportunities to mitigate costs or change 
care patterns through disease management, including use of appropriate medications (e.g., 
cholinesterase inhibitors), discharge planning, education, counseling, and support for 
caregivers [Fillit et al., 2002b; Kaufer et al., 2005], which may delay time to nursing home 
care. Better care coordination, such as medication management by nurses or pharmacists, is 
needed for improving adherence to drug therapies for concomitant conditions in addition to 
AD. 
Without risk adjustment, payers using capitation payment methods are likely to 
overpay (or underpay) providers for healthier plan enrollees (or sicker groups). If payers do 
not reimburse more money to providers who serve enrollees with above-average levels of 
health care needs, plans will be penalized for enrolling sicker patients and quality of care may 
be jeopardized [Kronick et al., 2000]. Diagnosis-based measures, such as the PIPDCG and 
the DCG-HCC, have been shown to under-predict (or over-predict) average expenditures for 
Medicare beneficiaries with (or without) ADL impairments [Riley, 2000]. The degree of 
under-prediction has been shown to increase with the number of ADL limitations, which are 
associated with Medicare expenditures, but not fully captured in demographic characteristics 
or diagnosis profiles. Beginning in 2004, frailty-adjusted Medicare payments were applied to 
some MCOs, such as Program of All Inclusive Care for the Elderly (PACE), Wisconsin 
Partnership Program, and Minnesota Senior Health Options, that specialize in providing care 
to the community-residing frail elderly [Kautter and Pope, 2004]. For individuals with AD, 
progressive functional decline and thus frailty is well documented. Using data from the 1994 
National Long Term Care Survey, Taylor and colleagues found that functional impairment 
was more predictive than cognitive status of total expenditures for individuals with AD and 
related dementias, and that risk adjustment measures should account for functional disability 
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and comorbidity rather than just AD status [Taylor et al., 2001]. However, under the current 
payment system, individuals with AD will not qualify for an enhanced capitation payment rate 
if they are enrolled in traditional Medicare MCOs. Our data showed that with frailty 
adjustment based on counts of ADL limitations, the best-performing model, CCI, had an 
adjusted R2 of 18.5%. Incorporating ADL limitations increased the explanatory power of the 
CMS-HCC model by 17%, an amount greater than the 11% improvement found by including 
this adjustment in developing payment for the general Medicare beneficiaries [Kautter and 
Pope, 2004]. Our results support including ADL limitations as a frailty adjuster in a 
diagnosis-based risk adjustment model until better measures of risk can be developed. 
Nevertheless, the acquisition, cleaning, and use of administrative data are often 
time-consuming and costly [Powers et al., 2005]. Unlike in long-term-care settings in which 
functional ability is collected routinely as part of the Minimum Data Set Nursing Home 
Assessment Record [CMS, 2008], payers should assess the time and cost of collecting 
additional information on functional ability for community-dwelling individuals, as this 
information is not readily available in administrative claims data. 
Risk adjustment models differ from each other in the characteristics used to explain 
expenditures and how this information is organized in the classification system [Greenwald, 
2000]. Compared with the other two diagnosis-based measures, the CCI consists of fewer 
disease categories and a simpler scoring algorithm. The CCI has been validated in many 
studies to predict mortality outcome [Schneeweiss and Maclure, 2000; Needham et al., 2005], 
but this methodology has not been thoroughly explored to predict expenditures. Surprisingly, 
the CCI outperformed the CMS-HCC and the CDPSM in many instances in our AD sample. 
In predicting total expenditures, the CCI produced an adjusted R2 of 17%, comparable to the 
20% threshold found in most prospective models based on diagnosis information or on 
pharmacy claims [Newhouse et al., 1989; Shwartz and Ash, 2003]. With frailty adjustment, 
the c-statistics of diagnosis-based models ranged between 0.64 and 0.66 in our AD sample. 
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The results are comparable to an assessment of risk adjustment models based on diagnosis, 
pharmacy claims, or prior expenditures among elderly managed care beneficiaries in which 
the c-statistics ranged between 0.65 and 0.69 in models given a highly stringent 1% 
high-expenditure threshold [Meenan et al., 2003]. We also validated the results by excluding 
individuals with extremely high overall expenditures (>$100,000) and extremely drug 
expenditures (>$10,000), and found little effect on our conclusions. Our findings support that, 
properly combining frailty adjustment and comorbidity profiles, risk adjustment measures 
appear promising in predicting health expenditures even in a population with substantial 
disabilities. 
In interpreting the results presented here, several notes of caution are important. First, 
the study sample excluded individuals residing in skilled nursing facilities who generally have 
more functional impairments and more comorbidities than community-dwelling individuals 
with AD [Hill et al., 2006]. In the future, diagnosis-based models with frailty adjustment will 
require further review and refinement for risk adjustment to be applicable to long-term-care 
settings. For example, an admission profile, such as the pressure ulcer prevalence rate, may 
be adjusted to recognize that some facilities admit sicker individuals [Berlowitz and Rosen, 
2003]. The study sample also excluded individuals with any managed care participation 
because their medical claims and diagnoses were not available in the MCBS. In general, 
these individuals were somewhat younger and healthier and had lower average overall and 
drug expenditures than our study sample. Future investigation should evaluate the 
performance of risk adjustment models for certain MCO subpopulations, especially 
individuals with functional impairments. 
According to the Medicare Part D risk adjustment model (i.e., RxHCC) [CMS, 2006a], 
dementia with depression or behavioral disturbance is associated with $1,104 (2006 dollars) 
increase in expenditures for community residents. However, we did not have ambulatory 
pharmacy claims data to determine whether pharmacy-based models, such as the Chronic 
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Disease Score [Von Korff et al., 1992] and the RxRisk model [Fishman et al., 2003], would 
have improved predictive accuracy, especially in predicting drug expenditures. Future 
research is needed to evaluate the performance of pharmacy-based measures in order to 
improve Part D payment methodology. For seniors with AD, assessment of pharmacy-based 
risk adjustment models can help policymakers to design formularies that offer better and 
more comprehensive drug coverage to meet their different needs, such as medications for 
treating common comorbidities including psychiatric disorders and diabetes [Rice et al., 
2001].  
Another issue concerns the quality of self- or proxy-reported functional status. In our 
sample, nearly 50% of proxy response occurred on behalf of individuals with AD. Although 
self-report may have greater errors in individuals with cognitive impairment relative to the 
general population, it is not clear whether proxy reports are systematically more or less 
accurate than self reports. Individuals with dementia may overestimate their cognitive and 
functional abilities compared with proxy ratings [Koss et al., 1993; Tierney et al., 1996; Farias 
et al., 2005]. On the other hand, greater caregiver burden may lead to overstated functional 
impairments of individuals with cognitive impairment [Rothman et al., 1991; Long et al., 1998]. 
In the future it will be important to investigate the validity of proxy reports in order to apply 
accurately the frailty adjuster based on functional ability. 
 
6.6 Conclusion 
In single-measure models, CCI outperformed CMS-HCC and CDPSM in predicting 
both total and drug expenditures among our sample of community-dwelling Medicare 
beneficiaries with AD. A frailty adjuster based on count of ADL limitations improved overall 
prediction and predictive accuracy of the diagnosis-based models, especially the CMS-HCC 
specification currently used by Medicare. No model except past use predicted drug 
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expenditures well. Future research is needed to evaluate the performance of risk adjustment 
measures based on ambulatory pharmacy data. 
 
CHAPTER 7 
STUDY LIMITATIONS AND FUTURE RESEARCH AGENDA 
 
7.1 Summary of Findings 
This dissertation examined the dynamics of overall health expenditures and 
prescription drug expenditures in Medicare beneficiaries with Alzheimer’s disease (AD), a 
population with progressive disabilities and associated with high expenditures. Previous 
cost-of-illness studies on AD yield great variation in cost and prevalence estimates. As well, 
little is known about the characteristics of individuals with AD who accrue high and 
persistently high expenditures. This dissertation sought to characterize their expenditure 
profiles prospectively using data from the 1999-2004 Medicare Current Beneficiary Survey 
(MCBS) linked with Medicare claims files. In addition, this study was the first, to our 
knowledge, to compare the performance of various risk adjustment measures to predict 
overall and prescription drug expenditures in the AD population. The findings of this 
dissertation may help payers to compensate health plans fairly for the expected expenditures 
associated with the disease burden of their enrollees with AD. 
The case-finding analysis presented in Chapter 4 identified the most sensitive and 
specific alternatives for identifying who has AD. The use of survey report, diagnosis listed in 
medical claims, use of Alzheimer-specific prescription medicine, or some combination of 
these three definitions identified different subsets of individuals with AD. Using diagnosis as a 
“gold-standard”, as is typical for other diseases and conditions, survey report was able to 
identify correctly individuals who do not have AD (i.e., highly specific) without losing the 
ability to identify correctly individuals who have AD (i.e., sensitivity) found when Alzheimer’s 
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medication use is used as a marker for the disease. As a consequence of the different 
disease definitions employed, the expenditure estimates for individuals with AD varied widely. 
Per capita health expenditures ranged from $16,547 to $24,937, and drug expenditures 
ranged from $2,303 to $3,519, depending on how AD was defined. Thus, one should 
exercise caution when interpreting current cost-of-illness studies and in applying these 
estimates to policy initiatives. In observational studies, the development of a comprehensive 
case definition, which incorporates all available markers for AD to the researcher, is a crucial 
first step to assessing the health care needs for persons with AD. 
Against the background of relatively high expenditures by Medicare beneficiaries with 
AD shown in Chapter 4, Chapter 5 provided information on the dynamic distribution of overall 
and prescription drug expenditures in this population. Specifically, individuals in the top 10% 
of the expenditure distribution (i.e., those with the highest expenditures) accounted for 
38%-47% of overall health expenditures and 31%-36% of overall drug expenditures, 
depending on the study year. Thus, health expenditures (both for drugs and other types of 
care) among Medicare beneficiaries with AD were highly concentrated in a relatively small 
proportion of individuals. A quarter of the highest-spending 10% for total health expenditures 
remained in the top decile in the next year, whereas 21% of them moved to the bottom half of 
the distribution in the subsequent year. Half of the highest 10% with drug expenditures 
retained this ranking but only 9% became the bottom 50% in a second year, indicating that 
prescription drug expenditures were more persistent than overall expenditures. Prior 
expenditures and comorbidities, but not functional status, were strong predictors of the level 
of future expenditures. The potential for high expenditures by a relatively small group of 
individuals in subsequent years, coupled with the likelihood for growth of AD among the 
aging population, suggests the need for providing evidence that additional care coordination 
and disease management programs may be necessary to improve health outcomes and to 
control costs. 
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Building upon the findings in Chapter 5 that expenditures among individuals with AD 
were correlated with personal characteristics and prior expenditures and, therefore, can be 
predicted, Chapter 6 compared the performance of various prospective risk adjustment 
models of predicting overall and prescription drug expenditures. The specific risk adjustment 
measures evaluated for this sample were constructed from diagnoses in medical claims (i.e., 
Charlson Comorbidity Index [CCI], Hierarchical Condition Category model used by Medicare 
[CMS-HCC], and Chronic Illness and Disability Payment System-Medicare version [CDPSM]), 
functional status (i.e., limitations of activities of daily living [ADLs]) as reported in the MCBS, 
prior expenditures, and some combination thereof. In line with the evidence found in the 
general Medicare population, this analysis demonstrated that total expenditure models with 
multiple risk adjustment measures outperformed single-measure models in this AD sample. 
The diagnosis-based models under-predicted the actual total expenditures among individuals 
in the highest quartile by approximately 50%, and over-predicted those in the lowest quartile 
by 6-fold. The frailty adjuster based on functional ability had very limited predictive power 
itself, whereas it improved overall prediction and predictive accuracy on the diagnosis-based 
models. Inclusion of the frailty adjuster in the diagnosis-based models in predicting total 
expenditures raised the adjusted R2 to 19%, very similar to the 20% threshold found in most 
prospective models based on diagnosis information or on pharmacy claims [Newhouse et al., 
1989; Shwartz and Ash, 2003]. With frailty adjustment, the c-statistics of diagnosis-based 
models ranged between 0.63 and 0.67 in our AD sample. The results are comparable to an 
assessment of risk adjustment models based on diagnosis, pharmacy claims, or prior 
expenditures among elderly managed care beneficiaries in which the c-statistics ranged 
between 0.65 and 0.69 in models given a 1% high-expenditure threshold [Meenan et al., 
2003]. However, for drug expenditures, only prior expenditures, but not comorbidities or 
functional status, predicted well. Incorporating prior drug expenditures increased the adjusted 
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R2 to 37%, which is still lower than the explanatory power observed in a nationally 
representative sample of Medicare beneficiaries (adjusted R2=55%) [Wrobel et al., 2003]. 
Based on these results, expenditure analysis for individuals with AD using 
observational data should incorporate all sources of definitions available to researchers as a 
first step to case ascertainment. If only diagnosis code data are available, as in administrative 
claim data, researchers should exercise substantial caution when reporting prevalence and 
expenditure data given the proportion of missed AD cases we noted in this study. The 
development of a comprehensive case definition that is reasonably sensitive yet specific is 
important for identifying individuals at different phases of AD and to assessing their health 
care needs. For persons with a chronic condition like AD that places substantial burdens on 
both the individual and the health care system, there is a critical need to understand the 
dynamics of their expenditure profiles. This dissertation found that overall health care and 
drug expenditures were highly concentrated and persistent over a two-year period in this AD 
population. Prior expenditures and comorbidities, were highly predictive of an individual’s 
percentile position in the subsequent-year expenditure distribution, much stronger than the 
effects of demographic characteristics and functional ability. Prospective risk adjustment 
models combining multiple measures, such as functional ability and comorbidity profiles, 
improve predictive accuracy of current diagnosis-based capitation payment methods. 
Therefore, with proper organization of information, risk adjustment measures appear 
promising in predicting health expenditures even in a population with substantial disabilities, 
such as individuals with AD. Predictive models identifying seniors with AD who are at high 
risk of accruing high expenditures can help MCOs to mitigate costs or change care patterns 
through disease management, including use of appropriate medications (e.g., cholinesterase 
inhibitors), discharge planning, education, counseling, and support for caregivers [Fillit et al., 
2002b; Kaufer et al., 2005], which may delay time to nursing home care. Better care 
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coordination, such as medication management by nurses or pharmacists, could improve 
adherence to drug therapies for concomitant conditions in addition to AD. 
 
7.2 Study Limitations 
Although these analyses provide important contributions to the study of dynamics of 
overall and drug expenditures among individuals with AD, there are limitations that present 
an opportunity for future investigation. First, the findings presented in Chapter 4 represent the 
necessary first step, not a definitive or absolute analysis, towards appropriate case 
ascertainment for identifying all individuals with AD. In our analysis, we were unable to rule 
out potentially false-positive cases, such as individuals who report being told by their 
physicians that they have AD but who do not have an AD diagnosis in their medical claims 
and/or who are not taking Alzheimer-specific medications (i.e., acetylcholinesterase inhibitors 
or memantine). They may be individuals with mild cognitive impairment (MCI) or early-stage 
AD who are under-diagnosed or uncoded in claims data because of social resistance to 
ageism and disabling stigma [Fillit, 2000; Rice et al., 2001]. It is also possible that AD is 
under-coded because the reimbursement scheme provides little financial incentive for coding 
AD as the primary diagnosis and instead encourages coding comorbidities, such as 
aspiration pneumonia as the primary diagnosis, to enhance reimbursement [Newcomer et al., 
1999; Fillit, 2000; Brummel-Smith, 2001; Rice et al., 2001]. Moreover, an estimated 50% of 
individuals with AD are diagnosed, and only half of those diagnosed are being treated [Evans, 
1990]. Individuals with AD may not take acetylcholinesterase inhibitors or memantine 
because these drugs may temporarily delay memory decline but none of them is known to 
stop the underlying degeneration of brain cells [Alzheimer's Association, 2007]. The lack of a 
uniformly accepted definition or a gold-standard diagnostic test result poses a challenge to 
verifying the validity of survey report, diagnosis, and medication use that we employed to 
define AD in the MCBS. 
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Second, although our sample was drawn from a nationally representative Medicare 
sample, use of secondary data brings limitations. There might be errors in data collection, 
editing and imputation, which are difficult to evaluate but can result in biased estimates. 
Particularly, the reliability of self report by persons with AD and proxy response may be 
imperfect. Our data revealed that proxy use was much higher in individuals with AD than in 
those without, probably due to great disabilities among this population. A number of studies 
have shown that, among individuals with dementia, self report often differs substantially from 
information collected from caregivers [DeBettignies et al., 1990; Farias et al., 2005], whereas 
it is unclear whether proxy reports are systematically more or less accurate than self reports. 
For instance, individuals with AD may experience a great loss of insight and thus 
overestimate their cognitive and functional abilities compared with proxy ratings [Koss et al., 
1993; Tierney et al., 1996; Farias et al., 2005]. On the other hand, greater caregiver burden 
may lead to overstated functional impairments of individuals with cognitive impairment 
[Rothman et al., 1991; Long et al., 1998]. Therefore, functional status collected from self 
report or proxy response should be validated, especially in a subpopulation with cognitive 
and memory loss, to enhance the performance of frailty adjustment on risk-adjusted 
capitation payments. 
Third, we had to limit our sample to individuals with complete claims records in the 
MCBS and excluded those enrolled in managed care because these plans do not submit 
detailed claims to the Centers for Medicare and Medicaid (CMS), and thus we were unable to 
construct their comorbid condition profiles using diagnoses listed in the medical claims. We 
examined these individuals separately using survey data and found that they were somewhat 
younger and healthier and had lower average overall and drug expenditures than our study 
sample. Therefore, one should be cautious in interpreting the results as these findings may 
not be generalizable to managed care enrollees. 
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Fourth, our sample also excluded residents in long-term-care facilities defined as 
individuals who were institutionalized for more than 90 days at a time during a year [CMS, 
2006c]. Evidence has shown that individuals with AD residing in skilled nursing facilities tend 
to have more functional impairments and more comorbidities than community residents [Hill 
et al., 2006]. They may be individuals with late-stage AD who require a significant amount of 
caregiving and supervision each day, rather than the ones who are well enough to live at 
home. Therefore, our findings may not be generalizable to individuals with AD living in 
long-term-care facilities. 
On the other hand, the act of institutionalization is a choice made by 
individuals/caregivers but may not necessarily define whether she or he requires such 
intensive care [Caro et al., 2001]. Therefore, our community-dwelling sample may be a 
heterogeneous group with individuals at different phases of AD and with various health care 
needs. Because the MCBS does not provide objective measures of severity of AD, such as 
the modified Mini-Mental State Examination [Folstein et al., 1975], our study was unable to 
examine the relationship between severity and expenditures. Nor were we able to determine 
whether individuals incurred persistently high expenditures was due to more advanced AD or 
more severe comorbid conditions, or the synergetic effect of both. 
Moreover, criticism also can be levied about the lack of automated ambulatory 
pharmacy data in our study, although drug expenditures were available in the MCBS based 
on survey information to impute payments from all sources, including Medicare, Medicaid, 
Medicare MCOs, private MCOs, the Veterans Administration, employer-sponsored private 
insurance, individually-purchased private insurance, private insurance from an unknown 
source, out-of-pocket payments, and public health plans other than Medicare or Medicaid 
[CMS, 2003]. In the case-finding analysis, information on prescription drug use was 
ascertained from survey data rather than actual claims records. However, prescriptions filled 
several months earlier may not be a salient event in the typical respondent’s memory 
 136 
[England et al., 1994], especially those with memory impairments like persons with AD. 
Individuals may have difficulty saving all prescription containers over the typical four-month 
span between interviews. As a result, the prevalence of AD based on prescription medication 
use was likely underestimated due to under-reporting of medication in addition to any 
under-treatment that may occur. Therefore, pharmacy data should be used only as a 
supplement definition for case ascertainment rather than a definitive measure for AD. 
Lastly, in the risk adjustment analysis, no model except prior expenditures predicted 
drug expenditures well. Nevertheless, inclusion of past use in a prospective risk adjustment 
model might not be practical because of the perverse incentives created for payment 
purposes [Ash et al., 2000; Greenwald, 2000; Ash et al., 2001]. For instance, models that pay 
more for expensive, heavy users may encourage both appropriate and inappropriate or 
unnecessary services [Ash et al., 2001]. Nevertheless, during the time frame of our study, 
Medicare Part D benefit was not yet available to its beneficiaries, and the MCBS does not 
supply any drug claims for us to construct pharmacy-based models, such as the Chronic 
Disease Score [Von Korff et al., 1992] and RxRisk [Fishman et al., 2003]. As a result, we 
were unable to determine whether pharmacy-based measures would have improved 
predictive accuracy on total and drug expenditure models. 
 
7.3 Future Research Agenda 
The conclusions as well as the limitations of this study suggest possible avenues for 
future research, including the use of alternative data sources and expansion of study 






Table 7.1: Directions for future research 
 
Case definition  Validate self- or proxy-reported AD and AD diagnosis listed in medical 
claims with objective measures 
Utilization patterns  Examine the type of service use and treatment patterns between 
individuals with persistently high and low expenditures 




 Validate information on functional status as a frailty adjuster 
 Evaluate the performance of pharmacy-based measures   
Long-term-care 
population 
 Estimate expenditure concentration and persistence in institutionalized 
individuals with AD 
 Study risk adjustment models in long-term-care settings 
 
One of the most important agenda items lies in continuing the development of a 
sensitive and specific definition for AD in observational studies. Future research should seek 
to validate self- or proxy-reported AD and AD diagnosis listed in medical claims with objective 
measures, such as cognitive function assessment, neurological examinations, apolipoprotein 
E genotype testing (i.e., a genetic test for Alzheimer’s risk gene), medical record review, 
physician questionnaires, for case ascertainment. Potential data sources may include AD 
registries and prospective community-based cohort studies (e.g., the Cache County Study 
[Tschanz et al., 2005] and the Cardiovascular Health Study [Fitzpatrick et al., 2004]). 
Studies suggest that more than 60% of individuals with AD have three or more 
comorbid conditions [Doraiswamy et al., 2002], and that comorbidities are an important driver 
of increased expenditures for AD [Gutterman et al., 1999]. We found that individuals with AD 
who had more comorbidities were more likely to incur high and persistently high expenditures. 
A more thorough understanding of this uneven distribution could be achieved by examining 
differences in specific service use and treatment patterns between individuals with 
persistently high and low expenditures. Which component of the total spending (e.g., 
hospitalization or outpatient care) is driving the expenditure persistence? Are there 
disparities by expenditure group in managing comorbid conditions, such as psychiatric 
disorders and diabetes, after controlling for disease severity? It would be interesting to 
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explore whether there exists subgroups who had relatively few comorbidities and few 
functional limitations but utilize a large share of medical services, and discuss opportunities 
for health plans to improve care coordination and lower cost. In addition, large claims 
databases from MCOs, such as the Integrated Healthcare Information Services (IHCIS), can 
be used to validate our analysis of expenditure concentration and persistence, and to 
evaluate specific utilization differences in inpatient care, outpatient visits, and prescription 
drugs between individuals with persistently high and low expenditures. 
In the comparison analysis of various risk adjustment measures, functional ability as 
measured by ADLs appeared to be a promising frailty adjuster to the diagnosis-based 
CMS-HCC model in the AD population. In the future, it will be important to validate self- and 
proxy-reported functional status using alternative and possibly more objective measures, 
such as physician rating or having people perform the task during survey interview, to 
improve predictive accuracy. Using measures specifically for assessing daily living abilities 
among individuals with AD, such as the Bristol Activities of Daily Living Scale [Bucks et al., 
1996], may improve predictive power, but disease-specific measures may not be applicable 
to the overall Medicare population. Moreover, future research should assess the time and 
cost of collecting additional information as functional status is not routinely available in 
administrative data, and the acquisition, cleaning and use of both administrative and survey 
data are often time-consuming and costly [Powers et al., 2005]. 
In the MCBS, prescription drug expenditures were imputed data aggregated from all 
payments but not actual expenditure data. Future work is needed to validate the current 
study using actual drug expenditures, such as large claims database from MCOs. With 
available pharmacy claims data, an extension of the current study would be to compare the 
performance of pharmacy-based risk adjustment measures against other measures in 
predicting overall and drug expenditures, and to discuss whether these measures provide a 
viable alternative approach to improving prediction for individuals with substantial disabilities, 
 139 
such as the AD population. Beginning 2006, outpatient prescription drug coverage was 
provided to all Medicare beneficiaries through Part D benefits. Risk adjustment for Medicare 
prescription drug plan payments will require review and update regularly as older drugs are 
going generic and newer, pricy drugs are becoming available [Robst et al., 2007]. 
Additional research should expand the scope to include long-term-care residents in 
that they may have different utilization patterns from community-dwelling individuals with AD. 
In long-term care, research has shown that the specific underlying condition is less important 
for measuring risk, whereas the extent of functional limitations may have a significant role for 
predicting both clinical and economic outcomes [Berlowitz and Rosen, 2003]. 
Diagnosis-based models with frailty adjustment will require further review and refinement for 
risk adjustment to be applicable to long-term-care settings. For example, an admission profile, 
such as the pressure ulcer prevalence rate, may be adjusted to recognize that some facilities 
admit sicker individuals [Berlowitz and Rosen, 2003]. Future investigation should determine 
how to scale functional limitations (e.g., count of functional impairments or dummy variables 
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